<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003564.pub2" GROUP_ID="AIRWAYS" ID="345500110715515504" MERGED_FROM="" MODIFIED="2013-09-26 11:27:08 +0100" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;CJC revision 24 Jan 2013. Thanks for the additional papers. The average correlation from the five papers with IPD measured using data at one hour after treatment is 0.36. I have therefore used this for the GIV analysis. I have also used the mean SD from all the other studies (Active arm mean SD of 10.3 and placebo arm mean of 14.5) and imputed these where the papers did not report an SD (and therefore have a blank line in the original analysis). Matteo, if you are not happy with this you can revert the SE to zero for these studies and they will not contribute to the meta-analysis. One study that sticks out is Bronski 1999, please recheck the data for this one. The SD for the Salmeterol Diskhaler arm is small in comparison with the mean, and I wonder if there has been a typo here? Please also check Hawksworth as the weight is very high and I think that the SD entered is more likely an SE, so I have used SD of 9 and 8.3 respectively for the GIV analysis. Appendix 3 now shows a table of the raw data used to derive the GIV figures, so when we are ready the Forest plot using means and SDs can go.&lt;/p&gt;&lt;p&gt;Please use the GIV data to carry out your subgroup analyses. I have copied the comparison tree with the results ready for you to split the trials into subgroups. If Bronski is wrong it will need changing in the subgroups as well.&lt;/p&gt;&lt;p&gt;Analyses 1.5 and 1.6 remain a problem as we have no IPD trials for the correlation coefficient. We cannot really estimate SDs for these outcomes and I have just imputed the same correlation coefficient for these GIV analyses. I think Van Haitsma for FEF might also be an SE??? Please check&lt;/p&gt;&lt;p&gt;Can you explain how you resolved the multiple time points between beta-agonist and the exercise tests in some studies. Did you just collect data from the earliest exercise challenge?&lt;/p&gt;&lt;p&gt;I will need to add something to the methods and results on how the GIV analyses were carried out.&lt;/p&gt;&lt;p&gt;Best wishes,&lt;/p&gt;&lt;p&gt;Chris&lt;/p&gt;&lt;p&gt;+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;CJC notes 30/11/2012&lt;/p&gt;&lt;p&gt;The cross-over trials should be entered using the GIV method. I have found two papers &lt;a link_type=&quot;STUDY&quot; href=&quot;Anderson 2001 Salb Disk&quot; protected=&quot;true&quot;&gt;Anderson 2001 Salb Disk&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Pearlman 2007 Salb 90&quot; protected=&quot;true&quot;&gt;Pearlman 2007 Salb 90&lt;/a&gt; with full data for the patients and calculated correlation coefficients for these two studies. From this I have chosed 0.44 as a correlation to apply to the other trials to work out SD of the paired maximal percentage fall in SD. I have divided the number in the cross-over by the number of arms in the study to allow the data to be entered without double counting the patients. The results are in outcome 1.11&lt;/p&gt;&lt;p&gt;Please have a look at this and we can discuss whether you want to go with this. If you are aware of other studies with individual patient level results I would be happy to have more data to support whatever correlation coefficient you would like to use.&lt;/p&gt;&lt;p&gt;Cheers&lt;/p&gt;&lt;p&gt;Chris&lt;/p&gt;&lt;p&gt;Emma notes 24/10/2012&lt;/p&gt;&lt;p&gt;Hi Matteo. Thanks for submitting your review- I can see it was a lot of work with a lot of studies! I have tidied up the language in places and some of the revisions have been left in as tracked changes for you to see. I would be grateful if you could go through the tracked changes and accept them if they are fine. If you do this, answer as many of the queries below and in the text as possible and then resubmit the review, I will pass it onto Chris Cates, our coordinating editor, for his comments before peer review. I have not looked in detail at the statistics because I think there are some more basic changes that need to be made first, so please don't see this as a complete editorial review at this stage.&lt;/p&gt;&lt;p&gt;Abstract&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Are we talking exercise induced bronchoconstriction, or exercises induced asthma? need to chose and be consistent (see first line of PLS to understand my confusion)&lt;/li&gt;&lt;li&gt;need to confirm the number of studies is it 50 or 53? It's a bit confusing as you talk about papers and not studies and arms so try to do that. Would also be worth noting the number of treatment arms&lt;/li&gt;&lt;li&gt;what does this mean? &amp;quot;Mean % protection was 66%&amp;quot;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Background&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Have made quite a few edits for style - there are a few queries highlighted in the text&lt;/li&gt;&lt;li&gt;not sure about the word 'pre-treatment'. I think you need a really clear definition in the review&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;methods - I activated the standard headings and a few were blank. We'll delete them later on, but leave them in for the time being in case we need to write something under them.&lt;/p&gt;&lt;p&gt;Data and analyses&lt;/p&gt;&lt;ul&gt;&lt;li&gt;are the statistically significant differences clinically significant?&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Discussion&lt;/p&gt;&lt;ul&gt;&lt;li&gt;quality of the evidence - Holger to complete as agreed.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;differences between protocol and review. You could do with a comment in the discussion to say that you revised the protocol to include only double blind trials and discuss the implications of incorporating the evidence from single or non-blinded trails - e.g. how many were potentially eligible, would that impact on the review results?&lt;/p&gt;&lt;p&gt;-------------------------------------------------------------------------------&lt;/p&gt;&lt;p&gt;CJC Editing Sept 19th 2008&lt;/p&gt;&lt;p&gt;This looks a good protocol. I have removed a sentence about direction of effect as this is now out of date:&lt;/p&gt;&lt;p&gt;&amp;quot;The data will be entered in such a way that when analysing the MetaView graphs, the area to the left of the midline indicates a favourable outcome for beta-2 agonists.&amp;quot;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;The following comments have come back from Peer Review with regard to previous treatment and problematic classification of severity:&lt;/p&gt;&lt;p&gt;&amp;quot;The most important thing I think you can take note of is the time since last medication with beta agonists.&lt;br&gt;If it is more than 3 days then it is unlikely that any tolerance would account for any loss of effect.&lt;br&gt;May be useful to take a closer look at SABA and LABA use and the duration between the dose and the exercise.&amp;quot;&lt;br&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&amp;quot;Why are you going to change the classification of severity. I would not do that if I were you when not on inhaled steroids &amp;gt;50% is severe, 10-25 mild and 25-50 moderate?&amp;#160; When on steroids &amp;gt;30% is severe.&amp;quot;&lt;/p&gt;&lt;p&gt;Please could the authors respond to these comments, and add text under Contribution of Authors?&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-26 11:24:01 +0100" NOTES_MODIFIED_BY="Emma Welsh" REVIEW_NO="SAB-AST" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.3">
<COVER_SHEET MODIFIED="2013-09-26 11:27:08 +0100" MODIFIED_BY="Emma Welsh">
<TITLE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">Beta<SUB>2</SUB>-agonists for exercise-induced asthma</TITLE>
<CONTACT MODIFIED="2013-09-26 11:27:08 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="E6274AB982E26AA2013849DFB68C9785" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Matteo</FIRST_NAME><LAST_NAME>Bonini</LAST_NAME><EMAIL_1>matte.bonini@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health and Infectious Diseases</DEPARTMENT><ORGANISATION>"Sapienza" University</ORGANISATION><CITY>Rome</CITY><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+393926852127</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-09-26 11:27:08 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="E6274AB982E26AA2013849DFB68C9785" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Matteo</FIRST_NAME><LAST_NAME>Bonini</LAST_NAME><EMAIL_1>matte.bonini@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Public Health and Infectious Diseases</DEPARTMENT><ORGANISATION>"Sapienza" University</ORGANISATION><CITY>Rome</CITY><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+393926852127</PHONE_1></ADDRESS></PERSON><PERSON ID="226CFEBB82E26AA2002F1D7A7ED324A5" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Corrado</FIRST_NAME><LAST_NAME>Di Mambro</LAST_NAME><POSITION>MD, Researcher</POSITION><EMAIL_1>corrado.dimambro@libero.it</EMAIL_1><MOBILE_PHONE>00393473497930</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Medical and Surgical Pediatric Cardiology - UOC Arrhythmology</DEPARTMENT><ORGANISATION>Children's Hospital "Bambino Gesù"</ORGANISATION><CITY>Rome</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="12214" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Moises</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Calderon</LAST_NAME><SUFFIX>MD PhD</SUFFIX><POSITION>Senior Clinical Fellow</POSITION><EMAIL_1>m.calderon@imperial.ac.uk</EMAIL_1><MOBILE_PHONE>07812 567435</MOBILE_PHONE><ADDRESS><DEPARTMENT>Section of Allergy and Clinical Immunology</DEPARTMENT><ORGANISATION>National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital</ORGANISATION><CITY>London</CITY><ZIP>SW3 6LY</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7351 8024</PHONE_1></ADDRESS></PERSON><PERSON ID="226ECFE182E26AA2002F1D7A39B0FE1D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Enrico</FIRST_NAME><LAST_NAME>Compalati</LAST_NAME><EMAIL_1>enrico.compalati@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Allergy and Respiratory Diseases Clinic, Department of Internal Medicine (DIMI)</DEPARTMENT><ORGANISATION>University of Genoa</ORGANISATION><CITY>Genoa</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="18105" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Holger</FIRST_NAME><LAST_NAME>Schünemann</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor and Chair</POSITION><EMAIL_1>schuneh@mcmaster.ca</EMAIL_1><URL>http://www.fhs.mcmaster.ca/ceb/inside_intro.htm</URL><MOBILE_PHONE>+19055375599</MOBILE_PHONE><ADDRESS><DEPARTMENT>Departments of Clinical Epidemiology and Biostatistics and of Medicine</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1280 Main Street West</ADDRESS_1><CITY>Hamilton</CITY><ZIP>L8N 4K1</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 525 9140 Ext: 24931 (assistant)</PHONE_1></ADDRESS></PERSON><PERSON ID="8562" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stephen</FIRST_NAME><LAST_NAME>Durham</LAST_NAME><EMAIL_1>s.durham@imperial.ac.uk</EMAIL_1><MOBILE_PHONE>447872850369</MOBILE_PHONE><ADDRESS><DEPARTMENT>Section of Allergy and Clinical Immunology</DEPARTMENT><ORGANISATION>National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital</ORGANISATION><CITY>London</CITY><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7351 8992</PHONE_1><FAX_1>+ 44 20 7351 8949</FAX_1></ADDRESS></PERSON><PERSON ID="86115B6682E26AA2015C072974109FA6" ROLE="AUTHOR"><FIRST_NAME>Giorgio</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Canonica</LAST_NAME><EMAIL_1>canonica@unige.it</EMAIL_1><ADDRESS><DEPARTMENT>Allergy and Respiratory Diseases Clinic, Department of Internal Medicine (DIMI)</DEPARTMENT><ORGANISATION>University of Genoa</ORGANISATION><ADDRESS_1>Pad. Maragliano</ADDRESS_1><ADDRESS_2>L. go R. Benzi 10</ADDRESS_2><CITY>Genoa</CITY><ZIP>16132</ZIP><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-09-13 10:14:06 +0100" MODIFIED_BY="Matteo Bonini">
<UP_TO_DATE>
<DATE DAY="13" MONTH="9" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="8" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="9" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2013-08-21 09:58:42 +0100" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2012-10-24 13:06:10 +0100" MODIFIED_BY="Emma J Welsh"/>
<SOURCES_OF_SUPPORT MODIFIED="2012-05-30 13:21:06 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-05-30 13:21:06 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-05-30 13:21:06 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Research Council, Institute of Translational Pharmacology (IFT)</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-05-30 13:20:22 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-05-30 13:20:22 +0100" MODIFIED_BY="[Empty name]">
<NAME>Italian National Drug Agency (AIFA)</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-08-26 17:25:37 +0100" MODIFIED_BY="[Empty name]">
<NAME>21st Century Canada Research Chairs Programme; Government of Canada (Ottawa, Ontario)</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-09-13 11:42:05 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-09-11 10:42:34 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-09-10 10:20:25 +0100" MODIFIED_BY="[Empty name]">Asthma reliever inhalers (beta<SUB>2</SUB>-agonists) used for exercise-induced asthma and exercise-induced bronchoconstriction</TITLE>
<SUMMARY_BODY MODIFIED="2013-09-11 10:42:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>Physical exercise may trigger symptoms such as cough, chest tightness and shortness of breath in people with asthma that is not adequately treated (exercise-induced asthma). Sometimes people who do not have asthma still experience asthma-like symptoms during exercise; this is called <I>exercise-induced bronchoconstriction</I>. We looked at both types of people in this review. The treatments we were interested in are called <I>beta<SUB>2</SUB>-agonists</I>. These are drugs that are known to open up the airways (small tubes in the lungs), making it easier for people to breathe. Two kinds of beta<SUB>2</SUB>-agonists are available: short-acting (SABA, e.g. salbutamol and terbutaline) and long-acting (LABA, e.g. formoterol and salmeterol).</P>
<P>
<B>What evidence did we find?</B>
</P>
<P>We found 53 trials consisting of 1139 participants. Forty-eight studies used a cross-over design, which meant that each person in the trial received two or more treatments&#65293;one or more active treatments, the beta-agonist and a placebo in random order. The rest were parallel-group trials, meaning that people received either the active treatment or a placebo. Most of the studies addressed the effect of a giving a single beta<SUB>2</SUB>-agonist treatment before exercise and recorded the effect on lung function following exercise. Only eight focused on longer treatment&#65293;longer treatments would be needed to assess whether these treatments were harmful over the longer term.</P>
<P>
<B>Results</B>
</P>
<P>Studies in which people received a single administration of a beta-agonist showed that FEV<SUB>1</SUB> (a measure of lung function) fell significantly less for people taking SABA or LABA compared with placebo (mean difference (MD) -17.67%; 95% confidence interval (CI) -19.51% to -15.84%). Other lung function measures confirmed that beta<SUB>2</SUB>-agonists were more beneficial compared with placebo. No significant difference in the number of side effects was noted in people taking SABA or LABA compared with people taking placebo. However, it is unlikely that people would be prescribed an inhaler for a single treatment, so we must consider longer-term studies to get a true measure of the side effects that inhalers can cause.</P>
<P>We found that included longer-term studies showed that beta<SUB>2</SUB>-agonists were helpful in terms of lung function for the first dose of treatment. However, studies that provided longer-term treatment with SABA or LABA showed that over time, people built up a tolerance to the effects of treatments, and the beneficial effects lasted for shorter periods of time.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Overall, we believe that the evidence was of low to moderate quality.</P>
<P>
<B>Conclusions</B>
</P>
<P>This review shows that beta<SUB>2</SUB>-agonists&#65293;both SABA and LABA&#65293;when administered in a single dose, are effective and safe in preventing the symptoms of EIA. Longer-term administration of inhaled beta<SUB>2</SUB>-agonists induces tolerance and lacks sufficient safety data. It is important to note that taking LABA without background inhaled steroids is considered unsafe and is not currently recommended in most of the clinical guidelines for asthma. We recommend that more studies are needed to determine whether it is safe to administer inhaled beta<SUB>2</SUB>-agonists alone to people who experience asthma symptoms when exercising.</P>
<P>This review is current as of August 2013.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-09-13 09:27:13 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-09-10 10:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>It is well known that physical exercise can trigger asthma symptoms and can induce bronchial obstruction in people without clinical asthma. International guidelines on asthma management recommend the use of beta<SUB>2</SUB>-agonists at any stage of the disease. At present, however, no consensus has been reached about the efficacy and safety of beta<SUB>2</SUB>-agonists in the pretreatment of exercise-induced asthma and exercise-induced bronchoconstriction. For the purpose of the present review, both of these conditions are referred to by the acronymous EIA, independently from the presence of an underlying chronic clinical disease.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-09-10 10:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of inhaled short- and long-acting beta<SUB>2</SUB>-agonists, compared with placebo, in the pretreatment of children and adults with exercise-induced asthma (or exercise-induced bronchoconstriction).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-09-10 10:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were identified by electronic searching of the Cochrane Airways Group Specialised Register of Trials and by handsearching of respiratory journals and meetings. Searches are current as of August 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-09-10 10:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised, double-blind, placebo-controlled trials of any study design, published in full text, that assessed the effects of inhaled beta<SUB>2</SUB>-agonists on EIA in adults and children. We excluded studies that did not clearly state diagnostic criteria for EIA.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-09-10 10:20:13 +0100" MODIFIED_BY="[Empty name]">
<P>We used standard methodological procedures as expected by The Cochrane Collaboration.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-10 10:20:13 +0100" MODIFIED_BY="[Empty name]">
<P>We included 53 trials consisting of 1139 participants. Forty-eight studies used a cross-over design, and five were performed in accordance with a parallel-group design. Forty-five studies addressed the effect of a single beta<SUB>2</SUB>-agonist administration, and eight focused on long-term treatment. We addressed these two different intervention regimens as different comparisons.</P>
<P>Among primary outcomes for short-term administration, data on maximum fall in forced expiratory volume in 1 second (FEV<SUB>1</SUB>) showed a significant protective effect for both short-acting beta-agonists (SABA) and long-acting beta-agonists (LABA) compared with placebo, with a mean difference of -17.67% (95% confidence interval (CI) -19.51% to -15.84%, P = 0.00001, 799 participants from 72 studies). The subgroup analysis of studies performed in adults compared with those performed in children showed high heterogeneity confined to children, despite the comparable mean bronchoprotective effect.</P>
<P>Secondary outcomes on other pulmonary function parameters confirmed a more positive and protective effect of beta<SUB>2</SUB>-agonists on EIA compared with placebo. Occurrence of side effects was not significantly different between beta<SUB>2</SUB>-agonists and placebo.</P>
<P>Overall evaluation of the included long-term studies suggests a beta<SUB>2</SUB>-agonist bronchoprotective effect for the first dose of treatment. However, long-term use of both SABA and LABA induced the onset of tolerance and decreased the duration of drug effect, even after a short treatment period.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-09-13 09:27:13 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence of low to moderate quality shows that beta<SUB>2</SUB>-agonists, both SABA and LABA, when administered in a single dose, are effective and safe in preventing EIA.</P>
<P>Long-term regular administration of inhaled beta<SUB>2</SUB>-agonists induces tolerance and lacks sufficient safety data. This finding appears to be of particular clinical relevance in view of the potential for prolonged regular use of beta<SUB>2</SUB>-agonists as monotherapy in the pretreatment of EIA, despite the warnings of drug agencies (FDA, EMA) regarding LABA.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-09-13 11:42:05 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<P>Exercise-induced asthma (EIA) is the term commonly used to describe the transient increase in airway resistance that follows vigorous exercise (<LINK REF="REF-Anderson-1997" TYPE="REFERENCE">Anderson 1997</LINK>). However a recent position paper suggested a preferred definition of exercise-induced bronchoconstriction (EIB) with or without asthma, depending on the presence of underlying clinical asthma (<LINK REF="REF-Weiler-2010" TYPE="REFERENCE">Weiler 2010</LINK>). Despite this new nomenclature, most of the relevant studies were published before these terms were proposed and often do not provide sufficient information to distinguish between the two conditions. We therefore decided to adopt the term <I>exercise-induced asthma </I>(EIA) throughout the review for the sake of better consistency and clarity.</P>
<P>The prevalence of EIA ranges from 5% to 20% in the general population, to even 100% in people with uncontrolled asthma. This huge variability depends not only on the criteria used for diagnosis, but also on the population samples studied. EIA is, in fact, reported to be particularly frequent in children (<LINK REF="REF-Randolph-2008" TYPE="REFERENCE">Randolph 2008</LINK>), in people with rhinitis (<LINK REF="REF-Brozek-2010" TYPE="REFERENCE">Brozek 2010</LINK>) and in athletes, with percentages varying according to different sport disciplines (<LINK REF="REF-Carlsen-2008" TYPE="REFERENCE">Carlsen 2008</LINK>).</P>
<P>The diagnosis of EIA is usually made by exercise testing, either in the field or in the laboratory; this second option allows more standardised procedures (<LINK REF="REF-Rundell-2000" TYPE="REFERENCE">Rundell 2000</LINK>). An individual's response to exercise is generally expressed by the maximal percent fall in forced expiratory volume in one second (FEV<SUB>1</SUB>). The maximal percent fall is considered an expression of severity of EIA and is calculated by subtracting the lowest FEV<SUB>1</SUB> value from the pre-exercise value and expressing it as a percentage of the pre-exercise value. Both European Respiratory Society (ERS) and American Respiratory Society (ATS) recommendations set a fall threshold of 10% as a diagnostic criterion for EIA and a value greater than 30% as a marker of severe bronchial hyperreactivity, particularly if the person is treated with inhaled steroids (<LINK REF="REF-Sterk-1993" TYPE="REFERENCE">Sterk 1993</LINK>). Other indirect tests such as eucapnic voluntary hyperpnoea (EVH) and mannitol challenge are usually considered surrogate tests for the diagnosis of EIA because they induce similar pathophysiological changes in the airways (<LINK REF="REF-Anderson-2003" TYPE="REFERENCE">Anderson 2003</LINK>).</P>
<P>The main principle of treating EIA involves reversing the bronchial obstruction induced by exercise with bronchodilators or preventing it with daily use of either controller drugs in people with asthma (<LINK REF="REF-Koh-2007" TYPE="REFERENCE">Koh 2007</LINK>; <LINK REF="REF-Bateman-2008" TYPE="REFERENCE">Bateman 2008</LINK>) or drugs that inhibit symptoms and improve pulmonary function immediately before exercise. Pretreatment before exercise includes mast cell stabilisers (<LINK REF="REF-Kelly-2000" TYPE="REFERENCE">Kelly 2000</LINK>; <LINK REF="REF-Spooner-2003" TYPE="REFERENCE">Spooner 2003</LINK>), leukotriene antagonists (<LINK REF="REF-Peroni-2011" TYPE="REFERENCE">Peroni 2011</LINK>), short-acting beta<SUB>2</SUB>-agonists (SABA) and, more recently, long-acting beta<SUB>2</SUB>-agonists (LABA), especially in endurance athletes (<LINK REF="REF-Shapiro-2002" TYPE="REFERENCE">Shapiro 2002</LINK>).</P>
<P>Both SABA and LABA, administered at standard doses immediately before exercise, have been shown to reduce the fall in FEV<SUB>1</SUB> by 70% to 80% in most people with EIA (<LINK REF="REF-Anderson-2006" TYPE="REFERENCE">Anderson 2006</LINK>). The mechanism of this protection is believed to be related to beta<SUB>2</SUB>-receptor&#65293;induced relaxation of bronchial smooth muscle, which opposes the contractile effects of the various mediators of bronchoconstriction. Protection from EIA is also afforded by beta<SUB>2</SUB>-receptor&#65293;induced inhibition of mediator release from mast cells.</P>
<P>At present, however, no consensus has been reached about the efficacy and safety of beta<SUB>2</SUB>-agonists in the pretreatment of EIA. The role of these molecules in preventing EIA was questioned when patients taking beta<SUB>2</SUB>-agonists daily reported breakthrough EIA within a dosing period. Several negative findings have been reported regarding the efficacy of daily treatment with beta<SUB>2</SUB>-agonists in controlling the severity of bronchoconstriction and recovery from EIA. In fact, in a significant minority of people, EIA is not prevented by beta<SUB>2</SUB>-agonists administered at the recommended dose (<LINK REF="STD-Anderson-1991" TYPE="STUDY">Anderson 1991</LINK>; <LINK REF="STD-Weiler-2005" TYPE="STUDY">Weiler 2005</LINK>). Furthermore, it has been reported how daily treatment with beta<SUB>2</SUB>-agonists can enhance the severity of EIA (<LINK REF="STD-Hancox-2002" TYPE="STUDY">Hancox 2002</LINK>) and decrease the duration of their protective effect, especially for LABA (<LINK REF="STD-Ramage-1994" TYPE="STUDY">Ramage 1994</LINK>). In addition, recovery from EIA after a standard dose of beta<SUB>2</SUB>-agonists is slower, and additional doses are often required when SABA or LABA are used daily (<LINK REF="STD-Hancox-2002" TYPE="STUDY">Hancox 2002</LINK>).</P>
<P>On the other hand, the reported association between administration of LABA, not in combination with inhaled corticosteroids, and increased numbers of severe cardiovascular side effects and sudden deaths (<LINK REF="REF-Nelson-2006" TYPE="REFERENCE">Nelson 2006</LINK>; <LINK REF="REF-Salpeter-2010" TYPE="REFERENCE">Salpeter 2010</LINK>) induced the U.S. Food and Drug Administration (FDA) to set a "black box" on these drugs, highlighting the urgent need to promote clear studies of pharmacovigilance (<LINK REF="REF-Martinez-2005" TYPE="REFERENCE">Martinez 2005</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-09-10 10:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of inhaled short- and long-acting beta<SUB>2</SUB>-agonists, compared with placebo, in the pretreatment of children and adults with exercise-induced asthma (or exercise-induced bronchoconstriction).</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-09-13 10:58:19 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-09-10 10:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>We included double-blind, randomised controlled trials (RCTs) of any study design. Data published in abstract form only were excluded. At least one primary outcome of this systematic review had to be reported for a study to be considered eligible.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-09-10 10:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>We included children and adults (aged 18 years or older) with a clear history of exercise-induced asthma and/or a positive response to a standardised exercise challenge, defined according to ERS and ATS guidelines as a fall in FEV<SUB>1</SUB> &#8805; 10%. Studies that did not clearly state criteria for EIA diagnosis were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-09-10 10:24:05 +0100" MODIFIED_BY="[Empty name]">
<P>Eligible interventions included inhaled beta<SUB>2</SUB>-agonists administered, at any dose, as short-term or long-term prophylactic treatment before participants underwent a standardised exercise challenge. SABA and LABA had to be administered within a time period before exercise challenge that did not exceed their pharmacological half-life (arbitrarily set at 1 hour for SABA, and at 12 hours for LABA). For studies with more than one drug arm, only the comparison with placebo was considered. Studies with more than one drug arm that evaluated different beta<SUB>2</SUB>-agonist molecules were considered as separate trials.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma J Welsh">
<UL>
<LI>Mean max % fall in FEV<SUB>1</SUB> (100 × (baseline pre-exercise value &#65293; lowest postexercise value)/baseline pre-exercise value) in people treated with a beta<SUB>2</SUB>-agonist versus mean max % fall in FEV<SUB>1</SUB> in people treated with placebo</LI>
<LI>Mean % protection afforded by beta<SUB>2</SUB>-agonists (% protection = 100 × (max % fall FEV<SUB>1</SUB> placebo &#65293; max % fall FEV<SUB>1</SUB> beta<SUB>2</SUB>-agonist)/max % fall FEV<SUB>1</SUB> placebo)</LI>
<LI>Mean area under the curve (AUC) of time course changes in FEV<SUB>1</SUB> after exercise in people treated with a beta<SUB>2</SUB>-agonist versus mean AUC of time course changes in FEV<SUB>1</SUB> after exercise in people treated with placebo</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-09-11 10:45:25 +0100" MODIFIED_BY="Emma J Welsh">
<UL>
<LI>Number of people with a max % fall in FEV<SUB>1</SUB> &lt; 10% (complete protection), &lt; 15% and &lt; 20%</LI>
<LI>Changes from baseline in symptom and sign scores</LI>
<LI>Mean max % fall in other pulmonary function parameters (peak expiratory flow (PEF), forced expiratory flow 25&#8211;75% (FEF), maximal expiratory flow at 50% (MEF) etc.)</LI>
<LI>Onset of tolerance (considered for long-term administration studies and in relation to concomitant treatment with inhaled corticosteroids)</LI>
<LI>Outcomes of physical performance</LI>
<LI>Side/adverse effects</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-09-10 10:24:23 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2013-09-10 10:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were identified using the Cochrane Airways Group Specialised Register of Trials, which is derived from systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, as well as handsearching of respiratory journals and meeting abstracts (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for additional details). The Register was searched using the terms in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> from the date of inception up to August 2013. No restriction was placed on language of publication.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-09-10 10:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>We screened reference lists of included studies, recent reviews and textbooks for relevant citations. We contacted authors of unpublished or 'in-progress' studies and selected manufacturers of beta<SUB>2</SUB>-agonists to identify additional studies. Furthermore, we searched national and international clinical trial websites (www.clinicalstudyresults.org; www.clinicaltrials.gov; www.fda.gov) for additional trials. Personal contacts with colleagues, collaborators and other trialists working in the field of asthma were at last made to identify further potentially relevant studies. No language or publication restrictions were applied to these searches.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-09-13 10:58:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-09-10 10:24:23 +0100" MODIFIED_BY="Emma J Welsh">
<P>Titles and abstracts of papers identified in the search were reviewed independently by two review authors (MB, CDM), and articles that appeared to fulfil the inclusion criteria were retrieved. From the full text of these papers, two review authors (MB, EC) independently established whether studies met the inclusion criteria. Studies that did not fulfil all of the inclusion criteria were excluded, and reasons for exclusion were reported. The percentage of agreement was recorded, and any disagreement was solved by consensus. If the two review authors did not reach an agreement, a third review author adjudication (MC) was used to resolve disagreements. In case of further uncertainty, study authors were contacted. Review authors were not blinded to authors, journals, results, etc.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-09-10 10:24:32 +0100" MODIFIED_BY="Emma J Welsh">
<P>Data extraction was performed independently by two review authors (MB, EC). Full texts were screened, and bibliographic details, as well as data regarding study design, participants, disease severity, intervention and outcomes, were recorded in predefined forms and entered into <LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK>. All data, numerical calculations and graphic extrapolations were independently confirmed. We did not deal with missing data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-09-10 10:24:32 +0100" MODIFIED_BY="Emma J Welsh">
<P>We assessed the risk of bias in included studies as high, low or unclear using The Cochrane Collaboration&#8217;s 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and the following headings.</P>
<UL>
<LI>Random sequence generation (selection bias).</LI>
<LI>Allocation concealment (selection bias).</LI>
<LI>Blinding of participants and personnel (performance bias).</LI>
<LI>Blinding of outcome assessment (detection bias).</LI>
<LI>Incomplete outcome data (attrition bias).</LI>
<LI>Selective reporting (reporting bias).</LI>
<LI>Other bias.</LI>
</UL>
<P>Discussion or third party adjudication was used to resolve disagreements when necessary.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-09-10 10:24:45 +0100" MODIFIED_BY="Emma J Welsh">
<P>Treatment effects were measured as mean differences (MDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-09-13 10:58:19 +0100" MODIFIED_BY="Emma J Welsh">
<P>Many included studies were of cross-over design, but many did not report the results of paired <I>t</I>-tests for continuous outcomes in this review. Some studies provided raw data that allowed a calculation of the correlation between treatment periods on beta<SUB>2</SUB>-agonists and placebo on maximum percentage fall in FEV<SUB>1</SUB> (see <A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=345500110715515504&amp;versionPK1=z1305230750042343348840653506005&amp;versionPK2=z1306101502104628536274520867778#APP-03">Appendix 3</A> for the raw data). We used the average correlation from these studies (0.36) to impute an appropriate standard error for within--participant differences (as described in Section 16.4.6.4 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We carried out a meta-analysis of the mean differences and their standard errors for this outcome using the Generic Inverse Variance method in RevMan 5.2.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-09-13 09:34:50 +0100" MODIFIED_BY="Emma J Welsh">
<P>Missing data on the correlation between results from participants in the cross-over studies were imputed using the average correlation from studies that reported appropriate raw data. Cross-over studies provided information on the number of participants in each arm who experienced a given drop in FEV<SUB>1</SUB>, but not the number of participants whose FEV<SUB>1</SUB> dropped on both interventions (active treatment and placebo). We were able to calculate marginal odds ratios for these outcomes but could not adjust the standard error to take advantage of the cross-over design.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-09-10 10:24:57 +0100" MODIFIED_BY="Emma J Welsh">
<P>To assess the level of heterogeneity, the Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic were used. In establishing the level of heterogeneity, we considered the following rules for interpretation of results (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<UL>
<LI>0 to 30% as low heterogeneity.</LI>
<LI>30% to 60% as moderate heterogeneity worthy of investigation.</LI>
<LI>60% to 90% as severe heterogeneity worthy of understanding.</LI>
<LI>90% to 100% as allowing aggregation only with major caution.</LI>
</UL>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-10-25 11:59:05 +0100" MODIFIED_BY="Emma J Welsh">
<P>Funnel plots were used to investigate the possibility of publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-09-10 10:24:57 +0100" MODIFIED_BY="Emma J Welsh">
<P>Data were entered into <LINK REF="REF-RevMan-5.2" TYPE="REFERENCE">RevMan 5.2</LINK>. For continuous measures, individual and pooled statistics were reported as mean difference (MD) of treatment effect with 95% confidence intervals (95% CIs) using the fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-09-10 10:24:57 +0100" MODIFIED_BY="Emma J Welsh">
<P>Heterogeneity worthy of investigation was examined using the following predefined subgroup analyses.<BR/>
</P>
<UL>
<LI>Type of beta<SUB>2</SUB>-agonist (SABA vs LABA).</LI>
<LI>Molecule of beta<SUB>2</SUB>-agonist (formoterol vs salmeterol).</LI>
<LI>Age of participants (children vs adults).</LI>
<LI>Concomitant treatments (beta<SUB>2</SUB>-agonist monotherapy vs concomitant inhaled corticosteroid treatment).</LI>
</UL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-09-13 11:42:05 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-09-13 11:42:05 +0100" MODIFIED_BY="[Empty name]">
<P>See:<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2013-09-13 11:42:05 +0100" MODIFIED_BY="[Empty name]">
<P>The search identified 2400 articles, and from these, 289 papers were independently selected by two review authors (k = 0.95) as being of potential interest on the basis of titles and abstracts. After non- interventional studies (n = 27) and articles published as abstract only (n = 52) were removed, we retrieved the remaining articles in full text and from these identified 51 studies for inclusion in the meta-analysis (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Two further articles were added through the cross-checking reference process. We excluded 158 studies with reasons provided in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>; one study is listed under <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> to be considered for inclusion when the review is next updated.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-09-10 10:25:16 +0100" MODIFIED_BY="[Empty name]">
<P>Full details can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables.</P>
<SUBSECTION>
<HEADING LEVEL="6">Study features and design</HEADING>
<P>All 53 included studies were double-blind, placebo-controlled, randomised trials. Forty-eight studies used a cross-over design, and five were performed in a parallel -group design. In the cross-over studies, washout periods ranged between 1 and 21 days. Nine studies did not mention duration of washout, and in two papers, no washout was performed. The exercise challenges involved treadmill (n = 35), cycle ergometer (n = 13) and free running (n = 5). All challenges were standardised and met recommended testing criteria. Trials were conducted between 1976 and 2010 in 12 different countries: Europe (N = 27), United States/Canada (N = 22) and Australia (N = 4). All articles except one (in Spanish) were written in English.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Population</HEADING>
<P>Collectively, included studies reported data on 1139 participants. Population sample size ranged from 10 to 161 participants (55 in a single drug arm of parallel-group studies and 46 in cross-over studies&#65293;the highest number of enrolled participants). Studies included children and adults (age range 4 to 64 years). A total of 20 studies were performed in children, 18 in adults and 12 in both children and adults. Three papers did not provide sufficient information to allocate people according to age. Nine studies provided only information about ethnicity, and Caucasian was the most represented race.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Interventions</HEADING>
<P>Of 53 included studies, 45 addressed beta<SUB>2</SUB>-agonist short-term administration, and eight focused on long-term treatment. Articles were grouped on the basis of the type of beta<SUB>2</SUB>-agonist drugs evaluated: SABA (N = 42; short-term administration n = 40 and long-term administration n = 2) and LABA (N = 27, short-term administration n = 21 and long-term administration n = 6). Among different beta<SUB>2</SUB>-agonists, salbutamol (n = 27), salmeterol (n = 14), formoterol (n = 13) and terbutaline (n = 6) represented the molecules most frequently investigated. Beta<SUB>2</SUB>-agonists were delivered through different devices (nebulisers, metered-dose inhalers (MDIs) and inhalers).</P>
<P>Details on dosage and types of beta<SUB>2</SUB>-agonist administration are summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, together with timing in relation to exercise.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcomes</HEADING>
<P>As per inclusion criteria, all 53 included studies reported data on at least one primary outcome of this review.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<P>An assessment of the risk of bias is presented in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables and is summarised in a risk of bias figure (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2013-09-10 10:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>Most of the included studies were judged at unclear risk for selection bias. Lack of information provided on random sequence generation and on allocation concealment may be explained by the high number of papers (40/53) conducted before 2000, when reporting of these risk of bias criteria was less common.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-09-10 10:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>Risks of performance and detection bias were minimised by the narrow inclusion criteria adopted, which allow inclusion in the systematic review of only randomised, at least double-blind, placebo-controlled trials.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-09-10 10:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>Three drug arms ( <LINK REF="STD-Konig-1984-Fen-0.4" TYPE="STUDY">Konig 1984 Fen 0.4</LINK>; <LINK REF="STD-Konig-1984-Fen-0.8" TYPE="STUDY">Konig 1984 Fen 0.8</LINK>; <LINK REF="STD-Boulet-1989-Salb" TYPE="STUDY">Boulet 1989 Salb</LINK>) reported incomplete data on outcomes as specified in this systematic review and were therefore assigned a high risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-09-10 10:25:26 +0100" MODIFIED_BY="[Empty name]">
<P>All studies except one (<LINK REF="STD-Ferrari-2000-Form-12" TYPE="STUDY">Ferrari 2000 Form 12</LINK>) were rated as having unclear risk for reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<P>The possibility of publication bias was investigated in the funnel plot shown in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. The presence of other potential sources of bias was rated as unclear risk because of the scarce information provided.</P>
<P>Several papers reported data derived from industry-funded studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-09-13 10:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Effects of intervention were separately assessed for short-term (single administration) and long-term beta<SUB>2</SUB>-agonist administration.</P>
<SUBSECTION>
<HEADING LEVEL="3">Short-term administration</HEADING>
<P>The 45 studies evaluating short-term beta<SUB>2</SUB>-agonist administration included 77 arms of active treatment (49 SABA and 28 LABA) in comparison with placebo.</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<P>Data on max % fall in FEV<SUB>1</SUB> were provided by 77 arms. Effects of SABA short-term administration were evaluated beyond the pharmacological half-life (1 hour) in five studies, which were therefore excluded. Analysis of the remaining 72 arms, including 799 participants (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), showed a significant protective effect of beta<SUB>2</SUB>-agonists compared with placebo (MD -17.67%, 95% CI -19.51% to -15.84%; P = 0.00001). In particular, 58 study arms favoured the active treatment, and 14 trial arms reported no significant difference. Heterogeneity was, however, high (I<SUP>2</SUP> = 71%).</P>
<P>Mean % protection was 66% (range 29% to 91%). In seven studies, beta<SUB>2</SUB>-agonist administration not only completely protected participants from EIA but also induced a bronchodilator effect compared with baseline values. In only one case (<LINK REF="STD-Bronski-1995-Salb-Pwd" TYPE="STUDY">Bronski 1995 Salb Pwd</LINK>), placebo offered greater protection compared with the active treatment.</P>
<P>Seventeen studies evaluating LABA short-term administration at different time points showed an FEV<SUB>1</SUB> % fall AUC that favoured the active treatment. Different study designs prevented merging of the data in a unique comprehensive analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<P>Secondary outcomes on pulmonary function parameters confirmed a positive protective effect of beta<SUB>2</SUB>-agonists on EIA compared with placebo. Complete protection from EIA as assessed by numbers of participants with an FEV<SUB>1</SUB> % fall &lt; 10% was evaluated in 19 studies (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). A significant difference was noted in the number of participants completely protected (OR 0.08, 95% CI 0.06 to 0.13; P = 0.00001). Similar results were obtained for thresholds of FEV<SUB>1</SUB> fall set at 15% (OR 0.06, 95% CI 0.03 to 0.15) and 20% (OR 0.09, 95% CI 0.06 to 0.14) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Max PEF and FEF25-75 % fall were assessed, respectively, in 14 and in 8 studies (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). However, statistical analysis for these two outcomes was based on a limited number of trials because dispersion data were lacking in most of the studies considered. Only three arms (<LINK REF="STD-Vasquez-1984-Salb-400" TYPE="STUDY">Vasquez 1984 Salb 400</LINK>; <LINK REF="STD-Carlsen-1995-Salm-25" TYPE="STUDY">Carlsen 1995 Salm 25</LINK>; <LINK REF="STD-Carlsen-1995-Salm-50" TYPE="STUDY">Carlsen 1995 Salm 50</LINK>) reported data on max MEF25-50 % fall. No study provided information on changes in symptoms and sign scores and effects on physical performance.</P>
<P>As far as they concern secondary outcomes related to safety, side effects were assessed in 55 trials (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Among these, 42 arms reported no adverse event for either active or placebo treatment. Analysis of the remaining 13 trials showed no significant difference between beta<SUB>2</SUB>-agonists and placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>The high heterogeneity (I<SUP>2 </SUP>= 71%) found for the primary outcome max FEV<SUB>1</SUB> % fall was investigated through the preplanned subgroup analysis.</P>
<P>We performed a subgroup analysis according to types of beta<SUB>2</SUB>-agonists (SABA vs LABA; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). Although subgroup analysis confirmed a significant bronchoprotective effect against EIA for both classes compared with placebo, it was not able to explain the marked heterogeneity observed in the entire population sample: SABA (I<SUP>2 </SUP>= 71%) and LABA (I<SUP>2 </SUP>= 67%). Accordingly, non-significant differences emerged from the analysis of the different beta<SUB>2</SUB>-agonist molecules administered (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). This evaluation was plotted only for the comparison between formoterol and salmeterol, because the number of studies evaluating different SABA molecules, apart from salbutamol, appeared to be too small for a reliable investigation. It is interesting to note that analysis of studies performed only in adults (n = 19) compared with those performed only in children (n = 32) showed that high heterogeneity was largely confined to studies in children (I<SUP>2 </SUP>= 11% and 80%, respectively), despite the comparable mean bronchoprotective effect (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>). Furthermore all studies that failed to show a positive protective effect against EIA of beta<SUB>2</SUB>-agonists compared with placebo dealt with the paediatric population.</P>
<P>The different study designs used and the limited information provided prevented assessment of the potential role of concomitant treatment with inhaled corticosteroids.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Long-term administration</HEADING>
<P>Long-term beta<SUB>2</SUB>-agonist administration was addressed in only eight papers. Five trials were performed with a cross-over design in a total of 64 people (50 adults and 14 children). Three studies adopted a parallel-group design and included 69 people (49 adults and 20 children) in the active arms and 73 (53 adults and 20 children) placebo controls. Treatment periods range from 7 to 29 days. Effects of SABA were evaluated in two protocols, and LABA administration was assessed in six studies. The limited number of trials, the small population samples and the different study designs and drugs tested allow only a descriptive approach and prevent plotting of data in a meta-analysis.</P>
<P>Garcia and coauthors (<LINK REF="STD-Garcia-2001-Form-12" TYPE="STUDY">Garcia 2001 Form 12</LINK>) evaluated the effects of 28-day formoterol administration in a parallel-group design (10 people in the beta<SUB>2</SUB>-agonist arm and 9 people in the placebo arm). The protective effect of salmeterol 12 mcg twice daily was assessed on the 1st, 14th and 28th study days, and results were not significantly greater than those provided by placebo at any time point. Furthermore, tachyphylaxis to the beta<SUB>2</SUB>-agonist effect was developed already after two weeks of treatment, although it was not progressive.</P>
<P>Hancox (<LINK REF="STD-Hancox-2002" TYPE="STUDY">Hancox 2002</LINK>) studied the effect of 200 mcg once daily of salbutamol in eight adults treated for seven days in a cross-over study. Results showed not only an increased max FEV<SUB>1</SUB> % fall after the exercise challenge, but also a sub-optimal bronchodilator response to further beta<SUB>2</SUB>-agonist administration at the end of the treatment period in the active group.</P>
<P>Ten adults who inhaled 200 mcg of salbutamol or placebo four times a day for seven days were studied by Inman and O'Byrne (<LINK REF="STD-Inman-1996" TYPE="STUDY">Inman 1996</LINK>) in a cross-over study. One week of regular inhaled salbutamol resulted in worsening of EIA.</P>
<P>A cross-over design was also adopted by Nelson (<LINK REF="STD-Nelson-1998" TYPE="STUDY">Nelson 1998</LINK>) in 20 adults treated for a month with inhaled salmeterol 42 mcg twice a day. Significant beta<SUB>2</SUB>-agonist protection against EIA was maintained for the entire study period. However, the length of time that the drug remained active after a single dose significantly decreased. Furthermore, the number of participants for whom salmeterol did not offer complete protection against EIA (FEV<SUB>1</SUB> % fall &lt; 10%) increased from two on study day 1 to 11 on day 29 (P = 0.02)</P>
<P>Ramage and coworkers (<LINK REF="STD-Ramage-1994" TYPE="STUDY">Ramage 1994</LINK>) studied 12 adults treated with inhaled salmeterol 50 mcg twice daily for 4 weeks in a cross-over manner. The significant protection provided by the first dose of salmeterol against EIA at 6 and 12 hours was no longer present at the end of the treatment period.</P>
<P>Fourteen children were studied by Simons (<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>) in a four-week cross-over study. The first dose of salmeterol had an excellent bronchoprotective effect against EIA at 1 and 9 hours. At the end of the study, however, the bronchoprotective effect was significantly greater than that of placebo only at 1 hour.</P>
<P>A parallel-group study design was adopted by Stelmach (<LINK REF="STD-Stelmach-2008" TYPE="STUDY">Stelmach 2008</LINK>) to compare the effects of formoterol 9 mcg daily against placebo in two arms, each consisting of 20 children. Both groups of people were receiving concomitant inhaled corticosteroid (ICS) treatment with budesonide 100 mcg daily. At the end of the four-week treatment period, bronchoconstriction induced by a standardised treadmill exercise challenge was significantly diminished in the active group compared with the placebo group,</P>
<P>At last, Storms (<LINK REF="STD-Storms-2004" TYPE="STUDY">Storms 2004</LINK>) in a four-week parallel-group study compared the protective effect of salmeterol 50 mcg twice daily against placebo. All enrolled people were receiving concomitant 100 mcg twice-daily fluticasone treatment. The protective effect against EIA was evaluated at weeks 1 and 4 and was not different between the two groups.</P>
<P>Only one study (<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>) took into consideration safety aspects of long-term beta<SUB>2</SUB>-adrenergic administration. Reported side effects were minor, were poorly related to study drug and anyway were not different between active and placebo groups.</P>
<P>The overall evaluation of presented studies seems to confirm the beta<SUB>2</SUB>-agonist bronchoprotective effect for the first dose of treatment. However, long-term use of both SABA and LABA induced the development of tolerance and decreased the duration of drug effect, even after short-term treatment. The few available data on concomitant therapy with inhaled corticosteroids did not allow a firm statement about their potential influence on the response to beta<SUB>2</SUB>-agonists.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-09-13 10:55:36 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-09-13 10:55:36 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence emerging from the meta-analysis of 45 short-term (single administration) studies shows that both short- and long-acting beta<SUB>2</SUB>-agonists administered as preventive treatment (within the time-effect period set at one hour for SABA and at 12 hours for LABA) prevent exercise-induced asthma, as shown by the primary outcomes related to the FEV<SUB>1</SUB> fall. This pharmacological effect appears to be clinically relevant and independent of the exercise challenge adopted (treadmill, cycle ergometer, free run). The assessment of secondary outcomes considered shows that the beta<SUB>2</SUB>-agonist preventive effect is also documented by the number of participants protected (complete protection detectable in 68% of participants) and by other pulmonary function variables (PEF, FEF 25%-75%, MEF 50%) and beta<SUB>2</SUB>-agonists did not cause side effects.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-09-10 10:26:16 +0100" MODIFIED_BY="[Empty name]">
<P>The choice to include only double-blind randomised trials may influence the completeness of the present review but was thought to reinforce the quality of evidence.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-09-10 10:26:24 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of the evidence gathered for the primary outcome of maximal percentage fall in FEV<SUB>1</SUB> and the number of participants with a fall in FEV<SUB>1</SUB> greater than 10% were moderate owing to some concerns about risk of bias (unclear allocation concealment) and detected and not completely explained inconsistency and indirectness (relation of FEV<SUB>1</SUB> to patient-important outcomes). The same concerns apply to all other outcomes reported in the 'Summary of findings' (SoF) Table. In addition, for the outcomes of maximal percentage fall in PEF, maximal percentage fall in FEF 25-75 and side effects, the quality was lowered further by the small numbers of participants for these outcomes and the resulting wide confidence intervals. It can be argued that this review started with the premise that pulmonary function measures are patient-important outcomes and that, therefore, the quality of evidence should not be lowered for indirectness because the primary outcome was measured in these studies. However, despite these considerations, the meaning of the degree of change in FEV<SUB>1</SUB> for patients remains unclear (as well as how it relates to their well-being). Furthermore, (small) concerns about inconsistency and risk of bias justify an overall rating of quality as presented in the SoF Table. Further research should focus on patient-important outcomes and the imprecision that was encountered for many of the secondary outcomes.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-09-10 10:26:24 +0100" MODIFIED_BY="[Empty name]">
<P>The review process was protected from bias by adherence to a prepublished protocol. We tried to prevent bias in our search process by using comprehensive search terms and by asking study authors to identify other published and non-published studies. We minimised bias by assessing studies independently and resolving differences of opinion by discussion. Extraction of data and assessment of risk of bias were performed in duplicate as well. We performed only subgroup analyses that were specified a priori in the protocol.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-09-10 10:26:24 +0100" MODIFIED_BY="[Empty name]">
<P>Our results appear to be in agreement with those obtained by Spooner and coworkers in a Cochrane review and meta-analysis published in 2009 and focused on quantitative comparison of the effects of inhaling mast cell stabilisers (nedocromil sodium or sodium cromoglycate) versus beta<SUB>2</SUB>-agonists (<LINK REF="REF-Spooner-2003" TYPE="REFERENCE">Spooner 2003</LINK>). However, the review authors confined their review to single-dose administration and to short-acting beta<SUB>2</SUB>-agonist molecules. As far as we know, no recent systematic reviews have specifically addressed the efficacy and safety of both SABA and LABA, in short-term and long-term administration, for prevention of exercise-induced asthma.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-09-10 10:26:45 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-09-10 10:26:34 +0100" MODIFIED_BY="[Empty name]">
<P>Beta<SUB>2</SUB>-agonists, both SABA and LABA, when administered in a single dose before exercise is undertaken, are effective and safe in preventing exercise-induced asthma. Long-term regular administration of inhaled beta<SUB>2</SUB>-agonists induces tolerance and lacks sufficient safety data. This finding appears to be of particular clinical relevance in view of the potential for regular prolonged use of beta<SUB>2</SUB>-agonists as monotherapy in the pretreatment of EIA, despite the drug agencies' warning on LABA.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-09-10 10:26:45 +0100" MODIFIED_BY="[Empty name]">
<P>Further research should focus on the following.</P>
<UL>
<LI>Distinguishing between EIA (exercise-induced bronchoconstriction with asthma) from exercise-induced bronchoconstriction without coexisting asthma as different phenotypes, in relation to clinical features, pathophysiological mechanisms, patterns of inflammation and response to treatments, including beta<SUB>2</SUB>-agonists.</LI>
<LI>Evaluating the potential influence of different genotypes (i.e. beta<SUB>2</SUB>-adrenergic receptor polymorphisms) and phenotypes on exercise-induced bronchoconstriction severity and response to beta<SUB>2</SUB>-adrenergic treatment.</LI>
<LI>Better defining response to therapy, not only according to functional parameters, but also on the basis of clinical endpoints (symptoms, disease control and patient-related outcomes), markers of inflammation and omic approaches.</LI>
<LI>Defining standardised operational procedures (i.e. exercise challenges, diagnostic thresholds, outcome measures) for clinical trials in EIA.</LI>
<LI>Performing additional independent trials to address long-term beta<SUB>2</SUB>-agonist administration in EIA, with special reference to concomitant inhaled corticosteroid treatment, to better assess the risk/benefit ratio between drug efficacy and potential cardiovascular side effects and onset of tolerance.</LI>
<LI>Establishing whether pretreatment of EIA with beta<SUB>2</SUB>-agonists may exert, beyond the bronchodilator effect, an anti-inflammatory action, as suggested by recent findings on the role of mechanical factors in inflammation and airways remodelling.</LI>
<LI>Designing protocols specifically addressed to clarify the potential role of generics and different devices in influencing the efficacy and safety of beta<SUB>2</SUB>-agonist prevention of EIA.</LI>
<LI>Developing systematic reviews and meta-analyses to assess which is the most appropriate and effective treatment strategy, among those available, for prevention of exercise-induced asthma.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-09-11 10:50:56 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Brian Rowe for conceiving the original idea for this review and drafting the first version of the protocol.</P>
<P>The authors would like to thank the staff of the Cochrane Airways Group, especially Toby Lasserson and Emma Welsh, who provided invaluable assistance in developing and refining the systematic review. Special thanks to Chris Cates for statistical support, Elizabeth Stovold for her precious assistance in the electronic search and retrieval of papers and Barbara Prediger for her kind help with the SoF Tables.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-09-10 10:26:45 +0100" MODIFIED_BY="[Empty name]">
<P>Disclosures of interest provided by the review authors did not imply any potential conflict of interest with reference to this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-09-11 10:50:28 +0100" MODIFIED_BY="[Empty name]">
<P>MB updated the protocol and was responsible for drafting the full text of the review. MB, CDM and EC selected the studies to be included in the review and extracted and collected data. EC and MB entered data into the Review Manager software for statistical analysis. HS created the 'Summary of findings' table, acting as expert contact for the assessment of risk of bias and for evaluation of the quality of evidence. GWC, MAC and SD acted as independent review authors for solving disagreements among rating authors. All authors critically reviewed the protocol and were involved in revising the full text of the systematic review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-09-10 10:26:55 +0100" MODIFIED_BY="[Empty name]">
<P>Compared with what was originally planned in the protocol, given the high number of papers retrieved in full and reviewed (N = 211), the review authors agreed to narrow the inclusion criteria, considering eligible only double-blind trials that assessed at least one primary outcome of the review. Lack of data reported selected outcomes and the low rate of heterogeneity prevented or made unnecessary some of the subgroup analyses defined a priori. We prepared a 'Summary of findings' table according to recommendations provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2001-Salb-Disk" MODIFIED="2012-10-26 11:09:12 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2001 Salb Disk" YEAR="2001">
<REFERENCE MODIFIED="2012-10-26 11:09:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Lambert S, Brannan JD, Wood RJ, Koskela H, Morton AR et al</AU>
<TI>Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices</TI>
<SO>Medicine &amp; Science in Sports &amp; Exercise</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>6</NO>
<PG>893-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-2001-Salb-MDI" MODIFIED="2012-10-26 11:15:17 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2001 Salb MDI" YEAR="2001">
<REFERENCE MODIFIED="2012-10-26 11:15:17 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Lambert S, Brannan JD, Wood RJ, Koskela H, Morton AR et al</AU>
<TI>Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices</TI>
<SO>Medicine &amp; Science in Sports &amp; Exercise</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>6</NO>
<PG>893-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-05-30 13:22:15 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blake-1999-Salb-180" MODIFIED="2012-10-26 11:52:13 +0100" MODIFIED_BY="[Empty name]" NAME="Blake 1999 Salb 180" YEAR="1999">
<REFERENCE MODIFIED="2012-10-26 11:52:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blake K, Pearlman DS, Scott C, Wang Y, Stahl E, Arledge T</AU>
<TI>Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>2</NO>
<PG>205-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blake-1999-Salm-25" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Blake 1999 Salm 25" YEAR="">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blake K, Pearlman DS, Scott C, Wang Y, Stahl E, Arledge T</AU>
<TI>Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>2</NO>
<PG>205-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blake-1999-Salm-50" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Blake 1999 Salm 50" YEAR="1999">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blake K, Pearlman DS, Scott C, Wang Y, Stahl E, Arledge T</AU>
<TI>Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>2</NO>
<PG>205-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boner-1994-Form-12" MODIFIED="2012-10-26 11:53:52 +0100" MODIFIED_BY="[Empty name]" NAME="Boner 1994 Form 12" YEAR="1994">
<REFERENCE MODIFIED="2012-10-26 11:53:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, Spezia E, Piovesan P, Chiocca E, Maiocchi G</AU>
<TI>Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1994</YR>
<VL>149</VL>
<NO>4</NO>
<PG>935-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boner-1994-Salb-200" MODIFIED="2012-10-26 11:54:07 +0100" MODIFIED_BY="[Empty name]" NAME="Boner 1994 Salb 200" YEAR="1994">
<REFERENCE MODIFIED="2012-10-26 11:54:07 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, Spezia E, Piovesan P, Chiocca E, Maiocchi G</AU>
<TI>Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1994</YR>
<VL>149</VL>
<NO>4</NO>
<PG>935-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boulet-1989-Salb" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Boulet 1989 Salb" YEAR="1989">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boulet LP, Turcotte H, Tennina S</AU>
<TI>Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>5</NO>
<PG>882-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bronski-1995-Salb-MDI" MODIFIED="2012-10-26 11:56:40 +0100" MODIFIED_BY="[Empty name]" NAME="Bronski 1995 Salb MDI" YEAR="1995">
<REFERENCE MODIFIED="2012-10-26 11:56:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bronsky EA, Spector SL, Pearlman DS, Justus SE, Bishop AL</AU>
<TI>Albuterol aerosol versus albuterol Rotacaps in exercise-induced bronchospasm in children</TI>
<SO>Journal of Asthma</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>3</NO>
<PG>207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bronski-1995-Salb-Pwd" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bronski 1995 Salb Pwd" YEAR="1995">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bronsky EA, Spector SL, Pearlman DS, Justus SE, Bishop AL</AU>
<TI>Albuterol aerosol versus albuterol Rotacaps in exercise-induced bronchospasm in children</TI>
<SO>Journal of Asthma</SO>
<YR>1995</YR>
<VL>32</VL>
<NO>3</NO>
<PG>207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bronski-1999-Salm-Disk" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bronski 1999 Salm Disk" YEAR="1999">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bronsky EA, Pearlman DS, Pobiner BF, Scott C, Wang Y, Stahl E</AU>
<TI>Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of two salmeterol powder delivery devices</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>104</VL>
<PG>501-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bronski-1999-Salm-Diskhal" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bronski 1999 Salm Diskhal" YEAR="1999">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bronsky EA, Pearlman DS, Pobiner BF, Scott C, Wang Y, Stahl E</AU>
<TI>Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of two salmeterol powder delivery devices</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>104</VL>
<PG>501-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bronski-2002-Form-12" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bronski 2002 Form 12" YEAR="2002">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bronsky EA, Yegen U, Yeh CM, Larsen LV, Della Cioppa G</AU>
<TI>Formoterol provides long-lasting protection against exercise-induced bronchospasm</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>4</NO>
<PG>407-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bronski-2002-Form-24" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bronski 2002 Form 24" YEAR="2002">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bronsky EA, Yegen U, Yeh CM, Larsen LV, Della Cioppa G</AU>
<TI>Formoterol provides long-lasting protection against exercise-induced bronchospasm</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>4</NO>
<PG>407-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bronski-2002-Salb" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bronski 2002 Salb" YEAR="2002">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bronsky EA, Yegen U, Yeh CM, Larsen LV, Della Cioppa G</AU>
<TI>Formoterol provides long-lasting protection against exercise-induced bronchospasm</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>4</NO>
<PG>407-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlsen-1995-Salm-25" MODIFIED="2012-10-31 11:15:31 +0000" MODIFIED_BY="[Empty name]" NAME="Carlsen 1995 Salm 25" YEAR="1995">
<REFERENCE MODIFIED="2012-10-31 11:15:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlsen KH, Roksund O, Olsholt K, Njå F, Leegaard J, Bratten G</AU>
<TI>Overnight protection by inhaled salmeterol on exercise-induced asthma in children</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>11</NO>
<PG>1852-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlsen-1995-Salm-50" MODIFIED="2012-10-31 11:15:47 +0000" MODIFIED_BY="[Empty name]" NAME="Carlsen 1995 Salm 50" YEAR="1995">
<REFERENCE MODIFIED="2012-10-31 11:15:47 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlsen KH, Roksund O, Olsholt K, Njå F, Leegaard J, Bratten G</AU>
<TI>Overnight protection by inhaled salmeterol on exercise-induced asthma in children</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>11</NO>
<PG>1852-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavagni-1993-Salb-Jet" MODIFIED="2012-10-31 11:22:39 +0000" MODIFIED_BY="[Empty name]" NAME="Cavagni 1993 Salb Jet" YEAR="1993">
<REFERENCE MODIFIED="2012-10-31 11:22:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavagni G, Caffarelli C, Manni PL, Stapane I, Preti PAM, Cantini L</AU>
<TI>Salbutamol administered through a new spacer device to prevent exercise-induced asthma</TI>
<SO>Advanced Therapy</SO>
<YR>1993</YR>
<VL>10</VL>
<NO>5</NO>
<PG>207-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavagni-1993-Salb-MDI" MODIFIED="2012-10-31 11:23:13 +0000" MODIFIED_BY="[Empty name]" NAME="Cavagni 1993 Salb MDI" YEAR="1993">
<REFERENCE MODIFIED="2012-10-31 11:23:13 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavagni G, Caffarelli C, Manni PL, Stapane I, Preti PAM, Cantini L</AU>
<TI>Salbutamol administered through a new spacer device to prevent exercise-induced asthma</TI>
<SO>Advanced Therapy</SO>
<YR>1993</YR>
<VL>10</VL>
<NO>5</NO>
<PG>207-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-1990-Fen" MODIFIED="2012-10-31 11:24:15 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 1990 Fen" YEAR="1990">
<REFERENCE MODIFIED="2012-10-31 11:24:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke PS, Ratowsky DA</AU>
<TI>Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1990</YR>
<VL>64</VL>
<PG>187-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daugbjerg-1996-Form-12" MODIFIED="2012-10-31 11:25:45 +0000" MODIFIED_BY="[Empty name]" NAME="Daugbjerg 1996 Form 12" YEAR="1996">
<REFERENCE MODIFIED="2012-10-31 11:25:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daugbjerg P, Nielsen KG, Skov M, Bisgaard H</AU>
<TI>Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children</TI>
<SO>Acta Paediatrica</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>6</NO>
<PG>684-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daugbjerg-1996-Salb" MODIFIED="2012-10-31 11:25:59 +0000" MODIFIED_BY="[Empty name]" NAME="Daugbjerg 1996 Salb" YEAR="1996">
<REFERENCE MODIFIED="2012-10-31 11:25:59 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daugbjerg P, Nielsen KG, Skov M, Bisgaard H</AU>
<TI>Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children</TI>
<SO>Acta Paediatrica</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>6</NO>
<PG>684-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Debelic-1988-Reproterol" MODIFIED="2012-10-31 11:27:29 +0000" MODIFIED_BY="[Empty name]" NAME="Debelic 1988 Reproterol" YEAR="1988">
<REFERENCE MODIFIED="2012-10-31 11:27:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Debelic M, Hertel G, Konig J</AU>
<TI>Double-blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1988</YR>
<VL>61</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeBenedictis-1996-Salm-25" MODIFIED="2012-10-31 11:31:08 +0000" MODIFIED_BY="[Empty name]" NAME="DeBenedictis 1996 Salm 25" YEAR="1996">
<REFERENCE MODIFIED="2012-10-31 11:31:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Benedictis FM, Tuteri G, Pazzelli P, Niccoli A, Mezzetti D, Vaccaro R</AU>
<TI>Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>10</NO>
<PG>2099-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeBenedictis-1996-Salm-50" MODIFIED="2012-10-31 11:31:14 +0000" MODIFIED_BY="[Empty name]" NAME="DeBenedictis 1996 Salm 50" YEAR="1996">
<REFERENCE MODIFIED="2012-10-31 11:31:14 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Benedictis FM, Tuteri G, Pazzelli P, Niccoli A, Mezzetti D, Vaccaro R</AU>
<TI>Salmeterol in exercise-induced bronchoconstriction in asthmatic children: comparison of two doses</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>10</NO>
<PG>2099-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeBenedictis-1998-Salb" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="DeBenedictis 1998 Salb" YEAR="1998">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Benedictis FM, Tuteri G, Pazzelli P, Solinas LF, Niccoli A, Parente C</AU>
<TI>Combination drug therapy for the prevention of exercise-induced bronchoconstriction in children</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>4</NO>
<PG>352-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Col-1993-Salb-Jet" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Del Col 1993 Salb Jet" YEAR="1993">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Col G, Spezia E, Richelli C, Piovesan P, Cantini L, Boner AL</AU>
<TI>Assessment of a new space device (Jet) for use with inhaled beta2-agonists in children with exercise-induced asthma</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>2</NO>
<PG>119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Col-1993-Salb-MDI" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Del Col 1993 Salb MDI" YEAR="1993">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Col G, Spezia E, Richelli C, Piovesan P, Cantini L, Boner AL</AU>
<TI>Assessment of a new space device (Jet) for use with inhaled beta2-agonists in children with exercise-induced asthma</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>2</NO>
<PG>119-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dinh-Xuan-1989-Terb" MODIFIED="2012-10-31 11:36:35 +0000" MODIFIED_BY="[Empty name]" NAME="Dinh Xuan 1989 Terb" YEAR="1989">
<REFERENCE MODIFIED="2012-10-31 11:36:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dinh Xuan AT, Lebeau C, Roche R, Ferriere A, Chaussain M</AU>
<TI>Inhaled terbutaline administered via a spacer fully prevents exercise-induced asthma in young asthmatic subjects: a double-blind, randomized, placebo-controlled study</TI>
<SO>Journal of International Medical Research</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>6</NO>
<PG>506-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egglestone-1981-Terb-250" MODIFIED="2012-05-31 10:30:12 +0100" MODIFIED_BY="[Empty name]" NAME="Egglestone 1981 Terb 250" YEAR="1981">
<REFERENCE MODIFIED="2012-05-31 10:30:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eggleston PA, Beasley PP</AU>
<TI>Bronchodilation and inhibition of induced asthma by adrenergic agonists</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1981</YR>
<VL>29</VL>
<NO>4</NO>
<PG>505-510</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrari-2000-Form-12" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Ferrari 2000 Form 12" YEAR="2000">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrari M, Balestreri F, Baratieri S, Biasin C, Oldani V, Lo Cascio V</AU>
<TI>Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma</TI>
<SO>Respiration</SO>
<YR>2000</YR>
<VL>67</VL>
<NO>5</NO>
<PG>510-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-2001-Form-12" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia 2001 Form 12" YEAR="2001">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia R, Guerra P, Feo F, Galindo PA, Gómez E, Borja J et al</AU>
<TI>Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm</TI>
<SO>Journal of Investigational Allergology and Clinical Immunology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1992-Salm-50" MODIFIED="2012-10-31 11:46:43 +0000" MODIFIED_BY="[Empty name]" NAME="Green 1992 Salm 50" YEAR="1992">
<REFERENCE MODIFIED="2012-10-31 11:46:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green CP, Price JF</AU>
<TI>Prevention of exercise induced asthma by inhaled salmeterol xinafoate</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<NO>8</NO>
<PG>1014-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gronnerod-2000-Form-4.5" MODIFIED="2012-10-31 11:48:02 +0000" MODIFIED_BY="[Empty name]" NAME="Gronnerod 2000 Form 4.5" YEAR="2000">
<REFERENCE MODIFIED="2012-10-31 11:48:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gronnerod TA, von Berg A, Schwabe G, Soliman S</AU>
<TI>Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents</TI>
<SO>Respiratory Medicine</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>7</NO>
<PG>661-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gronnerod-2000-Form-9" MODIFIED="2012-10-31 11:48:15 +0000" MODIFIED_BY="[Empty name]" NAME="Gronnerod 2000 Form 9" YEAR="2000">
<REFERENCE MODIFIED="2012-10-31 11:48:15 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gronnerod TA, von Berg A, Schwabe G, Soliman S</AU>
<TI>Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents</TI>
<SO>Respiratory Medicine</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>7</NO>
<PG>661-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gronnerod-2000-Terb-500" MODIFIED="2012-10-31 11:48:27 +0000" MODIFIED_BY="[Empty name]" NAME="Gronnerod 2000 Terb 500" YEAR="2000">
<REFERENCE MODIFIED="2012-10-31 11:48:27 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gronnerod TA, von Berg A, Schwabe G, Soliman S</AU>
<TI>Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents</TI>
<SO>Respiratory Medicine</SO>
<YR>2000</YR>
<VL>94</VL>
<NO>7</NO>
<PG>661-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hancox-2002" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hancox 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD</AU>
<TI>Beta2-agonist tolerance and exercise-induced bronchospasm</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>8</NO>
<PG>1068-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawksworth-2002-Salb-HFA" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hawksworth 2002 Salb HFA" YEAR="2002">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawksworth RJ, Sykes AP, Faris M, Mant T, Lee TH</AU>
<TI>Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>5</NO>
<PG>473-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawksworth-2002-Salb-MDI" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hawksworth 2002 Salb MDI" YEAR="2002">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawksworth RJ, Sykes AP, Faris M, Mant T, Lee TH</AU>
<TI>Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2002</YR>
<VL>88</VL>
<NO>5</NO>
<PG>473-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henricksen-1983-Terb" MODIFIED="2013-09-11 11:02:32 +0100" MODIFIED_BY="[Empty name]" NAME="Henricksen 1983 Terb" YEAR="1983">
<REFERENCE MODIFIED="2013-09-11 11:02:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henriksen JM, Dahl R</AU>
<TI>Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1983</YR>
<VL>128</VL>
<NO>6</NO>
<PG>993-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henricksen-1992-Salb" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Henricksen 1992 Salb" YEAR="1992">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henriksen JM, Agertoft L, Pedersen S</AU>
<TI>Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1992</YR>
<VL>89</VL>
<NO>6</NO>
<PG>1176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henriksen-1992-Form-12" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Henriksen 1992 Form 12" YEAR="1992">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henriksen JM, Agertoft L, Pedersen S</AU>
<TI>Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1992</YR>
<VL>89</VL>
<NO>6</NO>
<PG>1176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hills-1976-Salb" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hills 1976 Salb" YEAR="1976">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hills EA, Davies S, Geary M</AU>
<TI>Salmefamol and salbutamol in exercise-induced asthma in children</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1976</YR>
<VL>70</VL>
<NO>2</NO>
<PG>78-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hills-1976-Salmefamol" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Hills 1976 Salmefamol" YEAR="1976">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hills EA, Davies S, Geary M</AU>
<TI>Salmefamol and salbutamol in exercise-induced asthma in children</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1976</YR>
<VL>70</VL>
<NO>2</NO>
<PG>78-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inman-1996" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Inman 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inman MD, O'Byrne PM</AU>
<TI>The effect of regular inhaled albuterol on exercise-induced bronchoconstriction</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>1</NO>
<PG>65-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemp-1994-Salb" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kemp 1994 Salb" YEAR="1994">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kemp JP, Dockhorn RJ, Busse WW, Bleecker ER, Van As A</AU>
<TI>Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>94</YR>
<VL>150</VL>
<PG>1612-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemp-1994-Salm-42" MODIFIED="2013-09-10 10:13:15 +0100" MODIFIED_BY="[Empty name]" NAME="Kemp 1994 Salm 42" YEAR="1994">
<REFERENCE MODIFIED="2013-09-10 10:13:15 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kemp JP, Dockhorn RJ, Busse WW, Bleecker ER, Van As A</AU>
<TI>Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>94</YR>
<VL>150</VL>
<PG>1612-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konig-1981-Metaprot" MODIFIED="2012-05-31 10:38:22 +0100" MODIFIED_BY="[Empty name]" NAME="Konig 1981 Metaprot" YEAR="1981">
<REFERENCE MODIFIED="2012-05-31 10:38:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konig P, Eggleston PA, Serby CW</AU>
<TI>Comparison of oral and inhaled metaproterenol for prevention of exercise-induced asthma</TI>
<SO>Clinical Allergy</SO>
<YR>1981</YR>
<VL>11</VL>
<NO>6</NO>
<PG>597-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konig-1984-Fen-0.4" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Konig 1984 Fen 0.4" YEAR="1984">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konig P, Hordvik NL, Serby CW</AU>
<TI>Fenoterol in exercise-induced asthma: effect of dose on efficacy and duration of action</TI>
<SO>Chest</SO>
<YR>1984</YR>
<VL>85</VL>
<PG>462-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konig-1984-Fen-0.8" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Konig 1984 Fen 0.8" YEAR="1984">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konig P, Hordvik NL, Serby CW</AU>
<TI>Fenoterol in exercise-induced asthma: effect of dose on efficacy and duration of action</TI>
<SO>Chest</SO>
<YR>1984</YR>
<VL>85</VL>
<PG>462-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larsson-1982-Fen" MODIFIED="2012-05-31 10:39:32 +0100" MODIFIED_BY="[Empty name]" NAME="Larsson 1982 Fen" YEAR="1982">
<REFERENCE MODIFIED="2012-05-31 10:39:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larsson K</AU>
<TI>Oxitropium bromide, ipratropium bromide and fenoterol in exercise-induced asthma</TI>
<SO>Respiration</SO>
<YR>1982</YR>
<VL>43</VL>
<NO>1</NO>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McAlpine-1990-Form-12" MODIFIED="2012-10-31 13:37:54 +0000" MODIFIED_BY="[Empty name]" NAME="McAlpine 1990 Form 12" YEAR="1990">
<REFERENCE MODIFIED="2012-10-31 13:37:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McAlpine LG, Thomson NC</AU>
<TI>Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist</TI>
<SO>Respiratory Medicine</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>4</NO>
<PG>293-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McAlpine-1990-Salb" MODIFIED="2012-10-31 13:38:05 +0000" MODIFIED_BY="[Empty name]" NAME="McAlpine 1990 Salb" YEAR="1990">
<REFERENCE MODIFIED="2012-10-31 13:38:05 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McAlpine LG, Thomson NC</AU>
<TI>Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist</TI>
<SO>Respiratory Medicine</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>4</NO>
<PG>293-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McFadden-1986-Salb-_x0028_I_x0029_" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="McFadden 1986 Salb (I)" YEAR="1986">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McFadden ER Jr, Mills R</AU>
<TI>Prevention of exercise-induced bronchospasm with aerosolized albuterol</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1986</YR>
<VL>39</VL>
<NO>1</NO>
<PG>112-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McFadden-1986-Salb-_x0028_II_x0029_" MODIFIED="2012-05-31 10:42:09 +0100" MODIFIED_BY="[Empty name]" NAME="McFadden 1986 Salb (II)" YEAR="1986">
<REFERENCE MODIFIED="2012-05-31 10:42:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McFadden ER, Mills R</AU>
<TI>Inhaled albuterol powder for the prevention of exercise-induced bronchospasm</TI>
<SO>Immunology and Allergy Practice</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>6</NO>
<PG>199-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morton-1989-Rimet" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Morton 1989 Rimet" YEAR="1989">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morton AR, Scott CA, Fitch KD</AU>
<TI>Rimiterol and the prevention of exercise-induced asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1989</YR>
<VL>83</VL>
<NO>1</NO>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1998" MODIFIED="2012-10-31 13:47:46 +0000" MODIFIED_BY="[Empty name]" NAME="Nelson 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-10-31 13:47:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr</AU>
<TI>Effect of long-term salmeterol treatment on exercise-induced asthma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>3</NO>
<PG>141-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newnham-1993-Salb-200" MODIFIED="2012-10-31 13:53:12 +0000" MODIFIED_BY="[Empty name]" NAME="Newnham 1993 Salb 200" YEAR="1993">
<REFERENCE MODIFIED="2012-10-31 13:53:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newnham DM, Ingram CG, Earnshaw J, Palmer JB, Dhillon DP</AU>
<TI>Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>6</NO>
<PG>439-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newnham-1993-Salm-50" MODIFIED="2012-10-31 13:53:37 +0000" MODIFIED_BY="[Empty name]" NAME="Newnham 1993 Salm 50" YEAR="1993">
<REFERENCE MODIFIED="2012-10-31 13:53:37 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newnham DM, Ingram CG, Earnshaw J, Palmer JB, Dhillon DP</AU>
<TI>Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>6</NO>
<PG>439-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-1986-Salb-200" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Patel 1986 Salb 200" YEAR="1986">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel KR</AU>
<TI>Bronchodilator activity of a new inhaled beta<SUB>2</SUB>-adrenoceptor agonist, tulobuterol, and its protective effect in exercise-induced asthma</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>21</VL>
<NO>2</NO>
<PG>234-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-1986-Tulob-200" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Patel 1986 Tulob 200" YEAR="1986">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel KR</AU>
<TI>Bronchodilator activity of a new inhaled beta<SUB>2</SUB>-adrenoceptor agonist, tulobuterol, and its protective effect in exercise-induced asthma</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>21</VL>
<NO>2</NO>
<PG>234-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-1986-Tulob-400" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Patel 1986 Tulob 400" YEAR="1986">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel KR</AU>
<TI>Bronchodilator activity of a new inhaled beta<SUB>2</SUB>-adrenoceptor agonist, tulobuterol, and its protective effect in exercise-induced asthma</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>21</VL>
<NO>2</NO>
<PG>234-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patessio-1991-Form-24" MODIFIED="2012-10-31 14:19:47 +0000" MODIFIED_BY="[Empty name]" NAME="Patessio 1991 Form 24" YEAR="1991">
<REFERENCE MODIFIED="2012-10-31 14:19:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patessio A, Podda A, Carone M, Trombetta N, Donner CF</AU>
<TI>Protective effect and duration of action of formoterol aerosol on exercise-induced asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>3</NO>
<PG>296-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patessio-1991-Salb-200" MODIFIED="2012-10-31 14:20:03 +0000" MODIFIED_BY="[Empty name]" NAME="Patessio 1991 Salb 200" YEAR="1991">
<REFERENCE MODIFIED="2012-10-31 14:20:03 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patessio A, Podda A, Carone M, Trombetta N, Donner CF</AU>
<TI>Protective effect and duration of action of formoterol aerosol on exercise-induced asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>3</NO>
<PG>296-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-2006-Form-12" MODIFIED="2012-10-31 14:22:01 +0000" MODIFIED_BY="[Empty name]" NAME="Pearlman 2006 Form 12" YEAR="2006">
<REFERENCE MODIFIED="2012-10-31 14:22:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman D, Milgrom H, Till D, Ziehmer B</AU>
<TI>Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>3</NO>
<PG>382-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-2006-Form-24" MODIFIED="2012-10-31 14:21:45 +0000" MODIFIED_BY="[Empty name]" NAME="Pearlman 2006 Form 24" YEAR="2006">
<REFERENCE MODIFIED="2012-10-31 14:21:45 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman D, Milgrom H, Till D, Ziehmer B</AU>
<TI>Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>3</NO>
<PG>382-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-2006-Salb-180" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Pearlman 2006 Salb 180" YEAR="2006">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman D, Milgrom H, Till D, Ziehmer B</AU>
<TI>Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>3</NO>
<PG>382-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-2007-Salb-90" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Pearlman 2007 Salb 90" YEAR="2007">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman DS, Rees W, Schaefer K, Huang H, Andrews WT</AU>
<TI>An evaluation of levalbuterol HFA in the prevention of exercise-induced bronchospasm</TI>
<SO>Journal of Asthma</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>9</NO>
<PG>729-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Philip-2007-Salm-50" MODIFIED="2012-10-31 14:24:39 +0000" MODIFIED_BY="[Empty name]" NAME="Philip 2007 Salm 50" YEAR="2007">
<REFERENCE MODIFIED="2012-10-31 14:24:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Philip G, Pearlman DS, Villarán C, Legrand C, Loeys T, Langdon RB et al</AU>
<TI>Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>3</NO>
<PG>875-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramage-1994" MODIFIED="2012-10-31 14:25:39 +0000" MODIFIED_BY="[Empty name]" NAME="Ramage 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-10-31 14:25:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP</AU>
<TI>Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol</TI>
<SO>Respiratory Medicine</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>5</NO>
<PG>363-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-2002-Form-12" MODIFIED="2012-10-31 14:28:06 +0000" MODIFIED_BY="[Empty name]" NAME="Richter 2002 Form 12" YEAR="2002">
<REFERENCE MODIFIED="2012-10-31 14:28:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter K, Janicki S, Jorres RA, Magnussen H</AU>
<TI>Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>5</NO>
<PG>865-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-2002-Salm-50" MODIFIED="2012-10-31 14:28:17 +0000" MODIFIED_BY="[Empty name]" NAME="Richter 2002 Salm 50" YEAR="2002">
<REFERENCE MODIFIED="2012-10-31 14:28:17 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter K, Janicki S, Jorres RA, Magnussen H</AU>
<TI>Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>5</NO>
<PG>865-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-2002-Terb-500" MODIFIED="2012-10-31 14:28:28 +0000" MODIFIED_BY="[Empty name]" NAME="Richter 2002 Terb 500" YEAR="2002">
<REFERENCE MODIFIED="2012-10-31 14:28:28 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter K, Janicki S, Jorres RA, Magnussen H</AU>
<TI>Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>5</NO>
<PG>865-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-2002-Form-12" MODIFIED="2012-10-31 14:29:39 +0000" MODIFIED_BY="[Empty name]" NAME="Shapiro 2002 Form 12" YEAR="2002">
<REFERENCE MODIFIED="2012-10-31 14:29:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GG, Kemp JP, DeJong R, Chapko M, Bierman CW, Altman LC et al</AU>
<TI>Effects of albuterol and procaterol on exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>4</NO>
<PG>273-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-2002-Form-24" MODIFIED="2012-10-31 14:30:22 +0000" MODIFIED_BY="[Empty name]" NAME="Shapiro 2002 Form 24" YEAR="2002">
<REFERENCE MODIFIED="2012-10-31 14:30:22 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GG, Kemp JP, DeJong R, Chapko M, Bierman CW, Altman LC et al</AU>
<TI>Effects of albuterol and procaterol on exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>4</NO>
<PG>273-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-2002-Salb-180" MODIFIED="2012-10-31 14:30:40 +0000" MODIFIED_BY="[Empty name]" NAME="Shapiro 2002 Salb 180" YEAR="2002">
<REFERENCE MODIFIED="2012-10-31 14:30:40 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GG, Kemp JP, DeJong R, Chapko M, Bierman CW, Altman LC et al</AU>
<TI>Effects of albuterol and procaterol on exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>4</NO>
<PG>273-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simons-1997" MODIFIED="2012-10-31 14:30:59 +0000" MODIFIED_BY="[Empty name]" NAME="Simons 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-10-31 14:30:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simons FE, Gerstner TV, Cheang MS</AU>
<TI>Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>99</VL>
<NO>5</NO>
<PG>655-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stelmach-2008" MODIFIED="2012-10-31 14:32:14 +0000" MODIFIED_BY="[Empty name]" NAME="Stelmach 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-31 14:32:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P</AU>
<TI>Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>2</NO>
<PG>383-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Storms-2004" MODIFIED="2012-10-31 14:33:15 +0000" MODIFIED_BY="[Empty name]" NAME="Storms 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-10-31 14:33:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM et al</AU>
<TI>A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge</TI>
<SO>Respiratory Medicine</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>11</NO>
<PG>1051-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sturani-1983-Fen-400" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Sturani 1983 Fen 400" YEAR="1983">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sturani C, Schiavina M, Tosi I, Gunella G</AU>
<TI>Comparison of inhaled fenoterol and salbutamol in the prevention of exercise-induced asthma</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<VL>128(Suppl)</VL>
<PG>526-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sturani-1983-Salb-200" MODIFIED="2012-10-31 14:36:06 +0000" MODIFIED_BY="[Empty name]" NAME="Sturani 1983 Salb 200" YEAR="1983">
<REFERENCE MODIFIED="2012-10-31 14:36:06 +0000" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sturani C, Schiavina M, Tosi I, Gunella G</AU>
<TI>Comparison of inhaled fenoterol and salbutamol in the prevention of exercise-induced asthma</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<VL>128</VL>
<PG>526-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VanHaitsma-2010-Salb" MODIFIED="2013-09-11 11:08:12 +0100" MODIFIED_BY="[Empty name]" NAME="VanHaitsma 2010 Salb" YEAR="2010">
<REFERENCE MODIFIED="2013-09-11 11:08:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>VanHaitsma TA, Mickleborough T, Stager JM, Koceja DM, Lindley MR, Chapman R</AU>
<TI>Comparative effects of caffeine and albuterol on the bronchoconstrictor response to exercise in asthmatic athletes</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>4</NO>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasquez-1984-Salb-400" MODIFIED="2012-10-31 14:39:53 +0000" MODIFIED_BY="[Empty name]" NAME="Vasquez 1984 Salb 400" YEAR="1984">
<REFERENCE MODIFIED="2012-10-31 14:39:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vazquez C, Fidalgo I, Virto MC, Labayru MT, Casas C</AU>
<TI>Efficacy of disodium chromoglycate, salbutamol and ipratroprium bromide on inhibition of exercise induced bronchospasm</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1984</YR>
<VL>20</VL>
<NO>8</NO>
<PG>756-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-1986-Bitolterol" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Walker 1986 Bitolterol" YEAR="1986">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker SB, Bierman CW, Pierson WE, Shapiro GG, Furukawa CT, Mingo TS</AU>
<TI>Bitolterol mesylate in exercise-induced asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1986</YR>
<VL>77</VL>
<PG>32-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolley-1990-Terb-500" MODIFIED="2012-05-31 11:38:41 +0100" MODIFIED_BY="[Empty name]" NAME="Wolley 1990 Terb 500" YEAR="1990">
<REFERENCE MODIFIED="2012-05-31 10:55:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woolley M, Anderson SD, Quigley BM</AU>
<TI>Duration of protective effect of terbutaline sulfate and cromolyn sodium alone and in combination on exercise-induced asthma</TI>
<SO>Chest</SO>
<YR>1990</YR>
<VL>97</VL>
<NO>1</NO>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aebischer-1984" MODIFIED="2012-11-01 09:02:36 +0000" MODIFIED_BY="[Empty name]" NAME="Aebischer 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-11-01 09:02:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aebischer JC, Benoit RC, Scherrer M</AU>
<TI>Pirbuterol and salbutamol aerosol for exercise-induced bronchoconstriction</TI>
<SO>Journal Suisse de Medecine</SO>
<YR>1984</YR>
<VL>114</VL>
<NO>46</NO>
<PG>1660-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agostini-1983-I" MODIFIED="2012-11-01 09:03:24 +0000" MODIFIED_BY="[Empty name]" NAME="Agostini 1983 I" YEAR="1983">
<REFERENCE MODIFIED="2012-11-01 09:03:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agostini M, Barlocco G, Mastella G</AU>
<TI>Protective effect of fenoterol spray, ipratropium bromide plus fenoterol spray, and oral clenbuterol, on exercise-induced asthma in children. Double blind controlled and randomized clinical trial</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<VL>128</VL>
<NO>2</NO>
<PG>529-32</PG>
<IDENTIFIERS MODIFIED="2012-07-27 14:33:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-27 14:28:57 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agostini-1983-II" MODIFIED="2012-11-01 09:07:57 +0000" MODIFIED_BY="[Empty name]" NAME="Agostini 1983 II" YEAR="1983">
<REFERENCE MODIFIED="2012-11-01 09:07:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agostini M, Barlocco G, Mastella G</AU>
<TI>Protection against exercise induced asthma in children. Double blind controlled clinical trial with fenoterol spray, fenoterol plus ipratropium and oral clenbuterol</TI>
<SO>Rivista Italiana di Pediatria</SO>
<YR>1983</YR>
<VL>9</VL>
<NO>4</NO>
<PG>347-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allegra-1976" MODIFIED="2012-11-01 09:08:59 +0000" MODIFIED_BY="[Empty name]" NAME="Allegra 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-11-01 09:08:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allegra J, Field J, Trautlein J, Gillin M, Zelis R</AU>
<TI>The pharmacologic effect of aerosolized terbutaline sulfate in exercise-induced bronchospasm</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>16</VL>
<NO>8-9</NO>
<PG>444-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1975" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 1975" YEAR="1975">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Rozea PJ, Dolton R, Lindsay DA</AU>
<TI>Inhaled and oral bronchodilator therapy in exercise induced asthma</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1975</YR>
<VL>5</VL>
<NO>6</NO>
<PG>544-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1976" MODIFIED="2012-11-01 09:22:51 +0000" MODIFIED_BY="[Empty name]" NAME="Anderson 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-11-01 09:22:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Seale JP, Rozea P, Bandler L, Theobald G, Lindsay D</AU>
<TI>Inhaled and oral salbutamol in exercise-induced asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1976</YR>
<VL>114</VL>
<NO>3</NO>
<PG>493-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1991" MODIFIED="2012-11-01 09:23:59 +0000" MODIFIED_BY="[Empty name]" NAME="Anderson 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-11-01 09:23:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Rodwell LT, Du Toit J, Young IH</AU>
<TI>Duration of protection by inhaled salmeterol in exercise-induced asthma</TI>
<SO>Chest</SO>
<YR>1991</YR>
<VL>100</VL>
<NO>5</NO>
<PG>1254-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aranda-1992" MODIFIED="2012-11-01 09:37:07 +0000" MODIFIED_BY="[Empty name]" NAME="Aranda 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-11-01 09:37:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aranda PC, Merello AM, Power A, Reus M, Astudillo P</AU>
<TI>Prevention of exercise induced asthma by bronchodilator drug aerosol</TI>
<SO>Revista Chilena de Pediatria</SO>
<YR>1992</YR>
<VL>63</VL>
<NO>4</NO>
<PG>202-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bakran-1980" MODIFIED="2012-11-01 09:40:47 +0000" MODIFIED_BY="[Empty name]" NAME="Bakran 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-11-01 09:40:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bakran I, Vrhovac B, Plavsi&#263; F</AU>
<TI>Aminophylline vs. salbutamol in exercise-induced asthma</TI>
<SO>International Journal of Clinical Pharmacology, Therapy and Toxicology</SO>
<YR>1980</YR>
<VL>18</VL>
<NO>10</NO>
<PG>442-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battistini-1980" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Battistini 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Battistini A, Grzincich GL, Gorni A, Baroni AL</AU>
<TI>Asthma and bronchodilator drugs. Evaluation of a newly developed beta<SUB>2</SUB>-agonist: clenbuterol</TI>
<SO>Rivista Italiana di Pediatria</SO>
<YR>1980</YR>
<VL>6</VL>
<NO>3</NO>
<PG>313-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baur-1979" MODIFIED="2012-11-01 09:45:30 +0000" MODIFIED_BY="[Empty name]" NAME="Baur 1979" YEAR="1979">
<REFERENCE MODIFIED="2012-11-01 09:45:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baur X</AU>
<TI>Concerning the therapy of exercise-induced asthma</TI>
<SO>Praxis und Klinik der Pneumologie</SO>
<YR>1979</YR>
<VL>33</VL>
<NO>6</NO>
<PG>791-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berkowitz-1986" MODIFIED="2012-11-01 09:46:18 +0000" MODIFIED_BY="[Empty name]" NAME="Berkowitz 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-11-01 09:46:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berkowitz R, Schwartz E, Bukstein D, Grunstein M, Chai H</AU>
<TI>Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate</TI>
<SO>Pediatrics</SO>
<YR>1986</YR>
<VL>77</VL>
<NO>2</NO>
<PG>173-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boner-1984" MODIFIED="2012-11-01 09:52:47 +0000" MODIFIED_BY="[Empty name]" NAME="Boner 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-11-01 09:52:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, Zamo CR, Marchiori MM, Biancotto R, Antolini I, Vallone G</AU>
<TI>Comparison of nebulized ipratropium, salbutamol and cromoglicate solutions, cromoglicate inhaled powder, theophylline elixir and placebo in exercise induced asthma of the children</TI>
<SO>Giornale Italiano delle Malattie del Torace</SO>
<YR>1984</YR>
<VL>38</VL>
<NO>6</NO>
<PG>395-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boner-1987" MODIFIED="2012-11-01 09:53:28 +0000" MODIFIED_BY="[Empty name]" NAME="Boner 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-11-01 09:53:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, De Stefano G, Niero E, Vallone G, Gaburro D</AU>
<TI>Salbutamol and ipratropium bromide solution in the treatment of bronchospasm in asthmatic children</TI>
<SO>Annals of Allergy</SO>
<YR>1987</YR>
<VL>58</VL>
<NO>1</NO>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boner-1988" MODIFIED="2012-11-01 09:54:15 +0000" MODIFIED_BY="[Empty name]" NAME="Boner 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-11-01 09:54:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, Vallone G, Brighenti C, Schiassi M, Miglioranzi P, Richelli C</AU>
<TI>Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>4</NO>
<PG>197-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bratteby-1986" MODIFIED="2012-11-01 09:56:18 +0000" MODIFIED_BY="[Empty name]" NAME="Bratteby 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-11-01 09:56:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bratteby LE, Foucard T, Lönnerholm G</AU>
<TI>Combined treatment with ipratropium bromide and beta-2-adrenoceptor agonists in childhood asthma</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1986</YR>
<VL>68</VL>
<NO>4</NO>
<PG>239-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1980" MODIFIED="2012-11-01 10:02:16 +0000" MODIFIED_BY="[Empty name]" NAME="Bundgaard 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-11-01 10:02:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard AF, Rasmussen FV, Madsen L</AU>
<TI>Pretreatment of exercise-induced asthma in adults with aerosols and pulverized tablets</TI>
<SO>Allergy</SO>
<YR>1980</YR>
<VL>35</VL>
<NO>8</NO>
<PG>639-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1983-I" MODIFIED="2012-11-01 10:03:05 +0000" MODIFIED_BY="[Empty name]" NAME="Bundgaard 1983 I" YEAR="1983">
<REFERENCE MODIFIED="2012-11-01 10:03:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard AF</AU>
<TI>Pretreatment of exercise-induced asthma with beta-2 agonists inhaled from RV to TLC or at TLC. A preliminary report</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<VL>128</VL>
<NO>2</NO>
<PG>518-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1983-II" MODIFIED="2012-11-01 10:03:59 +0000" MODIFIED_BY="[Empty name]" NAME="Bundgaard 1983 II" YEAR="1983">
<REFERENCE MODIFIED="2012-11-01 10:03:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard AF, Buch D, Schmidt A, Bach-Mortensen N</AU>
<TI>Pretreatment of exercise-induced asthma in children using disodium cromoglycate and fenoterol inhalation powder</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<VL>130</VL>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bundgaard-1983-III" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bundgaard 1983 III" YEAR="1983">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bundgaard A, Schmidt A</AU>
<TI>Double-blind pretreatment of exercise-induced asthma with sequential inhalations of fenoterol from an aerosol and as a powder; second of two parts</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1983</YR>
<VL>130</VL>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bye-1980" MODIFIED="2012-11-01 10:05:50 +0000" MODIFIED_BY="[Empty name]" NAME="Bye 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-11-01 10:05:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bye PT, Anderson SD, Daviskas E, Marty JJ, Sampson D</AU>
<TI>Plasma cyclic AMP levels in response to exercise and terbutaline sulphate aerosol in normal and asthmatic subjects</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1980</YR>
<VL>61</VL>
<NO>5</NO>
<PG>287-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ceugniet-1997" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Ceugniet 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ceugniet F, Cauchefer F, Fragneaud C, Evano-Celli I</AU>
<TI>Prophylactic treatment of exercise-induced asthma in children: salmeterol or sodium cromoglycate single dose before exercise?</TI>
<SO>Annales De Pediatrie</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>9</NO>
<PG>625-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colice-1999" MODIFIED="2012-11-01 10:08:47 +0000" MODIFIED_BY="[Empty name]" NAME="Colice 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-11-01 10:08:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colice GL, Klinger NM, Ekholm BP, Dockhorn RJ</AU>
<TI>Proventil HFA prevents exercise-induced bronchoconstriction in children</TI>
<SO>Journal of Asthma</SO>
<YR>1999</YR>
<VL>36</VL>
<NO>8</NO>
<PG>671-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coreno-2000" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Coreno 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coreno A, Skowronski M, Kotaru C, McFadden ER Jr</AU>
<TI>Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2000</YR>
<VL>106</VL>
<NO>3</NO>
<PG>500-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corrias-1989" MODIFIED="2012-11-01 10:11:03 +0000" MODIFIED_BY="[Empty name]" NAME="Corrias 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-11-01 10:11:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corrias A, Pelosi U, Corona GB, Minelli R, Peri M, Corda R</AU>
<TI>Efficacy of broxaterol vs salbutamol in asthma induced by physical exercise in children</TI>
<SO>Pediatria Medica e Chirurgica</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>161-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dal-Col-1995" MODIFIED="2012-11-01 10:15:16 +0000" MODIFIED_BY="[Empty name]" NAME="Dal Col 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-11-01 10:15:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dal Col G, Martinati L, Mingoni S, Boner A, Cantini L</AU>
<TI>Salbutamol powder, administered via a multidose and a single-dose powder inhaler, in the prevention of exercise-induced asthma in children</TI>
<SO>Pediatric Asthma, Allergy and Immunology</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>3</NO>
<PG>165-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Bono-1979" MODIFIED="2012-11-01 10:15:52 +0000" MODIFIED_BY="[Empty name]" NAME="Del Bono 1979" YEAR="1979">
<REFERENCE MODIFIED="2012-11-01 10:15:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Bono N, Quartieri F, Vibelli C</AU>
<TI>Aerosolized clenbuterol NAB 365 and salbutamol in exercise-induced asthma</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1979</YR>
<VL>6</VL>
<NO>4</NO>
<PG>237-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Gioacchino-1987" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Di Gioacchino 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Gioacchino M, Mezzetti A, Mancini M, Guglielmi MD, Lo Medico E, Proietti Franceschilli G et al</AU>
<TI>Study of the cardiovascular effects of clenbuterol in exercise-induced asthma</TI>
<SO>Respiration</SO>
<YR>1987</YR>
<VL>51</VL>
<NO>3</NO>
<PG>205-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-27 15:27:35 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dockhorn-1997" MODIFIED="2012-11-01 10:18:45 +0000" MODIFIED_BY="[Empty name]" NAME="Dockhorn 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-11-01 10:18:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dockhorn RJ, Wagner DE, Burgess GL, Hafner KB, Letourneau K, Colice GL et al</AU>
<TI>Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin</TI>
<SO>Annals of Allergy</SO>
<YR>1997</YR>
<VL>79</VL>
<NO>1</NO>
<PG>85-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edelman-2000" MODIFIED="2012-11-01 10:22:58 +0000" MODIFIED_BY="[Empty name]" NAME="Edelman 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-11-01 10:22:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edelman JL, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF et al</AU>
<TI>Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>132</VL>
<NO>2</NO>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eggleston-1981" MODIFIED="2012-11-01 10:23:34 +0000" MODIFIED_BY="[Empty name]" NAME="Eggleston 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-11-01 10:23:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eggleston PA, Beasley PP, Kindley RT</AU>
<TI>The effects of oral doses of theophylline and fenoterol on exercise-induced asthma</TI>
<SO>Chest</SO>
<YR>1981</YR>
<VL>79</VL>
<NO>4</NO>
<PG>399-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrari-2002" MODIFIED="2012-11-01 10:24:16 +0000" MODIFIED_BY="[Empty name]" NAME="Ferrari 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-11-01 10:24:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrari M, Segattini C, Zanon R, Bertaiola M, Balestreri F, Brotto E et al</AU>
<TI>Comparison of the protective effect of formoterol and of salmeterol against exercise-induced bronchospasm when given immediately before a cycloergometric test</TI>
<SO>Respiration</SO>
<YR>2002</YR>
<VL>69</VL>
<NO>6</NO>
<PG>509-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fogel-2010" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Fogel 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fogel BR, Rosario N, Aristizabal G, Loeys T, Noonan G, Gaile S et al</AU>
<TI>Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2010</YR>
<VL>104</VL>
<PG>511-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francis-1980" MODIFIED="2012-11-01 10:25:03 +0000" MODIFIED_BY="[Empty name]" NAME="Francis 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-11-01 10:25:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francis PW, Krastins IR, Levison H</AU>
<TI>Oral and inhaled salbutamol in the prevention of exercise-induced bronchospasm</TI>
<SO>Pediatrics</SO>
<YR>1980</YR>
<VL>66</VL>
<NO>1</NO>
<PG>103-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-1989" MODIFIED="2012-11-01 10:32:57 +0000" MODIFIED_BY="[Empty name]" NAME="Freeman 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-11-01 10:32:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman W, Packe GE, Cayton RM</AU>
<TI>Effect of nebulised salbutamol on maximal exercise performance in men with mild asthma</TI>
<SO>Thorax</SO>
<YR>1989</YR>
<VL>44</VL>
<NO>11</NO>
<PG>942-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibson-1978" MODIFIED="2012-11-01 10:33:38 +0000" MODIFIED_BY="[Empty name]" NAME="Gibson 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-11-01 10:33:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibson GJ, Greenacre JK, König P, Conolly ME, Pride NB</AU>
<TI>Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1978</YR>
<VL>72</VL>
<NO>3</NO>
<PG>199-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gimeno-1985" MODIFIED="2012-11-01 10:34:33 +0000" MODIFIED_BY="[Empty name]" NAME="Gimeno 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-11-01 10:34:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gimeno F, van Veenen R, Steenhuis EJ, Berg WC</AU>
<TI>Comparison of disodium cromoglycate, terbutaline and thiazinamium in the prevention of exercise-induced asthma and its relation to non-specific bronchial responsiveness</TI>
<SO>Respiration</SO>
<YR>1985</YR>
<VL>48</VL>
<NO>2</NO>
<PG>108-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-GlaxoSmithKline-2006-I" MODIFIED="2013-09-10 10:14:10 +0100" MODIFIED_BY="[Empty name]" NAME="GlaxoSmithKline 2006 I" YEAR="2006">
<REFERENCE MODIFIED="2013-09-10 10:13:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A study measuring asthma control in pediatric and adolescent subjects whose asthma is worsened by activity or exercise</TI>
<SO>clinicaltrials.gov</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-GlaxoSmithKline-2006-II" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="GlaxoSmithKline 2006 II" YEAR="2006">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline</AU>
<TI>A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg BID versus Fluticasone Propionate DISKUS 100 mcg BID in Pediatric and in Adolescent Subjects With Activity-Induced Bronchospasm</TI>
<SO>GlaxoSmithKline Clinical Trial Register</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godfrey-1975" MODIFIED="2012-11-01 10:35:50 +0000" MODIFIED_BY="[Empty name]" NAME="Godfrey 1975" YEAR="1975">
<REFERENCE MODIFIED="2012-11-01 10:35:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godfrey S, König P</AU>
<TI>Suppression of exercise-induced asthma by salbutamol, theophylline, atropine, cromolyn, and placebo in a group of asthmatic children</TI>
<SO>Pediatrics</SO>
<YR>1975</YR>
<VL>56</VL>
<NO>5 pt 2 suppl</NO>
<PG>930-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godfrey-1976" MODIFIED="2012-11-01 10:38:49 +0000" MODIFIED_BY="[Empty name]" NAME="Godfrey 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-11-01 10:38:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godfrey S, König P</AU>
<TI>Inhibition of exercise-induced asthma by different pharmacological pathways</TI>
<SO>Thorax</SO>
<YR>1976</YR>
<VL>31</VL>
<NO>2</NO>
<PG>137-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guerin-1992" MODIFIED="2012-11-01 10:39:26 +0000" MODIFIED_BY="[Empty name]" NAME="Guerin 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-11-01 10:39:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerin JC, Brambilla C, Godard P, de Muizon H, Aubert B, Bons J</AU>
<TI>Prolonged effect against exercise-induced bronchospasm: salmeterol versus sodium cromoglycate</TI>
<SO>Revue des Maladies Respiratoires</SO>
<YR>1992</YR>
<VL>9</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunawardena-2005" MODIFIED="2013-01-18 14:52:25 +0000" MODIFIED_BY="[Empty name]" NAME="Gunawardena 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-18 14:52:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunawardena K, Palmer P, Das S, Hewitt A</AU>
<TI>Using exercise-induced bronchoconstriction as a method to compare formoterol inhalers in children</TI>
<SO>Journal of Applied Therapeutic Research</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>3</NO>
<PG>16-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermansen-2006" MODIFIED="2012-11-01 10:42:58 +0000" MODIFIED_BY="[Empty name]" NAME="Hermansen 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-11-01 10:42:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermansen MN, Nielsen KG, Buchvald F, Jespersen JJ, Bengtsson T, Bisgaard H</AU>
<TI>Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>5</NO>
<PG>1203-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Higgs-1983" MODIFIED="2012-11-01 10:43:47 +0000" MODIFIED_BY="[Empty name]" NAME="Higgs 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-11-01 10:43:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Higgs CM, Laszlo G</AU>
<TI>The duration of protection from exercise-induced asthma by inhaled salbutamol, and a comparison with inhaled reproterol</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1983</YR>
<VL>77</VL>
<NO>3</NO>
<PG>262-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ienna-1997" MODIFIED="2012-11-01 10:44:26 +0000" MODIFIED_BY="[Empty name]" NAME="Ienna 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-11-01 10:44:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ienna TM, McKenzie DC</AU>
<TI>The asthmatic athlete: metabolic and ventilatory responses to exercise with and without pre-exercise medication</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>2</NO>
<PG>142-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iikura-1988" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Iikura 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iikura Y, Inui H, Obata T, Nagakura T, Sugimoto H, Lee TH et al</AU>
<TI>Drug effects on exercise-induced late asthmatic responses</TI>
<SO>New England and Regional Allergy Proceedings</SO>
<YR>1988</YR>
<VL>9</VL>
<NO>3</NO>
<PG>203-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ioli-1986" MODIFIED="2012-11-01 11:21:05 +0000" MODIFIED_BY="[Empty name]" NAME="Ioli 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-11-01 11:21:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ioli F, Donner CF, Fracchia C, Manini G, Patessio A, Spada EL et al</AU>
<TI>A new bronchodilating agent, procaterol, in preventing exercise-induced asthma</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>5</NO>
<PG>389-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1986" MODIFIED="2012-11-01 11:29:10 +0000" MODIFIED_BY="[Empty name]" NAME="Johnson 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-11-01 11:29:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson CE, Belfield PW, Davis S, Cooke NJ, Spencer A, Davies JA</AU>
<TI>Platelet activation during exercise induced asthma: effect of prophylaxis with cromoglycate and salbutamol</TI>
<SO>Thorax</SO>
<YR>1986</YR>
<VL>41</VL>
<NO>4</NO>
<PG>290-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koch-1972" MODIFIED="2012-11-01 11:29:35 +0000" MODIFIED_BY="[Empty name]" NAME="Koch 1972" YEAR="1972">
<REFERENCE MODIFIED="2012-11-01 11:29:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koch G</AU>
<TI>Terbutaline in bronchial asthma. Effect on lung volumes, ventilatory performance, pulmonary gas exchange and circulation at rest and during exercise</TI>
<SO>Scandinavian Journal of Respiratory Diseases</SO>
<YR>1972</YR>
<VL>53</VL>
<NO>4</NO>
<PG>187-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-1988" MODIFIED="2012-07-28 16:29:54 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-07-28 16:29:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar AS</AU>
<TI>Salmeterol in exercise induced asthma</TI>
<SO>Indian Pediatrics</SO>
<YR>1988</YR>
<VL>35</VL>
<NO>7</NO>
<PG>681-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopes-Dos-Santos-1991" MODIFIED="2012-11-01 11:36:00 +0000" MODIFIED_BY="[Empty name]" NAME="Lopes Dos Santos 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-11-01 11:36:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>dos Santos JM, Costa H, Ståhl E, Wirén JE</AU>
<TI>Bricanyl Turbuhaler and Ventolinrho Rotahaler in exercise-induced asthma in children</TI>
<SO>Allergy</SO>
<YR>1991</YR>
<VL>46</VL>
<NO>3</NO>
<PG>203-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Machado-2012" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Machado 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Machado D, Pereira G, Tavares B, Loureiro G, Segorbe-Luis A</AU>
<TI>Airways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics</TI>
<SO>European Annals of Allergy and Clinical Immunology</SO>
<YR>2012</YR>
<VL>44</VL>
<NO>1</NO>
<PG>12-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macucci-2004" MODIFIED="2012-11-01 11:37:58 +0000" MODIFIED_BY="[Empty name]" NAME="Macucci 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-11-01 11:37:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macucci F, Guerrini L., Strambi M</AU>
<TI>Oral montelukast compared with inhaled salbutamol to prevent exercise-induced asthma in children</TI>
<SO>Minerva Pneumologica</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>1</NO>
<PG>41-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magnussen-1984" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Magnussen 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magnussen H, Reuss G</AU>
<TI>Blockade of exercise-induced asthma by fenoterol</TI>
<SO>Klinische Wochenschrift</SO>
<YR>1984</YR>
<VL>62</VL>
<NO>4</NO>
<PG>168-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Makela-2012" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Makela 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Makela MJ, Malmberg LP, Csonka P, Klemola T, Kajosaari M, Pelkonen AS</AU>
<TI>Salmeterol and fluticasone in young children with multiple-trigger wheeze</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2012</YR>
<VL>109</VL>
<PG>65-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinsson-1985" MODIFIED="2012-11-01 11:39:29 +0000" MODIFIED_BY="[Empty name]" NAME="Martinsson 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-11-01 11:39:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinsson A, Larsson K, Hjemdahl P</AU>
<TI>Reduced beta 2-adrenoceptor responsiveness in exercise-induced asthma</TI>
<SO>Chest</SO>
<YR>1985</YR>
<VL>88</VL>
<NO>4</NO>
<PG>594-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Merck-2005-I" MODIFIED="2012-07-28 16:31:28 +0100" MODIFIED_BY="[Empty name]" NAME="Merck 2005 I" YEAR="2005">
<REFERENCE MODIFIED="2012-07-27 14:39:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Merck</AU>
<TI>An investigational drug to prevent exercise-induced bronchospasm</TI>
<SO>clinicaltrials.gov</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Merck-2005-II" MODIFIED="2012-07-28 14:57:25 +0100" MODIFIED_BY="[Empty name]" NAME="Merck 2005 II" YEAR="2005">
<REFERENCE MODIFIED="2012-07-28 14:57:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Merck</AU>
<TI>Two investigational drugs in the prevention of airway constriction brought on by exercise in asthmatic patients</TI>
<SO>clinicaltrials.gov</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mickleborough-2007" MODIFIED="2012-11-01 11:42:30 +0000" MODIFIED_BY="[Empty name]" NAME="Mickleborough 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-11-01 11:42:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mickleborough TD, Lindley MR, Turner LA</AU>
<TI>Comparative effects of a high-intensity interval warm-up and salbutamol on the bronchoconstrictor response to exercise in asthmatic athletes</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>6</NO>
<PG>456-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millqvist-2000" MODIFIED="2012-11-01 11:42:58 +0000" MODIFIED_BY="[Empty name]" NAME="Millqvist 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-11-01 11:42:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millqvist EB, Bengtsson U, Löwhagen O</AU>
<TI>Combining a beta2-agonist with a face mask to prevent exercise-induced bronchoconstriction</TI>
<SO>Allergy</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>7</NO>
<PG>672-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morandini-1982" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Morandini 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morandini GC,</AU>
<TI>Protection of exercise-induced asthma: comparative study of drugs with a different mechanism of action</TI>
<SO>Minerva Pneumologica</SO>
<YR>1982</YR>
<VL>21</VL>
<NO>2</NO>
<PG>75-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morooka-1987" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Morooka 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morooka T, Nishima S, Ota S</AU>
<TI>Prevention of exercise-induced bronchospasm in asthmatic children. Effect of aerosol and oral procaterol hydrochloride</TI>
<SO>Journal of Asthma</SO>
<YR>1987</YR>
<VL>24</VL>
<NO>6</NO>
<PG>335-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morse-1976" MODIFIED="2012-11-01 11:51:52 +0000" MODIFIED_BY="[Empty name]" NAME="Morse 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-11-01 11:51:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morse J, Jones NL, Anderson GD</AU>
<TI>The effect of terbutaline in exercise-induced asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1976</YR>
<VL>113</VL>
<NO>1</NO>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morton-1992" MODIFIED="2012-11-01 13:11:58 +0000" MODIFIED_BY="[Empty name]" NAME="Morton 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-11-01 13:11:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morton AR, Papalia SM, Morton PS, Fitch KD</AU>
<TI>The efficacy of the nebuhaler method of administration of terbutaline sulphate in the prevention and amelioration of exercise induced asthma</TI>
<SO>Australian Journal of Science and Medicine in Sport</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>4</NO>
<PG>103-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murray-2011" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Murray 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murray JJ, Waitkus-Edwards KR, Yancey SW</AU>
<TI>Evaluation of fluticasone propionate and fluticasone propionate/salmeterol combination on exercise in pediatric and adolescent patients with asthma</TI>
<SO>The Open Respiratory Medicine Journal</SO>
<YR>2011</YR>
<VL>5</VL>
<PG>11-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-2009" MODIFIED="2012-11-01 13:13:09 +0000" MODIFIED_BY="[Empty name]" NAME="Pearlman 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-11-01 13:13:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman D, Qaqundah P, Matz J, Yancey SW, Stempel DA, Ortega HG</AU>
<TI>Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2009</YR>
<VL>44</VL>
<NO>5</NO>
<PG>429-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfleger-2002" MODIFIED="2012-11-01 13:13:55 +0000" MODIFIED_BY="[Empty name]" NAME="Pfleger 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-11-01 13:13:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pfleger A, Eber E, Weinhandl E, Zach MS</AU>
<TI>Effects of nedocromil and salbutamol on airway reactivity in children with asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>3</NO>
<PG>624-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichaipat-1995" MODIFIED="2012-11-01 13:14:42 +0000" MODIFIED_BY="[Empty name]" NAME="Pichaipat 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-11-01 13:14:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichaipat V, Tongpenyai Y, Nerntong T, Sriprapachiranont C</AU>
<TI>The protective effect of inhaled terbutaline, sodium cromoglycate and budesonide on exercise-induced asthma in children</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>1995</YR>
<VL>78</VL>
<NO>10</NO>
<PG>505-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pichon-2005" MODIFIED="2012-11-01 13:16:50 +0000" MODIFIED_BY="[Empty name]" NAME="Pichon 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-11-01 13:16:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pichon A, Roulaud M, Denjean A, de Bisschop C</AU>
<TI>Airway tone during exercise in healthy subjects: effects of salbutamol and ipratropium bromide</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>5</NO>
<PG>321-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poppius-1973" MODIFIED="2012-11-01 13:18:41 +0000" MODIFIED_BY="[Empty name]" NAME="Poppius 1973" YEAR="1973">
<REFERENCE MODIFIED="2012-11-01 13:18:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poppius H, Salorinne Y</AU>
<TI>Comparative trial of salbutamol and an anticholinergic drug, SCH 1000, in prevention of exercise-induced asthma</TI>
<SO>Scandinavian Journal of Respiratory Diseases</SO>
<YR>1973</YR>
<VL>54</VL>
<NO>3</NO>
<PG>142-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabe-1993" MODIFIED="2012-11-01 13:29:10 +0000" MODIFIED_BY="[Empty name]" NAME="Rabe 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-11-01 13:29:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabe KF, Jörres R, Magnussen H</AU>
<TI>The effect of 10, 50 and 200 micrograms inhaled fenoterol on exercise induced asthma</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>1993</YR>
<VL>23</VL>
<NO>5</NO>
<PG>440-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Raissy-2006" MODIFIED="2013-09-10 10:15:04 +0100" MODIFIED_BY="[Empty name]" NAME="Raissy 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-09-10 10:15:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Raissy HH</AU>
<TI>Exercise induced bronchospasm in children</TI>
<SO>clinicaltrials.gov</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raissy-2008" MODIFIED="2012-11-01 13:39:32 +0000" MODIFIED_BY="[Empty name]" NAME="Raissy 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-11-01 13:39:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raissy HH, Harkins M, Kelly F, Kelly HW</AU>
<TI>Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children</TI>
<SO>Pharmacotherapy</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>3</NO>
<PG>287-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Revill-1998" MODIFIED="2012-11-01 13:30:16 +0000" MODIFIED_BY="[Empty name]" NAME="Revill 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-11-01 13:30:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Revill SM, Morgan MD</AU>
<TI>The cardiorespiratory response to submaximal exercise in subjects with asthma following pretreatment with controlled release oral salbutamol and high-dose inhaled salmeterol</TI>
<SO>Respiratory Medicine</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>8</NO>
<PG>1053-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robertson-1994" MODIFIED="2012-11-01 13:40:33 +0000" MODIFIED_BY="[Empty name]" NAME="Robertson 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-11-01 13:40:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robertson W, Simkins J, O'Hickey SP, Freeman S, Cayton RM</AU>
<TI>Does single dose salmeterol affect exercise capacity in asthmatic men?</TI>
<SO>European Respiratory Journal</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>11</NO>
<PG>1978-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rohr-1987" MODIFIED="2012-11-01 13:41:13 +0000" MODIFIED_BY="[Empty name]" NAME="Rohr 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-11-01 13:41:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rohr AS, Siegel SC, Katz RM, Rachelefsky GS, Spector SL, Lanier R</AU>
<TI>A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm</TI>
<SO>Annals of Allergy</SO>
<YR>1987</YR>
<VL>59</VL>
<NO>2</NO>
<PG>107-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanguinetti-1986" MODIFIED="2012-11-01 13:42:06 +0000" MODIFIED_BY="[Empty name]" NAME="Sanguinetti 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-11-01 13:42:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanguinetti CM, De Luca S, Gasparini S, Massei V</AU>
<TI>Evaluation of Duovent in the prevention of exercise-induced asthma</TI>
<SO>Respiration</SO>
<YR>1986</YR>
<VL>50</VL>
<NO>2</NO>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaanning-1996" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Schaanning 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaanning J, Vilsvik J, Henriksen AH, Bratten G</AU>
<TI>Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1996</YR>
<VL>76</VL>
<NO>1</NO>
<PG>57-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shah-1983" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Shah 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah S, Johnston D, Woodcock AA, Johnson M, Geddes DM</AU>
<TI>Breathlessness and exercise tolerance in chronic airflow obstruction: 2-hourly versus 4-hourly salbutamol by inhalation</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1983</YR>
<VL>8</VL>
<NO>5</NO>
<PG>343-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-1981" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Shapiro 1981" YEAR="1981">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GG, McPhillips JJ, Smith K, Furukawa CT, Pierson WE, Bierman CW</AU>
<TI>Effectiveness of terbutaline and theophylline alone and in combination in exercise-induced bronchospasm</TI>
<SO>Pediatrics</SO>
<YR>1981</YR>
<VL>67</VL>
<NO>4</NO>
<PG>508-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shapiro-1990" MODIFIED="2012-11-01 13:51:50 +0000" MODIFIED_BY="[Empty name]" NAME="Shapiro 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-11-01 13:51:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GG, Kemp JP, DeJong R, Chapko M, Bierman CW, Altman LC et al</AU>
<TI>Effects of albuterol and procaterol on exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1990</YR>
<VL>65</VL>
<NO>4</NO>
<PG>273-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sichletidis-1993" MODIFIED="2012-11-01 13:59:46 +0000" MODIFIED_BY="[Empty name]" NAME="Sichletidis 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-11-01 13:59:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sichletidis L, Daskalopoulou E, Kyriazis G, Kosmidou I, Koupidou S, Pechlivanidis T et al</AU>
<TI>Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma</TI>
<SO>Journal of International Medical Research</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>2</NO>
<PG>81-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silverman-1973" MODIFIED="2012-11-01 14:02:48 +0000" MODIFIED_BY="[Empty name]" NAME="Silverman 1973" YEAR="1973">
<REFERENCE MODIFIED="2012-11-01 14:02:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silverman M, Konig P, Godfrey S</AU>
<TI>Use of serial exercise tests to assess the efficacy and duration of action of drugs for asthma</TI>
<SO>Thorax</SO>
<YR>1973</YR>
<VL>28</VL>
<NO>5</NO>
<PG>574-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1992" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh JP, Singh R, Gupta RC, Bharadwaja B</AU>
<TI>A comparative study of bronchodilator actions of ipratropium bromide (Atrovent) and salbutamol (Ventolin) on exercise induced bronchial asthma</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1992</YR>
<VL>40</VL>
<NO>8</NO>
<PG>545-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sly-1968" MODIFIED="2012-11-01 14:06:33 +0000" MODIFIED_BY="[Empty name]" NAME="Sly 1968" YEAR="1968">
<REFERENCE MODIFIED="2012-11-01 14:06:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sly RM, Heimlich EM, Ginsburg J, Busser RJ, Strick L</AU>
<TI>Exercise-induced bronchospasm: evaluation of metaproterenol</TI>
<SO>Annals of Allergy</SO>
<YR>1968</YR>
<VL>26</VL>
<NO>5</NO>
<PG>253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sly-1975" MODIFIED="2012-11-01 14:14:39 +0000" MODIFIED_BY="[Empty name]" NAME="Sly 1975" YEAR="1975">
<REFERENCE MODIFIED="2012-11-01 14:14:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sly RM, Puapan P, Ghazanshahi S, Midha R</AU>
<TI>Exercise-induced bronchospasm: evaluation of albuterol aerosol</TI>
<SO>Annals of Allergy</SO>
<YR>1975</YR>
<VL>34</VL>
<NO>1</NO>
<PG>7-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sly-1982" MODIFIED="2012-11-01 14:19:35 +0000" MODIFIED_BY="[Empty name]" NAME="Sly 1982" YEAR="1982">
<REFERENCE MODIFIED="2012-11-01 14:19:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sly RM, O'Brien SR</AU>
<TI>Effect of oral terbutaline on exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1982</YR>
<VL>48</VL>
<NO>3</NO>
<PG>151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spada-1985" MODIFIED="2012-11-01 14:22:36 +0000" MODIFIED_BY="[Empty name]" NAME="Spada 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-11-01 14:22:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spada EL, Donner CF, Meriggi A, Vecchio C</AU>
<TI>Pharmacologic prevention of exercise-induced asthma</TI>
<SO>Minerva Pneumologica</SO>
<YR>1985</YR>
<VL>24</VL>
<NO>2</NO>
<PG>159-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stark-1981" MODIFIED="2012-11-01 14:24:30 +0000" MODIFIED_BY="[Empty name]" NAME="Stark 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-11-01 14:24:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stark RD, Gambles SA</AU>
<TI>Effects of salbutamol, ipratropium bromide and disodium cromoglycate on breathlessness induced by exercise in normal subjects</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1981</YR>
<VL>12</VL>
<NO>4</NO>
<PG>497-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinshamn-2004" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Steinshamn 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinshamn S, Sandsund M, Sue-Chu M, Bjermer L</AU>
<TI>Effects of montelukast and salmeterol on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>4</NO>
<PG>1154-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svenonius-1983" MODIFIED="2012-11-01 14:26:08 +0000" MODIFIED_BY="[Empty name]" NAME="Svenonius 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-11-01 14:26:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svenonius E, Kautto R, Arborelius M Jr</AU>
<TI>Improvement after training of children with exercise-induced asthma</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1983</YR>
<VL>72</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svenonius-1988" MODIFIED="2012-11-01 14:29:02 +0000" MODIFIED_BY="[Empty name]" NAME="Svenonius 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-11-01 14:29:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svenonius E, Arborelius M Jr, Wiberg R, Ekberg P</AU>
<TI>Prevention of exercise-induced asthma by drugs inhaled from metered aerosols</TI>
<SO>Allergy</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>4</NO>
<PG>252-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svenonius-1994" MODIFIED="2012-11-01 14:29:47 +0000" MODIFIED_BY="[Empty name]" NAME="Svenonius 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-11-01 14:29:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svenonius E, Arborelius M, Wiberg R, Ståhl E, Svensson M</AU>
<TI>A comparison of terbutaline inhaled by Turbuhaler and by a chlorofluorocarbon CFC inhaler in children with exercise-induced asthma</TI>
<SO>Allergy</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>6</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tabas-1985" MODIFIED="2012-11-01 14:30:41 +0000" MODIFIED_BY="[Empty name]" NAME="Tabas 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-11-01 14:30:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tabas A, Rodríguez A, Lobera T, Diéguez I, Oehling A</AU>
<TI>Carbuterol, salbutamol and DSCG in exercise-induced asthma</TI>
<SO>Allergologia et Immunopathologia</SO>
<YR>1985</YR>
<VL>13</VL>
<NO>6</NO>
<PG>493-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tammivaara-1979" MODIFIED="2012-07-28 16:42:03 +0100" MODIFIED_BY="[Empty name]" NAME="Tammivaara 1979" YEAR="1979">
<REFERENCE MODIFIED="2012-07-28 16:42:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tammivaara R</AU>
<TI>The efficacy of terbutaline and fenoterol aerosols on adult exercise-induced asthma</TI>
<SO>Scandinavian Journal of Respiratory Diseases</SO>
<YR>1979</YR>
<VL>103</VL>
<PG>212-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Unnithan-1994" MODIFIED="2012-11-01 14:31:38 +0000" MODIFIED_BY="[Empty name]" NAME="Unnithan 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-11-01 14:31:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Unnithan VB, Thomson KJ, Aitchison TC, Paton JY</AU>
<TI>Beta 2-agonists and running economy in prepubertal boys</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>6</NO>
<PG>378-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verini-1983" MODIFIED="2012-11-01 14:32:11 +0000" MODIFIED_BY="[Empty name]" NAME="Verini 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-11-01 14:32:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verini M, Chiarelli F, Di Tullio A, Morgese G, Pallotta R</AU>
<TI>Pharmacological prevention of exercise-induced bronchospasm: review of the literature and trial of disodium cromoglycate, fenoterol and ipratropium bromide in a pediatric population</TI>
<SO>Pediatria Medica e Chirurgica</SO>
<YR>1983</YR>
<VL>5</VL>
<NO>6</NO>
<PG>501-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verini-1985" MODIFIED="2012-11-01 14:32:47 +0000" MODIFIED_BY="[Empty name]" NAME="Verini 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-11-01 14:32:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verini M, Ansaloni A, Di Vincenzo MG, Napoleone M, Morgese G</AU>
<TI>Evaluation of reproterol's effectiveness in preventing exercise-induced bronchospasm in children</TI>
<SO>Journal of International Medical Research</SO>
<YR>1985</YR>
<VL>13</VL>
<NO>1</NO>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verini-1999" MODIFIED="2012-11-01 14:36:44 +0000" MODIFIED_BY="[Empty name]" NAME="Verini 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-11-01 14:36:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verini M, Verrotti A, Greco R, Chiarelli F</AU>
<TI>Functional effects of controlled physical activity in children and young adults affected by exercise-induced asthma treated with corticosteroids and beta-2 agonists</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>6</NO>
<PG>467-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villaran-1999" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Villaran 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villaran C, O'Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG et al</AU>
<TI>Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>3</NO>
<PG>547-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vilsvik-1991" MODIFIED="2013-09-10 10:16:30 +0100" MODIFIED_BY="[Empty name]" NAME="Vilsvik 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-09-10 10:16:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vilsvik J, Schaanning J, Ståhl E, Holthe S</AU>
<TI>Comparison between Bricanyl Turbuhaler and Ventolin metered dose inhaler in the treatment of exercise-induced asthma in adults</TI>
<SO>Annals of Allergy</SO>
<YR>1991</YR>
<VL>67</VL>
<NO>3</NO>
<PG>315-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vilsvik-2001" MODIFIED="2012-11-01 14:39:04 +0000" MODIFIED_BY="[Empty name]" NAME="Vilsvik 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-11-01 14:39:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vilsvik J, Ankerst J, Palmqvist M, Persson G, Schaanning J, Schwabe G et al</AU>
<TI>Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis</TI>
<SO>Respiratory Medicine</SO>
<YR>2001</YR>
<VL>95</VL>
<NO>6</NO>
<PG>484-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Berg-2002" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Von Berg 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Von Berg A, Albrecht B, Darlath W, Vo HW, Berdel D</AU>
<TI>Intraindividual, randomised, double-blind comparison between sodium cromoglycate and reproterol to assess the protective effect of the single drugs and their combination in children with exercise-induced asthma</TI>
<SO>Allergologie</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>11</NO>
<PG>557-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiler-2005" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Weiler 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, Dorinsky PM</AU>
<TI>Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>1</NO>
<PG>65-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberg-1982" MODIFIED="2012-07-29 09:20:54 +0100" MODIFIED_BY="[Empty name]" NAME="Weinberg 1982" YEAR="1982">
<REFERENCE MODIFIED="2012-07-29 09:20:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg EG</AU>
<TI>The effect of terbutaline sulphate on exercise-induced asthma in children</TI>
<SO>South African Medical Journal</SO>
<YR>1982</YR>
<VL>61</VL>
<NO>16</NO>
<PG>587-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeung-1980" MODIFIED="2012-11-01 14:56:46 +0000" MODIFIED_BY="[Empty name]" NAME="Yeung 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-11-01 14:56:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yeung R, Nolan GM, Levison H</AU>
<TI>Comparison of the effects of inhaled SCH 1000 and fenoterol on exercise-induced bronchospasm in children</TI>
<SO>Pediatrics</SO>
<YR>1980</YR>
<VL>66</VL>
<NO>1</NO>
<PG>109-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zanconato-1990" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Zanconato 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zanconato S, Baraldi E, Santuz P, Magagnin G, Zacchello F</AU>
<TI>Effect of inhaled disodium cromoglycate and albuterol on energy: cost of running in asthmatic children</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>4</NO>
<PG>240-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimmermann-2003" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Zimmermann 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimmermann T, Gulyas A, Bauer CP, Steinkamp G, Trautmann M</AU>
<TI>Salmeterol versus sodium cromoglycate for the protection of exercise induced asthma in children&#65293;a randomised cross-over study</TI>
<SO>European Journal of Medical Research</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>9</NO>
<PG>428-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma J Welsh">
<STUDY DATA_SOURCE="PUB" ID="STD-Kupper-2012" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma J Welsh" NAME="Kupper 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Küpper T, Goebbels K, Kennes LN, Netzer NC</AU>
<TI>Cromoglycate, reproterol, or both&#65293;what's best for exercise-induced asthma?</TI>
<SO>Sleep and Breathing</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>4</NO>
<PG>1229-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Anderson-1997" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Dolores Matthews" NAME="Anderson 1997" TYPE="BOOK_SECTION">
<AU>Anderson SD</AU>
<TI>Exercise-induced asthma</TI>
<SO>Allergy and Allergic Disease</SO>
<YR>1997</YR>
<PG>692-711</PG>
<ED>Kay AB</ED>
<PB>Blackwell Scientific Publications</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2003" MODIFIED="2012-07-29 11:16:53 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Brannan JD</AU>
<TI>Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols</TI>
<SO>Clinical Reviews in Allergy &amp; Immunology</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>1</NO>
<PG>27-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2006" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Anderson SD, Caillaud C, Brannan JD</AU>
<TI>Beta2-agonists and exercise-induced asthma</TI>
<SO>Clinical Reviews in Allergy &amp; Immunology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>2-3</NO>
<PG>163-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bateman-2008" MODIFIED="2012-11-01 15:14:16 +0000" MODIFIED_BY="[Empty name]" NAME="Bateman 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M et al</AU>
<TI>Global strategy for asthma management and prevention: GINA executive summary</TI>
<SO>European Respiratory Journal</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>1</NO>
<PG>143-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brozek-2010" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Brozek 2010" TYPE="JOURNAL_ARTICLE">
<AU>Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al</AU>
<TI>Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2010</YR>
<VL>126</VL>
<NO>3</NO>
<PG>466-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlsen-2008" MODIFIED="2012-11-01 15:17:52 +0000" MODIFIED_BY="[Empty name]" NAME="Carlsen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Carlsen KH, Anderson SD, Bjermer L, Bonini S, Brusasco V, Canonica W et al</AU>
<TI>Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN</TI>
<SO>Allergy</SO>
<YR>2008</YR>
<VL>63</VL>
<NO>4</NO>
<PG>387-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0</SO>
<YR>2011</YR>
<PB>www.cochranehandbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2000" MODIFIED="2008-09-18 15:36:39 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2000" TYPE="COCHRANE_REVIEW">
<AU>Kelly KD, Spooner CH, Rowe BH</AU>
<TI>Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-09-02 10:50:04 +0100" MODIFIED_BY="Toby J Lasserson">
<IDENTIFIER MODIFIED="2008-09-02 10:50:04 +0100" MODIFIED_BY="Toby J Lasserson" TYPE="DOI" VALUE="10.1002/14651858.CD002731"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koh-2007" MODIFIED="2012-11-01 15:19:00 +0000" MODIFIED_BY="[Empty name]" NAME="Koh 2007" TYPE="COCHRANE_REVIEW">
<AU>Koh MS, Tee A, Lasserson TJ, Irving LB</AU>
<TI>Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-09-18 15:39:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-18 15:39:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002739.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martinez-2005" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Martinez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Martinez FD</AU>
<TI>Safety of long-acting beta-agonists&#65293;an urgent need to clear the air</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>2637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2006" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Nelson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, for the SMART Study Group</AU>
<TI>The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<PG>15-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peroni-2011" MODIFIED="2012-11-01 15:20:52 +0000" MODIFIED_BY="[Empty name]" NAME="Peroni 2011" TYPE="JOURNAL_ARTICLE">
<AU>Peroni DG, Pescollderungg L, Sandri M, Chinellato I, Boner AL, Piacentini GL</AU>
<TI>Time-effect of montelukast on protection against exercise-induced bronchoconstriction</TI>
<SO>Respiratory Medicine</SO>
<YR>2011</YR>
<VL>105</VL>
<NO>12</NO>
<PG>1790-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Randolph-2008" MODIFIED="2012-07-29 11:18:16 +0100" MODIFIED_BY="[Empty name]" NAME="Randolph 2008" TYPE="JOURNAL_ARTICLE">
<AU>Randolph C</AU>
<TI>Exercise-induced bronchospasm in children</TI>
<SO>Clinical Reviews in Allergy &amp; Immunology</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>2</NO>
<PG>205-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.2" MODIFIED="2013-09-10 10:17:15 +0100" MODIFIED_BY="Emma J Welsh" NAME="RevMan 5.2" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) Version 5.2</TI>
<YR>2012</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS MODIFIED="2013-09-10 10:17:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rundell-2000" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Rundell 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rundell KW, Wilber RL, Szmedra L, Jenkinson DM, Mayers LB, Im J</AU>
<TI>Exercise-induced asthma screening of elite athletes: field versus laboratory exercise challenge</TI>
<SO>Medicine &amp; Science in Sports &amp; Exercise</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>2</NO>
<PG>309-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salpeter-2010" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Salpeter 2010" TYPE="JOURNAL_ARTICLE">
<AU>Salpeter SR, Wall AJ, Buckley NS</AU>
<TI>Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events</TI>
<SO>American Journal of Medicine</SO>
<YR>2010</YR>
<VL>123</VL>
<NO>4</NO>
<PG>322-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shapiro-2002" MODIFIED="2012-11-01 15:22:39 +0000" MODIFIED_BY="[Empty name]" NAME="Shapiro 2002" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro GS, Yegen U, Xiang J, Kottakis J, Della Cioppa G</AU>
<TI>A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>12</NO>
<PG>2077-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spooner-2003" MODIFIED="2012-10-26 10:46:08 +0100" MODIFIED_BY="[Empty name]" NAME="Spooner 2003" TYPE="COCHRANE_REVIEW">
<AU>Spooner CH, Spooner GR, Rowe BH</AU>
<TI>Mast-cell stabilising agents to prevent exercise-induced bronchoconstriction</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-10-26 10:46:08 +0100" MODIFIED_BY="Emma Jackson">
<IDENTIFIER MODIFIED="2012-10-26 10:46:08 +0100" MODIFIED_BY="Emma Jackson" TYPE="DOI" VALUE="10.1002/14651858.CD002307"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterk-1993" MODIFIED="2012-11-01 15:23:59 +0000" MODIFIED_BY="[Empty name]" NAME="Sterk 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD et al</AU>
<TI>Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>Suppl</NO>
<PG>53-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiler-2010" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Weiler 2010" TYPE="JOURNAL_ARTICLE">
<AU>Weiler JM, Anderson SD, Randolph C, Bonini S, Craig TJ, Pearlman DS et al</AU>
<TI>Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>6 suppl</NO>
<PG>1-47</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-05-30 13:36:05 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-08-21 18:24:37 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-08-21 18:24:37 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-08-02 23:58:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-2001-Salb-Disk">
<CHAR_METHODS MODIFIED="2012-05-30 13:25:37 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: 2 centres, Australia</P>
<P>Wash-out: 1-14 days</P>
<P>Exercise challenge: Cycle-ergometer for 8 min up to 50-60% of MVV</P>
<P>Criteria for EIB diagnosis: Positive history, FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 13:25:37 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 29</P>
<P>% of males: 40%</P>
<P>Age range: 18-40 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 13:25:37 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 30 min.</P>
<P>Intervention: Salbutamol MDI 200 mcg; Salbutamol diskus 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed on the study day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 13:25:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: max FEV1 % fall, % protection</P>
<P>Secondary available: Number of patients with a max FEV1 % fall &lt;10%, &lt;15%, &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 23:58:54 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 13:27:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-2001-Salb-MDI">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 13:27:25 +0100" MODIFIED_BY="[Empty name]">
<P>See: Anderson 2001 Salb Disk</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-21 18:24:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blake-1999-Salb-180">
<CHAR_METHODS MODIFIED="2012-05-30 14:01:04 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 3-14 days</P>
<P>Exercise challenge: Treadmill for 6 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-21 18:24:37 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 26</P>
<P>% of males: 65%</P>
<P>Age range: 4-11 years</P>
<P>Ethnicity: 81% Caucasians, 15% Blacks, 4% Hispanic</P>
<P>Withdrawal or drop out: 3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:01:04 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 30 min, 5:30 hours, 11:30 hours</P>
<P>Intervention: Albuterol 180 mcg, Salmeterol 25 mcg Diskus, Salmeterol 50 mcg Diskus</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:01:04 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: max FEV1 % fall, % protection, FEV1 fall AUC</P>
<P>Secondary available: Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 23:59:09 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:04:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blake-1999-Salm-25">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:04:10 +0100" MODIFIED_BY="[Empty name]">
<P>See: Blake 1999 Salb</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:04:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blake-1999-Salm-50">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>See: Blake 1999 Salb</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 23:59:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boner-1994-Form-12">
<CHAR_METHODS MODIFIED="2012-05-30 14:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Italy</P>
<P>Wash-out: 2-10 days</P>
<P>Exercise challenge: Treadmill for 6 min at 90±4% of max HR</P>
<P>Criteria for EIB diagnosis: Positive history, asthma according to ATS, FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 16</P>
<P>% of males: 68%</P>
<P>Age range: 6-12 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:06:02 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 3 hours, 12 hours</P>
<P>Intervention: Salbutamol 200 mcg, Formoterol 12 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:06:01 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: max FEV1 % fall, % protection, FEV1 fall AUC</P>
<P>Secondary available: Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 23:59:26 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:07:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boner-1994-Salb-200">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>See: Boner 1994 Form</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 23:59:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boulet-1989-Salb">
<CHAR_METHODS MODIFIED="2012-05-30 14:09:06 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Canada</P>
<P>Wash-out: &gt;2 days</P>
<P>Exercise challenge: Ergometer for 6 min at 80% of VO2 max</P>
<P>Criteria for EIB diagnosis: Positive history, asthma according to ATS, FEV1 fall &gt;10% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:09:06 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 36%</P>
<P>Age range: 19-49 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:09:06 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 30 min.</P>
<P>Intervention: Salbutamol 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Ipratroprium bromide, Sodium cromoglycate</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:09:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: % protection</P>
<P>Secondary available: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 23:59:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 23:59:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bronski-1995-Salb-MDI">
<CHAR_METHODS MODIFIED="2012-05-30 14:11:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 2-7 days</P>
<P>Exercise challenge: Treadmill for 6 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:11:55 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 46</P>
<P>% of males: 59%</P>
<P>Age range: 4-11 years</P>
<P>Ethnicity: 87% Caucasians, 13% Others</P>
<P>Withdrawal or drop out: 2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:11:55 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min.</P>
<P>Intervention: Albuterol MDI 180 mcg, Albuterol rotacaps 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: max FEV1 % fall, % protection</P>
<P>Secondary available: Side effects, Number of patients with a max FEV1 % fall &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 23:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:12:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bronski-1995-Salb-Pwd">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>See: Bronski 1995 Salb MDI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-21 18:24:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bronski-1999-Salm-Disk">
<CHAR_METHODS MODIFIED="2012-05-30 14:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 2-14 days</P>
<P>Exercise challenge: Treadmill for 6 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 24</P>
<P>% of males: 58%</P>
<P>Age range: 4-11 years</P>
<P>Ethnicity: 91% Caucasians, 9% Blacks</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-21 18:24:37 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 30 min, 5:30 hours, 11:30 hours</P>
<P>Intervention: Salmeterol 50 mcg Diskus, Salmeterol 50 mcg Diskhaler</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: max FEV1 % fall, % protection, FEV1 fall AUC</P>
<P>Secondary available: Side effects, Number of patients with a max FEV1 % fall &lt;15%, &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:00:03 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:15:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bronski-1999-Salm-Diskhal">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:15:56 +0100" MODIFIED_BY="[Empty name]">
<P>See: Bronski 1999 Salm Disk</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 00:00:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bronski-2002-Form-12">
<CHAR_METHODS MODIFIED="2012-05-30 14:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 3-7 days</P>
<P>Exercise challenge: Treadmill for 6 min at 90% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 18</P>
<P>% of males: 78%</P>
<P>Age range: 13-36 years</P>
<P>Ethnicity: 88% Caucasians, 12% Others</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min, 4 hours, 8 hours, 12 hours</P>
<P>Intervention: Albuterol 180 mcg, Formoterol 12 mcg, Formoterol 24 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 23:26:19 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: max FEV1 % fall; % protection; FEV1 fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;20%; Max PEF % fall</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:00:19 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:22:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bronski-2002-Form-24">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>See: Bronski 2002 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:22:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bronski-2002-Salb">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:22:40 +0100" MODIFIED_BY="[Empty name]">
<P>See: Bronski 2002 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 00:00:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carlsen-1995-Salm-25">
<CHAR_METHODS MODIFIED="2012-05-30 14:23:29 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Norway</P>
<P>Wash-out: 2-14 days</P>
<P>Exercise challenge: Treadmill for 6 min up to 170-180 bpm</P>
<P>Criteria for EIB diagnosis: Positive history, FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:23:29 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 23</P>
<P>% of males: 47%</P>
<P>Age range: 8-16 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:23:29 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: between 10-12 hours</P>
<P>Intervention: Salmeterol diskhaler 25 mcg, Salmeterol diskhaler 50 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:23:29 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Number of patients with a max FEV1 % fall &lt;15%; Max MEF25-50 % fall</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:00:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:27:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carlsen-1995-Salm-50">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>See: Carlsen Salm 25</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 00:01:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cavagni-1993-Salb-Jet">
<CHAR_METHODS MODIFIED="2012-05-30 14:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Italy</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Treadmill for 6 min up to 170-180 bpm</P>
<P>Criteria for EIB diagnosis: Positive history, FEV1 fall &gt;15% after exercise challenge, FEV1 &gt;15% after bronchodilator</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 9</P>
<P>% of males: 66%</P>
<P>Age range: 5-9 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 10 min.</P>
<P>Intervention: Salbutamol MDI 200 mcg, Salbutamol jet disposable 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Side effects; Max PEF % fall; Max FEF25-75 % fall</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:01:09 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:31:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cavagni-1993-Salb-MDI">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:31:13 +0100" MODIFIED_BY="[Empty name]">
<P>See: Cavagni 1993 Salb Jet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 00:01:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-1990-Fen">
<CHAR_METHODS MODIFIED="2012-05-30 14:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Australia</P>
<P>Wash-out: &lt;14 days</P>
<P>Exercise challenge: Treadmill at 15° inclination for 6 min. up to 150 bpm</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 20</P>
<P>% of males: 70%</P>
<P>Age range: Not reported</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 10 min.</P>
<P>Intervention: Fenoterol 100 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Sodim cromoglycate 20 mg; Sodium cromoglycate 20 mg + Fenoterol 100 mcg</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:01:30 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:40:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daugbjerg-1996-Form-12">
<CHAR_METHODS MODIFIED="2012-05-30 14:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Denmark</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Treadmill for 6 min. up to 150 bpm</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;22% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 14:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 16</P>
<P>% of males: 81%</P>
<P>Age range: 10-14 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 14:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 3 hours, 12 hours</P>
<P>Intervention: Salbutamol 400 mcg, Formoterol 12 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 14:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:40:01 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 14:51:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daugbjerg-1996-Salb">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 14:51:08 +0100" MODIFIED_BY="[Empty name]">
<P>See: Daugbjerg 1996 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-24 13:15:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Debelic-1988-Reproterol">
<CHAR_METHODS MODIFIED="2012-10-24 13:15:39 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Germany</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Free running for 6 min up to 160-180 bpm</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:18:49 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 16</P>
<P>% of males: Not reported</P>
<P>Age range: 8-20 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 15:18:49 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min.</P>
<P>Intervention: Reproterol 1 mg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Any drug suspended 12 hours before exercise challenge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 15:18:49 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:40:10 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:40:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeBenedictis-1996-Salm-25">
<CHAR_METHODS MODIFIED="2012-05-30 15:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Italy</P>
<P>Wash-out: 2-10 days</P>
<P>Exercise challenge: Treadmill for 6 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 83%</P>
<P>Age range: 7-14 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 15:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 1 hour, 12 hours</P>
<P>Intervention: Salmeterol 25 mcg, Salmeterol 50 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 15:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:40:19 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 15:29:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeBenedictis-1996-Salm-50">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 15:29:28 +0100" MODIFIED_BY="[Empty name]">
<P>See: De Benedictis 1996 Salm 25</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:40:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeBenedictis-1998-Salb">
<CHAR_METHODS MODIFIED="2012-05-30 15:30:14 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Italy</P>
<P>Wash-out: &lt;10 days</P>
<P>Exercise challenge: Treadmill for 6 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:30:14 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 66%</P>
<P>Age range: 7-13 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 15:30:14 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 20 min.</P>
<P>Intervention: Salbutamol 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Salbutamol 200 mcg + Nedocromil 4 mg</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 15:30:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:40:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:40:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Del-Col-1993-Salb-Jet">
<CHAR_METHODS MODIFIED="2012-05-30 15:33:20 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Italy</P>
<P>Wash-out: 2-6 days</P>
<P>Exercise challenge: Treadmill for 6 min at 90±4% of max HR</P>
<P>Criteria for EIB diagnosis: Positive history</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:33:20 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 15</P>
<P>% of males: 60%</P>
<P>Age range: 9-13 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 15:33:20 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 10 min.</P>
<P>Intervention: Salbutamol MDI 200 mcg, Salbutamol Jet device 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 15:33:20 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Side effects; Max PEF % fall</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:40:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 15:33:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Del-Col-1993-Salb-MDI">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-30 15:33:56 +0100" MODIFIED_BY="[Empty name]">
<P>See: Del Col 1993 Salb Jet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:40:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dinh-Xuan-1989-Terb">
<CHAR_METHODS MODIFIED="2012-05-30 15:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: France</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Cycle-ergometer for 5 min at 90% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 10</P>
<P>% of males: 70%</P>
<P>Age range: 6-16 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 15:35:14 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min.</P>
<P>Intervention: Terbutaline 500 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-03 07:54:22 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Number of patients with a max FEV1 % fall &lt;10%, &lt;15% and &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:40:49 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:40:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Egglestone-1981-Terb-250">
<CHAR_METHODS MODIFIED="2012-05-30 15:38:58 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: &#8807;2 days</P>
<P>Exercise challenge: Treadmill for 5 min at 90% of max HR</P>
<P>Criteria for EIB diagnosis: Positive history; FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:38:58 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 17</P>
<P>% of males: Not reported</P>
<P>Age range: 18-32 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 15:38:58 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 1 hour</P>
<P>Intervention: Terbutaline 250 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Isoproterenol 100 mcg</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 15:38:58 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Side effects; Max FEF25-75 % fall;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:40:57 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:41:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrari-2000-Form-12">
<CHAR_METHODS MODIFIED="2012-05-30 15:41:01 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Italy</P>
<P>Wash-out: &#8807;2 days</P>
<P>Exercise challenge: Cycle-ergometer for 7 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:41:01 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 14</P>
<P>% of males: 92%</P>
<P>Age range: 12-28 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 15:41:01 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min, 4 hours</P>
<P>Intervention: Formoterol 12 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 15:41:01 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:41:05 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-01 10:36:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia-2001-Form-12">
<CHAR_METHODS MODIFIED="2012-07-29 17:27:00 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, parallel groups</P>
<P>Study location: Spain</P>
<P>Wash-out: Not applicable</P>
<P>Exercise challenge: Cycle-ergometer for 6 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:44:44 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 19</P>
<P>% of males: 42%</P>
<P>Age range: Not reported</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-01 10:36:14 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Chronic administration (4 weeks)</P>
<P>Time of exercise challenge after drug administration: 30 min, 12 hours at day 1, 14 and 28</P>
<P>Intervention: Formoterol 12 mcg twice daily</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 15:44:44 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Onset of tolerance; Number of patients with a max FEV1 % fall &lt;10%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:41:16 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:41:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-1992-Salm-50">
<CHAR_METHODS MODIFIED="2012-05-30 15:46:39 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United Kingdom</P>
<P>Wash-out: 4-10 days</P>
<P>Exercise challenge: Treadmill for 8 min up to 170 bpm</P>
<P>Criteria for EIB diagnosis: Positive history, FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 15:46:39 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 13</P>
<P>% of males: 61%</P>
<P>Age range: 8-15 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 15:46:40 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 1 hour, 5 hours, 9 hours</P>
<P>Intervention: Salmeterol 50 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-30 15:46:39 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;15%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:41:25 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:41:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gronnerod-2000-Form-4.5">
<CHAR_METHODS MODIFIED="2012-07-29 14:33:14 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Germany and Norway</P>
<P>Wash-out: &#8807;3 days</P>
<P>Exercise challenge: Treadmill for 4-8 min up to 180 bpm</P>
<P>Criteria for EIB diagnosis: Asthma according ATS; FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 14:34:09 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 27</P>
<P>% of males: 55%</P>
<P>Age range: 8-17 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 14:36:29 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min, 4 hours, 8 hours, 12 hours</P>
<P>Intervention: Terbutaline 500 mcg; Formoterol 9 mcg; Formoterol 4.5 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 14:37:56 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:41:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-29 14:40:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gronnerod-2000-Form-9">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-29 14:40:40 +0100" MODIFIED_BY="[Empty name]">
<P>See: Gronnerod 2000 Form 4.5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-29 14:41:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gronnerod-2000-Terb-500">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-29 14:41:19 +0100" MODIFIED_BY="[Empty name]">
<P>See: Gronnerod 2000 Form 4.5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:41:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hancox-2002">
<CHAR_METHODS MODIFIED="2012-07-29 14:47:58 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Canada</P>
<P>Wash-out: No</P>
<P>Exercise challenge: Cycle ergometer for 7 min at 80% of max work rate</P>
<P>Criteria for EIB diagnosis: Positive history; FEV1 fall &gt;15% after exercise challenge which was sustained &gt;10% for at least 5 minutes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 14:49:39 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 9</P>
<P>% of males: 11%</P>
<P>Age range: 18-44 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 14:58:10 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Chronic administration (1 week)</P>
<P>Time of exercise challenge after drug administration: 8 hours</P>
<P>Intervention: Salbutamol 800 mcg daily</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 14:52:10 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Tolerance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:41:44 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:41:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hawksworth-2002-Salb-HFA">
<CHAR_METHODS MODIFIED="2012-07-29 15:03:36 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United Kingdom</P>
<P>Wash-out: 1-14 days</P>
<P>Exercise challenge: Treadmill for 6 min at &gt;80% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 15:05:20 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 24</P>
<P>% of males: 75%</P>
<P>Age range: 18-45 years</P>
<P>Ethnicity: Caucasian 83%; Asian 17%</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 15:06:36 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 30 min</P>
<P>Intervention: Salbutamol 180 HFA; Salbutamol 180 mcg MDI</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 15:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:41:53 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-29 14:59:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hawksworth-2002-Salb-MDI">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-29 14:59:06 +0100" MODIFIED_BY="[Empty name]">
<P>See: Hawksworth 2002 Salb HFA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:42:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henricksen-1983-Terb">
<CHAR_METHODS MODIFIED="2012-07-29 15:31:51 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Denmark</P>
<P>Wash-out: No</P>
<P>Exercise challenge: Free running for 6 min at 80-85% of max work capacity</P>
<P>Criteria for EIB diagnosis: PEF fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 15:33:16 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 14</P>
<P>% of males: Not reported</P>
<P>Age range: 8-15 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 15:35:31 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min</P>
<P>Intervention: Terbutaline 32.5 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 15:37:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Max PEF % fall; Side effects; Number of patients with a max FEV1 % fall &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:42:04 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-29 15:40:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henricksen-1992-Salb">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-29 15:40:04 +0100" MODIFIED_BY="[Empty name]">
<P>See: Henricksen 1992 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:42:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henriksen-1992-Form-12">
<CHAR_METHODS MODIFIED="2012-07-29 15:43:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Denmark</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Treadmill for 6 min up to 180 bpm</P>
<P>Criteria for EIB diagnosis: PEF or FEV1 fall &gt;25% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 15:43:38 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: Not reported</P>
<P>Age range: 8-15 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 15:46:05 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 30 min, 3 hours, 5.30 hours, 8 hours</P>
<P>Intervention: Salbutamol 200 mcg; Formoterol 12 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 15:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Max PEF % fall; Side effects; Number of patients with a max FEV1 % fall &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:42:11 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:42:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hills-1976-Salb">
<CHAR_METHODS MODIFIED="2012-07-29 15:56:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United Kingdom</P>
<P>Wash-out: &lt; 7 days</P>
<P>Exercise challenge: Free running for 8 min at max speed</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 15:56:52 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 19</P>
<P>% of males: 42%</P>
<P>Age range: 5-15 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 15:57:41 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 20 min</P>
<P>Intervention: Salbutamol 200 mcg; Salmefamol 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 15:58:42 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:42:21 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-29 15:48:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hills-1976-Salmefamol">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-29 15:48:52 +0100" MODIFIED_BY="[Empty name]">
<P>See: Hills 1976 Salb</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:42:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inman-1996">
<CHAR_METHODS MODIFIED="2012-07-29 16:36:46 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Canada</P>
<P>Wash-out: 7-21 days</P>
<P>Exercise challenge: Cycle ergometer for 5 min at 80% of max work rate</P>
<P>Criteria for EIB diagnosis: Positive history</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 16:37:08 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 10</P>
<P>% of males: 70%</P>
<P>Age range: 19-37 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 16:42:17 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Chronic administration 81 week)</P>
<P>Time of exercise challenge after drug administration: 24 hours</P>
<P>Intervention: Salbutamol 800 mcg daily</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 16:42:53 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Onset of tolerance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:42:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:42:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kemp-1994-Salb">
<CHAR_METHODS MODIFIED="2012-07-29 17:23:48 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, parallel groups</P>
<P>Study location: United States</P>
<P>Wash-out: Not applicable</P>
<P>Exercise challenge: Treadmill for 6 min at 80% of max HR</P>
<P>Criteria for EIB diagnosis: Asthma according to ATS; FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 17:28:45 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 161</P>
<P>% of males: 42%</P>
<P>Age range: 12-35 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 17:30:27 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 30 min, 5.30 hours, 11.30 hours</P>
<P>Intervention: Salbutamol 180 mcg; Salmeterol 42 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 17:33:36 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10% and 20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-29 17:34:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kemp-1994-Salm-42">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-29 17:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>See: Kemp 1994 Salb</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:42:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konig-1981-Metaprot">
<CHAR_METHODS MODIFIED="2012-07-29 17:45:21 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Treadmill for 6 min at 90% of max HR</P>
<P>Criteria for EIB diagnosis: Asthma according to ATS; FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 17:46:01 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 24</P>
<P>% of males: 67%</P>
<P>Age range: 17-34 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 17:47:31 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 10 min, 1 hour</P>
<P>Intervention: Metaproterenol 130 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Oral metaproterenol</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 17:48:46 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Max FEF 25--75 % fall; Side effects; Number of patients with a max FEV1 % fall &lt;10%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:42:58 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:43:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konig-1984-Fen-0.4">
<CHAR_METHODS MODIFIED="2012-07-29 17:52:27 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Treadmill up to 90% of max HR</P>
<P>Criteria for EIB diagnosis: Asthma according to ATS; FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 17:52:45 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 100%</P>
<P>Age range: 17-29 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 17:53:51 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 10 min, 2 hours, 4 hours</P>
<P>Intervention: Fenoterol 40 mcg; Fenoterol 80 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 17:49:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Max FEF 25--75 % fall; Side effects; Number of patients with a max FEV1 % fall &lt;10%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:43:08 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-29 17:50:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Konig-1984-Fen-0.8">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-29 17:50:34 +0100" MODIFIED_BY="[Empty name]">
<P>See: Konig 1984 Fen 0.4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-24 13:15:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Larsson-1982-Fen">
<CHAR_METHODS MODIFIED="2012-10-24 13:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Sweden</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Cycle ergometer for 6-9 min till exhaustion</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 18:11:40 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 8</P>
<P>% of males: 69%</P>
<P>Age range: 29-64 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 18:14:12 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 10 min</P>
<P>Intervention: Fenoterol 400 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Oxitropium bromide; Ipratropium bromide</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Any anti-asthmatic drug suspended 12 hours before the test</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 18:15:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Number of patients with a max FEV1 % fall &lt;15%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:43:18 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:43:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McAlpine-1990-Form-12">
<CHAR_METHODS MODIFIED="2012-07-29 18:20:14 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United Kingdom</P>
<P>Wash-out: 1-7 days</P>
<P>Exercise challenge: Treadmill for 5-8 min up to 90% of max HR</P>
<P>Criteria for EIB diagnosis: Documented exercise-induced bronchoconstriction</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 18:20:51 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 41%</P>
<P>Age range: 19-41 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 18:22:14 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 2 hours, 4 hours</P>
<P>Intervention: Salbutamol 200 mcg; Formoterol 12 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 18:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:43:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-29 18:24:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McAlpine-1990-Salb">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-07-29 18:24:28 +0100" MODIFIED_BY="[Empty name]">
<P>See: McAlpine 1990 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-21 10:04:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_">
<CHAR_METHODS MODIFIED="2013-08-21 10:04:48 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 1-15 days</P>
<P>Exercise challenge: Cycle ergometer for 4-5 min till exhaustion</P>
<P>Criteria for EIB diagnosis: Positive screening exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 21:45:36 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 20</P>
<P>% of males: 60%</P>
<P>Age range: 21-42 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 21:46:21 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min</P>
<P>Intervention: Salbutamol 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 21:47:26 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Max FEF 25--75 % fall; Side effects; Number of patients with a max FEV1 % fall &lt;20%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:43:45 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-25 12:01:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_">
<CHAR_METHODS MODIFIED="2012-10-25 12:01:21 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 1-10 days</P>
<P>Exercise challenge: Cycle ergometer for 4-5 min till exhaustion</P>
<P>Criteria for EIB diagnosis: Positive screening exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-29 21:51:08 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 20</P>
<P>% of males: 60%</P>
<P>Age range: Not reported</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-29 21:51:22 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min</P>
<P>Intervention: Salbutamol 180 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-29 21:49:52 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Max FEF 25--75 % fall; Side effects; Number of patients with a max FEV1 % fall &lt;20%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:44:00 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:44:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morton-1989-Rimet">
<CHAR_METHODS MODIFIED="2012-08-02 09:55:35 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Australia</P>
<P>Wash-out: 2-7 days</P>
<P>Exercise challenge: Treadmill for 8 min at 80% of anaerobic threshold</P>
<P>Criteria for EIB diagnosis: Asthma according to ATS; FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 09:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 10</P>
<P>% of males: 70%</P>
<P>Age range: 15-30 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 09:57:12 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 2 min</P>
<P>Intervention: Rimeterol 400 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 09:57:36 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;15%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:44:09 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 16:07:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nelson-1998">
<CHAR_METHODS MODIFIED="2012-08-02 15:59:52 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 7 days</P>
<P>Exercise challenge: Cycle ergometer for 4 min at exhausting work</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 16:00:18 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 20</P>
<P>% of males: 45%</P>
<P>Age range: Not reported</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 16:03:21 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Chronic administration (29 days)</P>
<P>Time of exercise challenge after drug administration: 30 min, 9 hours</P>
<P>Intervention: Salmeterol 84 mcg daily</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 16:07:12 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Onset of tolerance; Number of patients with a max FEV1 % fall &lt;10%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 16:04:23 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:44:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newnham-1993-Salb-200">
<CHAR_METHODS MODIFIED="2012-08-02 10:01:56 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United Kingdom</P>
<P>Wash-out: &#8805;2 days</P>
<P>Exercise challenge: Treadmill for 6 min up to 90% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 10:02:38 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 50%</P>
<P>Age range: 21-33 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 10:03:53 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 1 hour, 6 hours, 12 hours</P>
<P>Intervention: Salbutamol 200 mcg; Salmeterol 50 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 10:04:45 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;20%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:44:26 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 10:06:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newnham-1993-Salm-50">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-02 10:06:07 +0100" MODIFIED_BY="[Empty name]">
<P>See: Newnham 1993 Salb 200</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:44:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-1986-Salb-200">
<CHAR_METHODS MODIFIED="2012-08-02 10:08:07 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United Kingdom</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Treadmill for 6-8 min</P>
<P>Criteria for EIB diagnosis: Diagnosis of exercise-induced bronchoconstriction</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 10:09:31 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 9</P>
<P>% of males: Not reported</P>
<P>Age range: 19-46 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 10:10:01 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 20 min</P>
<P>Intervention: Salbutamol 200 mcg; Tolobuterol 200 mcg; Tolobuterol 400 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 10:10:26 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 08:44:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 10:11:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-1986-Tulob-200">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-02 10:11:34 +0100" MODIFIED_BY="[Empty name]">
<P>See: Patel 1986 Salb 200</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 10:12:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-1986-Tulob-400">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-02 10:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>See: Patel 1986 Salb 200</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 16:17:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patessio-1991-Form-24">
<CHAR_METHODS MODIFIED="2012-08-02 10:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Italy</P>
<P>Wash-out: 1 day</P>
<P>Exercise challenge: Treadmill for 7 min up to 90% of max HR</P>
<P>Criteria for EIB diagnosis: Asthma according to ATS; FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 10:16:10 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects:12</P>
<P>% of males: 16%</P>
<P>Age range: Not reported</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 10:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 2 hours, 8 hours</P>
<P>Intervention: Salbutamol 200 mcg; Formoterol 24 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 10:19:12 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;15%;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 16:17:26 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 10:22:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patessio-1991-Salb-200">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-02 10:22:37 +0100" MODIFIED_BY="[Empty name]">
<P>See: Patessio 1991 Form 24</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 16:17:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pearlman-2006-Form-12">
<CHAR_METHODS MODIFIED="2012-08-02 10:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: &#8805;3 days</P>
<P>Exercise challenge: Treadmill for 6 min up to 80-90% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 10:34:12 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects:23</P>
<P>% of males: 30%</P>
<P>Age range: 4-11 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 10:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min, 4 hours, 8 hours, 12 hours</P>
<P>Intervention: Salbutamol 180 mcg; Formoterol 12 mcg; Formoterol 24 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 10:35:45 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10% and &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 16:17:11 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 10:38:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pearlman-2006-Form-24">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-02 10:38:09 +0100" MODIFIED_BY="[Empty name]">
<P>See: Pearlman 2006 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 10:38:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pearlman-2006-Salb-180">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-08-02 10:38:36 +0100" MODIFIED_BY="[Empty name]">
<P>See: Pearlman 2006 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 16:16:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pearlman-2007-Salb-90">
<CHAR_METHODS MODIFIED="2012-08-02 10:43:12 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 3-7 days</P>
<P>Exercise challenge: Treadmill for at least 4 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: Exercise-induced bronchoconstriction for at least 6 months; FEV1 fall &gt;20% and &lt;50% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 10:43:52 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects:15</P>
<P>% of males: 86%</P>
<P>Age range: Not reported</P>
<P>Ethnicity: 100% Caucasian</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 10:44:28 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 20 min</P>
<P>Intervention: Salbutamol 90 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 10:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10%, &lt;15% and &lt;20%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 16:16:38 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 16:16:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Philip-2007-Salm-50">
<CHAR_METHODS MODIFIED="2012-08-02 10:48:10 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: South America</P>
<P>Wash-out: 3-7 days</P>
<P>Exercise challenge: Treadmill for 6 min up to 80-90% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% and &lt;40% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 10:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects:47</P>
<P>% of males: 49%</P>
<P>Age range: 15-45 years</P>
<P>Ethnicity: 55% Caucasian; 45% Others</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 10:50:29 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 2 hours, 8.30 hours, 24 hours</P>
<P>Intervention: Salmeterol 50 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Oral Montelukast 10 mg</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 10:51:03 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 16:16:15 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 16:15:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ramage-1994">
<CHAR_METHODS MODIFIED="2012-08-02 16:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United Kingdom</P>
<P>Wash-out: 7 days</P>
<P>Exercise challenge: Treadmill for 6 min up to 80-90% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% and &lt;40% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 16:11:09 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 66%</P>
<P>Age range: 19-36 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 16:13:41 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Chronic administration (28 days)</P>
<P>Time of exercise challenge after drug administration: 6 hours, 12 hours</P>
<P>Intervention: Salmeterol 100 mcg daily</P>
<P>Control: Placebo</P>
<P>Other drug arms: No</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 16:14:59 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Onset of tolerance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 16:15:22 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 00:03:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richter-2002-Form-12">
<CHAR_METHODS MODIFIED="2012-05-31 15:16:16 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Germany</P>
<P>Wash-out: &#8805;2 days</P>
<P>Exercise challenge: Cycle-ergometer for 6 min up to 85% of max HR</P>
<P>Criteria for EIB diagnosis: Positive history; Positive methacholine test (PC20 &lt;8mg/ml); Positive exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-31 15:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 25</P>
<P>% of males: 66%</P>
<P>Age range: 19-36 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-31 15:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 5 min, 30 min, 1 hour</P>
<P>Intervention: Terbutaline 500 mcg; Formoterol 12 mcg; Salmeterol 50 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-31 15:18:11 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:03:51 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-31 15:09:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richter-2002-Salm-50">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-31 15:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>See: Richter Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-31 15:09:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richter-2002-Terb-500">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-31 15:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>See: Richter Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 08:19:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shapiro-2002-Form-12">
<CHAR_METHODS MODIFIED="2012-05-31 14:50:53 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: 3-7 days</P>
<P>Exercise challenge: Treadmill for 6 min at 90% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-31 14:52:29 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 20</P>
<P>% of males: 45%</P>
<P>Age range: 13-41 years</P>
<P>Ethnicity: Caucasians 90%; Others 10%</P>
<P>Withdrawal or drop out: 3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-31 14:53:41 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min, 4 hours, 8 hours, 12 hours</P>
<P>Intervention: Salbutamol 180 mcg; Formoterol 12 mcg; Formoterol 24 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-03 08:19:55 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;20%; Max PEF % fall;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:03:29 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-31 14:49:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shapiro-2002-Form-24">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-31 14:49:40 +0100" MODIFIED_BY="[Empty name]">
<P>See: Shapiro 2002 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-31 14:50:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shapiro-2002-Salb-180">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-31 14:50:01 +0100" MODIFIED_BY="[Empty name]">
<P>See: Shapiro 2002 Form 12</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-24 13:15:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simons-1997">
<CHAR_METHODS MODIFIED="2012-10-24 13:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Canada</P>
<P>Wash-out: 14 days</P>
<P>Exercise challenge: Treadmill for 8 min up to 90% of max HR or 180 bpm</P>
<P>Criteria for EIB diagnosis: Asthma according to ATS; Positive exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 16:41:18 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 16</P>
<P>% of males: 41%</P>
<P>Age range: 12-16 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 16:38:16 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Chronic administration (28 weeks)</P>
<P>Time of exercise challenge after drug administration: 1 hour, 9 hours</P>
<P>Intervention: Salmeterol 50 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 16:42:27 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 16:39:55 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 17:26:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stelmach-2008">
<CHAR_METHODS MODIFIED="2012-08-02 17:18:01 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, parallel groups</P>
<P>Study location: Poland</P>
<P>Wash-out: Not applicable</P>
<P>Exercise challenge: Treadmill for six min at 95% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 17:20:30 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 100</P>
<P>% of males: Not reported</P>
<P>Age range: 6-18 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 17:25:31 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Chronic administration (28 weeks)</P>
<P>Time of exercise challenge after drug administration: 1 hour, 9 hours</P>
<P>Intervention: Formoterol 9 mcg daily</P>
<P>Control: Placebo</P>
<P>Other drug arms: Oral Montelukast</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 17:25:44 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Onset of tolerance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 17:26:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-02 17:36:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Storms-2004">
<CHAR_METHODS MODIFIED="2012-08-02 17:31:57 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, parallel groups</P>
<P>Study location: United States</P>
<P>Wash-out: Not applicable</P>
<P>Exercise challenge: Treadmill for six min at 95% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;20% (or &gt;15% if on ICS) after an exercise challenge in the last year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-02 17:34:54 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 122</P>
<P>% of males: Not reported</P>
<P>Age range: 15-58 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 13</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-02 17:35:37 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Chronic administration (28 weeks)</P>
<P>Time of exercise challenge after drug administration: 1 hour, 9 hours</P>
<P>Intervention: Salmeterol 100 mcg daily</P>
<P>Control: Placebo</P>
<P>Other drug arms: Oral Montelukast 10 mg</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-02 17:27:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection; FEV1 % fall AUC</P>
<P>Secondary available: Onset of tolerance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-02 17:36:16 +0100" MODIFIED_BY="[Empty name]">
<P>Industry funded study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-18 15:58:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sturani-1983-Fen-400">
<CHAR_METHODS MODIFIED="2012-05-31 14:22:19 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Italy</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Free running for 6 min up to 85% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-31 14:22:46 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 58%</P>
<P>Age range: 16-42 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-31 14:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 30 min.</P>
<P>Intervention: Fenoterol 400 mcg; Salbutamol 200 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-18 15:58:37 +0000" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection</P>
<P>Secondary available: None</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:02:57 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-31 14:48:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sturani-1983-Salb-200">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2012-05-31 14:48:54 +0100" MODIFIED_BY="[Empty name]">
<P>See: Sturani 1983 Fen 400</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-18 16:34:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-VanHaitsma-2010-Salb">
<CHAR_METHODS MODIFIED="2013-01-18 16:29:41 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross-over</P>
<P>Study location: United States</P>
<P>Wash-out: &#8805;2 days</P>
<P>Exercise challenge: Treadmill for at least 3 min at 85% of max HR</P>
<P>Criteria for EIB diagnosis: Physician diagnosed asthma; FEV1 fall &gt;10% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-18 16:29:04 +0000" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 10</P>
<P>% of males: 70%</P>
<P>Age range: Not reported</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-18 15:57:11 +0000" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min.</P>
<P>Intervention: Salbutamol 180 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: None</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-18 16:34:57 +0000" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Max Pef % fall; Max FEF 25--75 % fall</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-18 15:54:27 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 00:02:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vasquez-1984-Salb-400">
<CHAR_METHODS MODIFIED="2012-05-31 13:58:51 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, parallel groups</P>
<P>Study location: Spain</P>
<P>Wash-out: Not applicable</P>
<P>Exercise challenge: Free running 5-8 min at max speed (around 170 bpm)</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-31 13:59:27 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 25</P>
<P>% of males: Not reported</P>
<P>Age range: Not reported</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-31 14:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 15 min.</P>
<P>Intervention: Salbutamol 400 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Disodium cromoglycate 200 mcg; Ipratropium bromide 40 mcg;</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-31 14:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Number of patients with a max FEV1 % fall &lt;15%; Max MEF50 % fall;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:02:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 00:02:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walker-1986-Bitolterol">
<CHAR_METHODS MODIFIED="2012-05-31 13:51:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: United States</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Cycle-ergometer for 6 min at 80% of max HR</P>
<P>Criteria for EIB diagnosis: FEV1 fall &gt;15% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-31 13:52:19 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 58%</P>
<P>Age range: 14-25 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-31 13:53:40 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 45 min.</P>
<P>Intervention: Bitolterol 1050 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Isoproterenol 255 mcg</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-31 13:55:05 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10%; Max PEF % fall; Max FEF25-75 % fall;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:02:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-03 00:02:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolley-1990-Terb-500">
<CHAR_METHODS MODIFIED="2012-05-31 13:44:58 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: Randomized, double blind, cross over</P>
<P>Study location: Australia</P>
<P>Wash-out: Not reported</P>
<P>Exercise challenge: Treadmill for 8 min at 60% of MVV</P>
<P>Criteria for EIB diagnosis: Positive history, FEV1 fall &gt;20% after exercise challenge</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-31 13:45:22 +0100" MODIFIED_BY="[Empty name]">
<P>Number of subjects: 12</P>
<P>% of males: 58%</P>
<P>Age range: 18-28 years</P>
<P>Ethnicity: Not reported</P>
<P>Withdrawal or drop out: 0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-31 13:47:13 +0100" MODIFIED_BY="[Empty name]">
<P>Drug administration: Single dose</P>
<P>Time of exercise challenge after drug administration: 25 min, 2 hours, 4 hours, 6 hours</P>
<P>Intervention: Terbutaline 500 mcg</P>
<P>Control: Placebo</P>
<P>Other drug arms: Cromolyn sodium 2 mg; Cromolyn sodium 2 mg + Terbutaline 500 mcg</P>
<P>Concomitant inhaled corticosteroid (ICS) treatment: Not allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-31 13:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>Primary available: Max FEV1 % fall; % protection;</P>
<P>Secondary available: Side effects; Number of patients with a max FEV1 % fall &lt;10%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-03 00:02:26 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-01-18 15:46:44 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:41:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aebischer-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:41:37 +0100" MODIFIED_BY="[Empty name]">
<P>No beta-2 agonist pretreatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 14:40:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agostini-1983-I">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 14:40:39 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:02:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agostini-1983-II">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:02:51 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allegra-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:20 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:03 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:12 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:22 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aranda-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:11 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:31:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bakran-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:31:32 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Battistini-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:28 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:03:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baur-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:03:06 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berkowitz-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:13 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boner-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:16 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:31:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boner-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:31:44 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boner-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:37 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:31:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bratteby-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:31:47 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:03:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bundgaard-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:03:10 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bundgaard-1983-I">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:28 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:03:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bundgaard-1983-II">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:03:14 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:03:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bundgaard-1983-III">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:03:16 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bye-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:31 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:31:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ceugniet-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:31:51 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colice-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:21 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coreno-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:23 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:31:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corrias-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:31:54 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dal-Col-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:25 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Del-Bono-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:27 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Di-Gioacchino-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:38 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dockhorn-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:29 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:31:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edelman-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:31:57 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eggleston-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:40 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:31:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrari-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:31:59 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-18 14:42:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fogel-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-18 14:42:16 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Francis-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:29 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freeman-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:31 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gibson-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gimeno-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:34 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GlaxoSmithKline-2006-I">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:04 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 16:04:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GlaxoSmithKline-2006-II">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 16:04:42 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 14:40:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godfrey-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 14:40:36 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godfrey-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:42 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guerin-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:07 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-18 14:52:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gunawardena-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-18 14:52:59 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:41:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hermansen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:41:47 +0100" MODIFIED_BY="[Empty name]">
<P>No beta-2 agonist pretreatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Higgs-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:09 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:03:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ienna-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:03:21 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iikura-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:41 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ioli-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:38 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:37 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koch-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:43 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumar-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:44 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:41:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopes-Dos-Santos-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:41:51 +0100" MODIFIED_BY="[Empty name]">
<P>No beta-2 agonist pretreatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-18 14:58:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Machado-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-18 14:58:31 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macucci-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:47 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Magnussen-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:45 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-18 15:43:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Makela-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-18 15:43:37 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinsson-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:48 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 14:40:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Merck-2005-I">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 14:40:43 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Merck-2005-II">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:17 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mickleborough-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:20 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Millqvist-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:49 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morandini-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:53 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morooka-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:39 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morse-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:53 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:54:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morton-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:54:53 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-18 15:46:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murray-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-18 15:46:44 +0000" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:39:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pearlman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:39:34 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:22:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfleger-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:22:19 +0100" MODIFIED_BY="[Empty name]">
<P>No exercise challenge</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:04:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichaipat-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:04:57 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pichon-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:40 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poppius-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:27 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:03:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabe-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:03:27 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raissy-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:29 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raissy-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:31 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Revill-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:32 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robertson-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:42 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rohr-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:34 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 11:01:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanguinetti-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 11:01:24 +0100" MODIFIED_BY="[Empty name]">
<P>Exercise challenge beyond beta-2 agonist pharmacological half-life</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:03:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schaanning-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:03:31 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shah-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:43 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shapiro-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:57 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:55:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shapiro-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:55:02 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sichletidis-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:38 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:05:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silverman-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:05:03 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:05:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:05:05 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:55:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sly-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:55:05 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 20:03:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sly-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 20:03:35 +0100" MODIFIED_BY="[Empty name]">
<P>No systematic review primary outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:30:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sly-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spada-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:45 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stark-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:45 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinshamn-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:05:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svenonius-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:05:09 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:55:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svenonius-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:55:09 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:41:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svenonius-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:41:57 +0100" MODIFIED_BY="[Empty name]">
<P>No beta-2 agonist pretreatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:31:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tabas-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:31:05 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:05:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tammivaara-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:05:12 +0100" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 15:01:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Unnithan-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 15:01:46 +0100" MODIFIED_BY="[Empty name]">
<P>No clear diagnosi of exercise-induced bronchoconstriction</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verini-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:54 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:31:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verini-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:31:09 +0100" MODIFIED_BY="[Empty name]">
<P>No inhaled beta-2 agonist administration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verini-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:32:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villaran-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:32:59 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-27 19:42:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vilsvik-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-27 19:42:01 +0100" MODIFIED_BY="[Empty name]">
<P>No beta-2 agonist pretreatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:33:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vilsvik-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:33:01 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:33:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Von-Berg-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:33:02 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:33:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiler-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:33:03 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 10:55:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinberg-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 10:55:21 +0100" MODIFIED_BY="[Empty name]">
<P>No double blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:33:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeung-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:33:05 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:33:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zanconato-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:33:07 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-28 15:33:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zimmermann-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-28 15:33:08 +0100" MODIFIED_BY="[Empty name]">
<P>No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-08-21 09:55:49 +0100" MODIFIED_BY="Emma J Welsh" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Kupper-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-01-18 16:23:48 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-01-18 16:23:48 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 13:25:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:44:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:02:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:45:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:07:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boner-1994-Form-12">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:46:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boner-1994-Salb-200">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:09:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boulet-1989-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:12:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:46:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-Pwd">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Diskhal">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-01 09:00:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:27:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carlsen-1995-Salm-25">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:48:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carlsen-1995-Salm-50">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:30:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:37:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1990-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:49:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:28:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1998-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debelic-1988-Reproterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:33:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:35:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dinh-Xuan-1989-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:39:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Egglestone-1981-Terb-250">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2000-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-2001-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:46:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1992-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 14:39:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-4.5">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:51:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-9">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:51:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 14:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hancox-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:38:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-HFA">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1983-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:52:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1992-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:47:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henriksen-1992-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:58:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:53:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salmefamol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:33:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salm-42">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1981-Metaprot">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:55:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.4">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:57:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.8">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:15:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsson-1982-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:24:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 21:49:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 21:52:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 09:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morton-1989-Rimet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:07:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:05:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:05:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:12:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:22:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patessio-1991-Form-24">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:22:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patessio-1991-Salb-200">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:37:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearlman-2006-Form-12">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:37:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearlman-2006-Form-24">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:38:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearlman-2006-Salb-180">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:45:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearlman-2007-Salb-90">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:46:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Philip-2007-Salm-50">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:17:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramage-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 15:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:55:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:56:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:43:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simons-1997">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 17:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stelmach-2008">
<DESCRIPTION>
<P>Randomization described explicitly</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 17:36:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Storms-2004">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:25:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Fen-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-18 16:23:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VanHaitsma-2010-Salb">
<DESCRIPTION>
<P> Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:03:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vasquez-1984-Salb-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 13:55:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1986-Bitolterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 13:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolley-1990-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 13:26:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:44:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:02:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:45:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:46:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:09:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boulet-1989-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:12:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:46:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-Pwd">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Diskhal">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:20:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:27:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:48:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:30:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:34:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1990-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:49:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:28:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1998-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debelic-1988-Reproterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:33:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:35:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dinh-Xuan-1989-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:39:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Egglestone-1981-Terb-250">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2000-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-2001-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:46:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1992-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 14:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-4.5">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:51:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-9">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:51:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 14:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hancox-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:09:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-HFA">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1983-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:52:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1992-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:47:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henriksen-1992-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:58:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:53:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salmefamol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:33:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salm-42">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1981-Metaprot">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:55:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.4">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:57:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.8">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:15:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsson-1982-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:24:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 21:49:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 21:52:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 09:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morton-1989-Rimet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:07:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:05:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:05:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:12:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:19:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:22:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:37:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:37:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:38:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:45:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2007-Salb-90">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:46:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Philip-2007-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:17:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramage-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 15:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:55:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:56:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:43:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simons-1997">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 17:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stelmach-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 17:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Storms-2004">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:25:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Fen-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VanHaitsma-2010-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:03:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vasquez-1984-Salb-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 13:55:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1986-Bitolterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 13:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolley-1990-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-05-30 11:20:38 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-01-18 15:59:24 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 13:26:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2001-Salb-Disk">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:44:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-2001-Salb-MDI">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:03:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blake-1999-Salb-180">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:45:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blake-1999-Salm-25">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:45:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blake-1999-Salm-50">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boner-1994-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:46:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boner-1994-Salb-200">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:09:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boulet-1989-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:12:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronski-1995-Salb-MDI">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronski-1995-Salb-Pwd">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:14:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronski-1999-Salm-Disk">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:47:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronski-1999-Salm-Diskhal">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:20:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronski-2002-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:47:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronski-2002-Form-24">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:48:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bronski-2002-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:27:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carlsen-1995-Salm-25">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:48:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carlsen-1995-Salm-50">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:30:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cavagni-1993-Salb-Jet">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:49:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cavagni-1993-Salb-MDI">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:34:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-1990-Fen">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 14:49:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daugbjerg-1996-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:49:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daugbjerg-1996-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:28:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeBenedictis-1996-Salm-25">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:50:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeBenedictis-1996-Salm-50">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:30:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeBenedictis-1998-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:19:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Debelic-1988-Reproterol">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:33:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del-Col-1993-Salb-Jet">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:50:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del-Col-1993-Salb-MDI">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:35:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dinh-Xuan-1989-Terb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:39:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Egglestone-1981-Terb-250">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:41:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferrari-2000-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia-2001-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-30 15:46:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Green-1992-Salm-50">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 14:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gronnerod-2000-Form-4.5">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:51:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gronnerod-2000-Form-9">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:51:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gronnerod-2000-Terb-500">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 14:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hancox-2002">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 15:09:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawksworth-2002-Salb-HFA">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:52:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawksworth-2002-Salb-MDI">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1983-Terb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:52:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henricksen-1992-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 15:47:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henriksen-1992-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 15:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hills-1976-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hills-1976-Salmefamol">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:43:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-1996">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 17:33:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kemp-1994-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 17:34:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kemp-1994-Salm-42">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 17:49:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konig-1981-Metaprot">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 17:55:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konig-1984-Fen-0.4">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 17:57:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Konig-1984-Fen-0.8">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 18:15:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Larsson-1982-Fen">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 18:24:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McAlpine-1990-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 18:24:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McAlpine-1990-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 21:49:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 21:52:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 09:57:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morton-1989-Rimet">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 16:07:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nelson-1998">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:05:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Newnham-1993-Salb-200">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:05:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Newnham-1993-Salm-50">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-1986-Salb-200">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:11:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-1986-Tulob-200">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:12:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-400">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:19:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patessio-1991-Form-24">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:22:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patessio-1991-Salb-200">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearlman-2006-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:37:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearlman-2006-Form-24">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:38:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearlman-2006-Salb-180">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:45:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pearlman-2007-Salb-90">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 10:46:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Philip-2007-Salm-50">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 16:17:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramage-1994">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 15:19:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richter-2002-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:56:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richter-2002-Salm-50">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:56:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richter-2002-Terb-500">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 14:56:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shapiro-2002-Form-12">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:56:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shapiro-2002-Form-24">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:56:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shapiro-2002-Salb-180">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 16:43:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simons-1997">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 17:26:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stelmach-2008">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-02 17:36:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Storms-2004">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 14:25:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sturani-1983-Fen-400">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-29 16:57:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sturani-1983-Salb-200">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-18 15:59:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-VanHaitsma-2010-Salb">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 14:03:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vasquez-1984-Salb-400">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 13:55:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walker-1986-Bitolterol">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 13:48:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wolley-1990-Terb-500">
<DESCRIPTION>
<P>Double blind study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 13:26:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:44:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:02:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:45:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:46:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:09:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boulet-1989-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:12:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-Pwd">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Diskhal">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:20:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:27:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:48:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:30:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:49:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:34:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1990-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 14:49:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:49:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:28:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1998-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debelic-1988-Reproterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:33:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:35:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dinh-Xuan-1989-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Egglestone-1981-Terb-250">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2000-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-2001-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-30 15:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1992-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 14:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-4.5">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:51:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-9">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:51:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 14:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hancox-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 15:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-HFA">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1983-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:52:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1992-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 15:47:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henriksen-1992-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 15:58:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:53:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salmefamol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 17:33:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 17:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salm-42">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 17:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1981-Metaprot">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 17:55:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.4">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 17:57:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.8">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 18:15:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsson-1982-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 18:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 18:24:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 21:49:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 21:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 09:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morton-1989-Rimet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 16:07:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:05:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:05:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:12:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:19:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:22:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:37:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:38:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:45:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2007-Salb-90">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 10:46:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Philip-2007-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 16:17:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramage-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 15:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:55:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 14:56:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:56:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:56:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 16:43:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simons-1997">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 17:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stelmach-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-02 17:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Storms-2004">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 14:25:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Fen-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-29 16:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VanHaitsma-2010-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 14:03:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vasquez-1984-Salb-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 13:55:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1986-Bitolterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-31 13:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolley-1990-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 13:26:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:44:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:02:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:45:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:46:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:11:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boulet-1989-Salb">
<DESCRIPTION>
<P>Data on primary and secondary outcomes are reported incompletely</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:12:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-Pwd">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:14:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Diskhal">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:20:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:27:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:48:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:30:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:49:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:34:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1990-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 14:49:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:49:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:28:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1998-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debelic-1988-Reproterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:33:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:50:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:35:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dinh-Xuan-1989-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Egglestone-1981-Terb-250">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2000-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-2001-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-30 15:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1992-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 14:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-4.5">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:51:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-9">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:51:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 14:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hancox-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 15:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-HFA">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1983-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:52:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1992-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 15:47:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henriksen-1992-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 15:58:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:53:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salmefamol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 17:33:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 17:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salm-42">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 17:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1981-Metaprot">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 17:56:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Konig-1984-Fen-0.4">
<DESCRIPTION>
<P>Data for max FEF 25--75 % fall not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 17:57:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Konig-1984-Fen-0.8">
<DESCRIPTION>
<P>Data for max FEF 25--75 % fall not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 18:15:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsson-1982-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 18:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 18:24:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 21:49:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 21:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 09:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morton-1989-Rimet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 16:07:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:05:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:05:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:11:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:12:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:19:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:22:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:37:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:38:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:45:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2007-Salb-90">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 10:46:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Philip-2007-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 16:17:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramage-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-31 15:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:55:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-31 14:56:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:56:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:56:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 16:43:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simons-1997">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 17:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stelmach-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 17:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Storms-2004">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-31 14:25:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Fen-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-29 16:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VanHaitsma-2010-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-31 14:03:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vasquez-1984-Salb-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-31 13:55:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1986-Bitolterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-31 13:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolley-1990-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 13:26:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:44:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:02:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:45:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:46:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:09:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boulet-1989-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:12:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-Pwd">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:14:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Diskhal">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:20:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:27:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:48:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:30:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:34:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1990-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:49:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:28:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1998-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:19:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debelic-1988-Reproterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:33:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:50:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:35:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dinh-Xuan-1989-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Egglestone-1981-Terb-250">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:44:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ferrari-2000-Form-12">
<DESCRIPTION>
<P>Statistical analysis and manuscript writing made by drug industry staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-2001-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1992-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 14:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-4.5">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:51:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-9">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:51:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 14:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hancox-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-HFA">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1983-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:52:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1992-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:47:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henriksen-1992-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:58:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:53:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salmefamol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:33:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salm-42">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1981-Metaprot">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:55:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.4">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:57:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.8">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:15:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsson-1982-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:24:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 21:49:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 21:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 09:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morton-1989-Rimet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:07:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:05:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:05:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:11:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:12:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:19:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:22:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:37:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:38:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:45:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2007-Salb-90">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:46:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Philip-2007-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:17:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramage-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 15:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:55:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:56:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:43:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simons-1997">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 17:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stelmach-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 17:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Storms-2004">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:25:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Fen-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VanHaitsma-2010-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:03:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vasquez-1984-Salb-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 13:55:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1986-Bitolterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 13:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolley-1990-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 13:26:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:44:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-2001-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:02:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:45:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:45:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1999-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:46:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boner-1994-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:09:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boulet-1989-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:12:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1995-Salb-Pwd">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:14:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Disk">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:47:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-1999-Salm-Diskhal">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:20:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bronski-2002-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:27:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:48:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carlsen-1995-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:30:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cavagni-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:34:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-1990-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 14:49:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Daugbjerg-1996-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:28:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-25">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1996-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:30:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeBenedictis-1998-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:19:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Debelic-1988-Reproterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:33:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-Jet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:50:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Col-1993-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:35:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dinh-Xuan-1989-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Egglestone-1981-Terb-250">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2000-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-2001-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 15:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Green-1992-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 14:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-4.5">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:51:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Form-9">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:51:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gronnerod-2000-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 14:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hancox-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-HFA">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawksworth-2002-Salb-MDI">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1983-Terb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:52:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henricksen-1992-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:47:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henriksen-1992-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 15:58:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:53:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hills-1976-Salmefamol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:33:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kemp-1994-Salm-42">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1981-Metaprot">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:55:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.4">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 17:57:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Konig-1984-Fen-0.8">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:15:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Larsson-1982-Fen">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 18:24:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McAlpine-1990-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 21:49:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 21:52:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 09:57:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morton-1989-Rimet">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:07:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nelson-1998">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:05:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:05:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Newnham-1993-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:10:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:11:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:12:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-1986-Tulob-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:19:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 10:22:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patessio-1991-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:17:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:16:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:16:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2006-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:16:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pearlman-2007-Salb-90">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:16:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Philip-2007-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:17:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramage-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 15:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:55:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Salm-50">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-2002-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:56:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-12">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Form-24">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:56:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shapiro-2002-Salb-180">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 16:43:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simons-1997">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 17:26:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stelmach-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 17:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Storms-2004">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:25:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Fen-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-29 16:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sturani-1983-Salb-200">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-18 15:59:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-VanHaitsma-2010-Salb">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 14:03:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vasquez-1984-Salb-400">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 13:55:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1986-Bitolterol">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-31 13:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolley-1990-Terb-500">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">Beta<SUB>2</SUB>-agonists compared with placebo (single administration) for exercise-induced asthma</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Beta<SUB>2</SUB>-agonists compared with placebo (single administration) for exercise-induced asthma</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>exercise-induced asthma<B> </B>
<BR/>
<B>Intervention: </B>beta<SUB>2</SUB>-agonists<BR/>
<B>Comparison: </B>placebo (single administration)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo (single administration)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Beta<SUB>2</SUB>-agonists</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Maximal percentage fall in FEV<SUB>1</SUB>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>The mean fall in FEV<SUB>1</SUB> in the intervention group was MD 17.67 lower (19.51 lower to 15.84 lower)<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#65293;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>799<BR/>(72 studies)<SUP>a,b,c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>d,e,f</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The results in the subgroup of LABA and SABA were similar: MD 15.6 lower (18.29 lower to 12.92 lower) and MD 18.99 lower (21.38 lower to 16.6 lower) in 44 and 28 studies, respectively</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Number of participants with an FEV<SUB>1</SUB> fall &gt; 10%</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>843 per 1000 (84.3)%</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>300 per 1000<BR/>(243 to 410)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.08</B> (0.06 to 0.13)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>773<BR/>(19 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>d,e</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Maximal percentage fall in PEF</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>The mean maximal percentage fall in PEF in the intervention group was MD 24.61 lower (37.57 lower to 11.65 lower)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#65293;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>92<BR/>(14 studies)<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>d,e,g</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Maximal percentage fall in FEF<SUB>25-75%</SUB>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>The mean maximal percentage fall in FEF<SUB>25-75%</SUB> in the intervention group was MD 20.75 lower (27.17 lower to 14.32 lower)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#65293;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>106<BR/>(8 studies)<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>d,e,g</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Side effects</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>50 per 1000 (5.0)%</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>42 per 1000<BR/>(22 to 77)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.83</B> (0.43 to 1.59)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2165<BR/>(55 studies)<SUP>h</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>e,g,I</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI: </B>Confidence interval; FEF<SUB>25-75%</SUB>: forced expiratory flow 25&#8211;75%; FEV1: forced expiratory volume in 1 minute; LABA: long-acting beta<SUB>2</SUB>-agonist; MD: mean difference; OR: odds ratio; peak expiratory flow (PEF); SABA: short-acting beta<SUB>2</SUB>-agonist.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Lower indicates that beta<SUB>2</SUB>-agonists are better than placebo.</P>
<P>
<SUP>b</SUP>In 51 studies that provided data for subgroup analysis, no difference was observed in the maximal percentage fall in FEV<SUB>1</SUB>, but the heterogeneity of the effect was seen primarily in the paediatric population.</P>
<P>
<SUP>c</SUP>These represent 72 study arms from 53 studies.</P>
<P>
<SUP>d</SUP>It is unclear how directly pulmonary function measures relate to what participants feel.</P>
<P>
<SUP>e</SUP>There was concern about lack of concealment, loss to follow-up and reporting bias.</P>
<P>
<SUP>f</SUP>Inconsistency was moderate to high and was explained in part by subgroup analyses of adults and children.</P>
<P>
<SUP>g</SUP>Small numbers of participants were included with resulting wide confidence intervals.</P>
<P>
<SUP>h</SUP>These represent 55 study arms rather than studies.</P>
<P>
<SUP>i</SUP>This represents a mix of outcomes, and not all of them are of equal importance to patients.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma J Welsh">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Emma J Welsh" NO="1">
<TITLE MODIFIED="2013-08-21 18:24:37 +0100" MODIFIED_BY="Emma J Welsh">Summary of study interventions</TITLE>
<TABLE COLS="4" ROWS="53">
<TR>
<TH VALIGN="TOP">
<P>Study</P>
</TH>
<TH VALIGN="TOP">
<P>Intervention (single dose)</P>
</TH>
<TH VALIGN="TOP">
<P>Study type (single-dose test or chronic [duration])</P>
</TH>
<TH VALIGN="TOP">
<P>When administered before challenge/exercise (min, h)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Anderson-2001-Salb-Disk" TYPE="STUDY">Anderson 2001 Salb Disk</LINK>;</P>
<P>
<LINK REF="STD-Anderson-2001-Salb-MDI" TYPE="STUDY">Anderson 2001 Salb MDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol diskus 200 mcg</P>
<P>Salbutamol MDI</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>30 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Blake-1999-Salb-180" TYPE="STUDY">Blake 1999 Salb 180</LINK>
</P>
<P>
<LINK REF="STD-Blake-1999-Salm-25" TYPE="STUDY">Blake 1999 Salm 25</LINK>
</P>
<P>
<LINK REF="STD-Blake-1999-Salm-50" TYPE="STUDY">Blake 1999 Salm 50</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Albuterol 180 mcg</P>
<P>Salmeterol diskus 25 mcg</P>
<P>Salmeterol diskus 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>30 min, 5 h 30, 11 h 30</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Boner-1994-Salb-200" TYPE="STUDY">Boner 1994 Salb 200</LINK>
</P>
<P>
<LINK REF="STD-Boner-1994-Form-12" TYPE="STUDY">Boner 1994 Form 12</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
<P>Formoterol 12 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>3 h, 12 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Boulet-1989-Salb" TYPE="STUDY">Boulet 1989 Salb</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>30 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bronski-1995-Salb-MDI" TYPE="STUDY">Bronski 1995 Salb MDI</LINK>
</P>
<P>
<LINK REF="STD-Bronski-1995-Salb-Pwd" TYPE="STUDY">Bronski 1995 Salb Pwd</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Albuterol MDI 180 mcg</P>
<P>Albuterol rotacaps 200 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bronski-1999-Salm-Disk" TYPE="STUDY">Bronski 1999 Salm Disk</LINK>
</P>
<P>
<LINK REF="STD-Bronski-1999-Salm-Diskhal" TYPE="STUDY">Bronski 1999 Salm Diskhal</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmetrol discus 50 mcg</P>
<P>Salmeterol diskhaler 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>30 min, 5 h 30, 11 h 30</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bronski-2002-Salb" TYPE="STUDY">Bronski 2002 Salb</LINK>
</P>
<P>
<LINK REF="STD-Bronski-2002-Form-12" TYPE="STUDY">Bronski 2002 Form 12</LINK>
</P>
<P>
<LINK REF="STD-Bronski-2002-Form-24" TYPE="STUDY">Bronski 2002 Form 24</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Albuterol 180 mcg</P>
<P>Formoterol 12 mcg</P>
<P>Formoterol 24 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min, 4 h, 8 h, 12 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Carlsen-1995-Salm-25" TYPE="STUDY">Carlsen 1995 Salm 25</LINK>
</P>
<P>
<LINK REF="STD-Carlsen-1995-Salm-50" TYPE="STUDY">Carlsen 1995 Salm 50</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmeterol diskhaler 25 mcg</P>
<P>Salmeterol diskhaler 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>10-12 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Cavagni-1993-Salb-MDI" TYPE="STUDY">Cavagni 1993 Salb MDI</LINK>
</P>
<P>
<LINK REF="STD-Cavagni-1993-Salb-Jet" TYPE="STUDY">Cavagni 1993 Salb Jet</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol MDI 200 mcg</P>
<P>Salbutamol jet disposable 200 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>10 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Clarke-1990-Fen" TYPE="STUDY">Clarke 1990 Fen</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Fenoterol 100 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>10 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Daugbjerg-1996-Salb" TYPE="STUDY">Daugbjerg 1996 Salb</LINK>
</P>
<P>
<LINK REF="STD-Daugbjerg-1996-Form-12" TYPE="STUDY">Daugbjerg 1996 Form 12</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 400 mcg</P>
<P>Formoterol 12 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>3 h, 12 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Debelic-1988-Reproterol" TYPE="STUDY">Debelic 1988 Reproterol</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Reproterol 1 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-DeBenedictis-1996-Salm-25" TYPE="STUDY">DeBenedictis 1996 Salm 25</LINK>
</P>
<P>
<LINK REF="STD-DeBenedictis-1996-Salm-50" TYPE="STUDY">DeBenedictis 1996 Salm 50</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmeterol 25 mcg</P>
<P>Salmeterol 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>1 h, 2 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-DeBenedictis-1998-Salb" TYPE="STUDY">DeBenedictis 1998 Salb</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>20 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Del-Col-1993-Salb-MDI" TYPE="STUDY">Del Col 1993 Salb MDI</LINK>
</P>
<P>
<LINK REF="STD-Del-Col-1993-Salb-Jet" TYPE="STUDY">Del Col 1993 Salb Jet</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol MDI 200 mcg</P>
<P>Salbutamol jet device 200 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>10 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dinh-Xuan-1989-Terb" TYPE="STUDY">Dinh Xuan 1989 Terb</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Terbutaline 500 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Egglestone-1981-Terb-250" TYPE="STUDY">Egglestone 1981 Terb 250</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Terbutaline 250 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>1 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ferrari-2000-Form-12" TYPE="STUDY">Ferrari 2000 Form 12</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Formoterol 12 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min, 4 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Garcia-2001-Form-12" TYPE="STUDY">Garcia 2001 Form 12</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Formoterol 12 mcg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term (4 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>30 min, 12 h at days 1, 14 and 28</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Green-1992-Salm-50" TYPE="STUDY">Green 1992 Salm 50</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmeterol 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>1 h, 5 h, 9 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gronnerod-2000-Terb-500" TYPE="STUDY">Gronnerod 2000 Terb 500</LINK>
</P>
<P>
<LINK REF="STD-Gronnerod-2000-Form-9" TYPE="STUDY">Gronnerod 2000 Form 9</LINK>
</P>
<P>
<LINK REF="STD-Gronnerod-2000-Form-4.5" TYPE="STUDY">Gronnerod 2000 Form 4.5</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Terbutaline 500 mcg</P>
<P>Formoterol 9 mcg</P>
<P>Formoterol 4.5 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min, 4 h, 8 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hancox-2002" TYPE="STUDY">Hancox 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 800 mcg daily</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term (1 week)</P>
</TD>
<TD VALIGN="TOP">
<P>8 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hawksworth-2002-Salb-HFA" TYPE="STUDY">Hawksworth 2002 Salb HFA</LINK>
</P>
<P>
<LINK REF="STD-Hawksworth-2002-Salb-MDI" TYPE="STUDY">Hawksworth 2002 Salb MDI</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 180 HFA</P>
<P>Salbutamol 180 mcg MDI</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>30 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Henricksen-1983-Terb" TYPE="STUDY">Henricksen 1983 Terb</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Terbutaline 32.5 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Henricksen-1992-Salb" TYPE="STUDY">Henricksen 1992 Salb</LINK>
</P>
<P>
<LINK REF="STD-Henriksen-1992-Form-12" TYPE="STUDY">Henriksen 1992 Form 12</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
<P>Formoterol 12 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>30 min, 3 h, 5 h 30, 8 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hills-1976-Salb" TYPE="STUDY">Hills 1976 Salb</LINK>
</P>
<P>
<LINK REF="STD-Hills-1976-Salmefamol" TYPE="STUDY">Hills 1976 Salmefamol</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
<P>Salmefamol 200 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>20 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Inman-1996" TYPE="STUDY">Inman 1996</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 800 mcg daily</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term (81 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>24 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Kemp-1994-Salb" TYPE="STUDY">Kemp 1994 Salb</LINK>
</P>
<P>
<LINK REF="STD-Kemp-1994-Salm-42" TYPE="STUDY">Kemp 1994 Salm 42</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 180 mcg</P>
<P>Salmeterol 42 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>30 min, 5 h 30, 11 h 30</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Konig-1981-Metaprot" TYPE="STUDY">Konig 1981 Metaprot</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Metaproterenol 130 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>10 min, 1 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Larsson-1982-Fen" TYPE="STUDY">Larsson 1982 Fen</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Fenoterol 400 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>10 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-McAlpine-1990-Salb" TYPE="STUDY">McAlpine 1990 Salb</LINK>
</P>
<P>
<LINK REF="STD-McAlpine-1990-Form-12" TYPE="STUDY">McAlpine 1990 Form 12</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
<P>Formoterol 12 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>2 h, 4 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-McFadden-1986-Salb-_x0028_I_x0029_" TYPE="STUDY">McFadden 1986 Salb (I)</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-McFadden-1986-Salb-_x0028_II_x0029_" TYPE="STUDY">McFadden 1986 Salb (II)</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 180 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Morton-1989-Rimet" TYPE="STUDY">Morton 1989 Rimet</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Rimeterol 400 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>2 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Nelson-1998" TYPE="STUDY">Nelson 1998</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmeterol 84 mcg daily</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term (29 days)</P>
</TD>
<TD VALIGN="TOP">
<P>30 min, 9 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Newnham-1993-Salb-200" TYPE="STUDY">Newnham 1993 Salb 200</LINK>
</P>
<P>
<LINK REF="STD-Newnham-1993-Salm-50" TYPE="STUDY">Newnham 1993 Salm 50</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
<P>Salmeterol 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>1 h, 6 h, 12 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Patel-1986-Salb-200" TYPE="STUDY">Patel 1986 Salb 200</LINK>
</P>
<P>
<LINK REF="STD-Patel-1986-Tulob-200" TYPE="STUDY">Patel 1986 Tulob 200</LINK>
</P>
<P>
<LINK REF="STD-Patel-1986-Tulob-400" TYPE="STUDY">Patel 1986 Tulob 400</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
<P>Tolobuterol 200 mcg</P>
<P>Tolobuterol 400 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>20 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Patessio-1991-Salb-200" TYPE="STUDY">Patessio 1991 Salb 200</LINK>
</P>
<P>
<LINK REF="STD-Patessio-1991-Form-24" TYPE="STUDY">Patessio 1991 Form 24</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 200 mcg</P>
<P>Formoterol 24 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>2 h, 8 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pearlman-2006-Salb-180" TYPE="STUDY">Pearlman 2006 Salb 180</LINK>
</P>
<P>
<LINK REF="STD-Pearlman-2006-Form-12" TYPE="STUDY">Pearlman 2006 Form 12</LINK>
</P>
<P>
<LINK REF="STD-Pearlman-2006-Form-24" TYPE="STUDY">Pearlman 2006 Form 24</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 180 mcg</P>
<P>Formoterol 12 mcg</P>
<P>Formoterol 24 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min, 4 h, 8 h, 12 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pearlman-2007-Salb-90" TYPE="STUDY">Pearlman 2007 Salb 90</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 90 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>20 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Philip-2007-Salm-50" TYPE="STUDY">Philip 2007 Salm 50</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmeterol 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>2 h, 8 h 30, 24 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ramage-1994" TYPE="STUDY">Ramage 1994</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmeterol 100 mcg daily</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term (28 days)</P>
</TD>
<TD VALIGN="TOP">
<P>6 h, 12 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Richter-2002-Terb-500" TYPE="STUDY">Richter 2002 Terb 500</LINK>
</P>
<P>
<LINK REF="STD-Richter-2002-Form-12" TYPE="STUDY">Richter 2002 Form 12</LINK>
</P>
<P>
<LINK REF="STD-Richter-2002-Salm-50" TYPE="STUDY">Richter 2002 Salm 50</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Terbutaline 500 mcg</P>
<P>Formoterol 12 mcg</P>
<P>Salmeterol 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>5 min, 30 min, 1 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="REF-Shapiro-2002" TYPE="REFERENCE">Shapiro 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 180 mcg</P>
<P>Formoterol 12 mcg</P>
<P>Formoterol 24 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min, 4 h, 8 h, 12 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmeterol 50 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term (28 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>1 h, 9 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Stelmach-2008" TYPE="STUDY">Stelmach 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Formoterol 9 mcg daily</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term (28 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>1 h, 9 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Storms-2004" TYPE="STUDY">Storms 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salmeterol 100 mcg daily</P>
</TD>
<TD VALIGN="TOP">
<P>Long-term (28 weeks)</P>
</TD>
<TD VALIGN="TOP">
<P>1 h, 9 h</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Sturani-1983-Fen-400" TYPE="STUDY">Sturani 1983 Fen 400</LINK>
</P>
<P>
<LINK REF="STD-Sturani-1983-Salb-200" TYPE="STUDY">Sturani 1983 Salb 200</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Fenoterol 400 mcg</P>
<P>Salbutamol 200 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>30 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-VanHaitsma-2010-Salb" TYPE="STUDY">VanHaitsma 2010 Salb</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 180 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Vasquez-1984-Salb-400" TYPE="STUDY">Vasquez 1984 Salb 400</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Salbutamol 400 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>15 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Walker-1986-Bitolterol" TYPE="STUDY">Walker 1986 Bitolterol</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Bitolterol 1050 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>45 min</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Wolley-1990-Terb-500" TYPE="STUDY">Wolley 1990 Terb 500</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Terbutaline 500 mcg</P>
</TD>
<TD VALIGN="TOP">
<P>Single dose</P>
</TD>
<TD VALIGN="TOP">
<P>25 min, 2 h, 4 h, 6 h</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-09-13 10:51:51 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-09-13 10:51:51 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Beta<SUB>2</SUB>-agonists versus placebo (single administration)</NAME>
<IV_OUTCOME CHI2="245.09551076297166" CI_END="-15.842249550064453" CI_START="-19.506398724826674" CI_STUDY="95" CI_TOTAL="95" DF="71" EFFECT_SIZE="-17.674324137445563" ESTIMABLE="YES" I2="71.03170116050673" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-09-10 03:33:12 +0100" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="55.08" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="72" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="40.0068816467022" TOTALS="YES" TOTAL_1="0" TOTAL_2="799" WEIGHT="100.00000000000003" Z="18.908094134965584">
<NAME>Maximal percentage fall in FEV<SUB>1</SUB>
</NAME>
<GROUP_LABEL_1>Beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-16.65057143358934" CI_START="-35.30942856641066" EFFECT_SIZE="-25.98" ESTIMABLE="YES" ESTIMATE="-25.98" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1620" SE="4.76" STUDY_ID="STD-Anderson-2001-Salb-Disk" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.3943399402893544"/>
<IV_DATA CI_END="-21.10977971714513" CI_START="-40.67022028285487" EFFECT_SIZE="-30.89" ESTIMABLE="YES" ESTIMATE="-30.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1617" SE="4.99" STUDY_ID="STD-Anderson-2001-Salb-MDI" TOTAL_1="0" TOTAL_2="13" WEIGHT="1.3461662733467357"/>
<IV_DATA CI_END="-1.2329555867869644" CI_START="-18.167044413213034" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1618" SE="4.32" STUDY_ID="STD-Blake-1999-Salb-180" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.4892902579528595"/>
<IV_DATA CI_END="2.5354429725946375" CI_START="-14.555442972594637" EFFECT_SIZE="-6.01" ESTIMABLE="YES" ESTIMATE="-6.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1627" SE="4.36" STUDY_ID="STD-Blake-1999-Salm-25" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.4805286109835145"/>
<IV_DATA CI_END="1.9050426124400364" CI_START="-15.225042612440037" EFFECT_SIZE="-6.66" ESTIMABLE="YES" ESTIMATE="-6.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1630" SE="4.37" STUDY_ID="STD-Blake-1999-Salm-50" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.4783417771779983"/>
<IV_DATA CI_END="-5.7341206517908185" CI_START="-18.865879348209184" EFFECT_SIZE="-12.3" ESTIMABLE="YES" ESTIMATE="-12.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1629" SE="3.35" STUDY_ID="STD-Boner-1994-Form-12" TOTAL_1="0" TOTAL_2="15" WEIGHT="1.7055757221530068"/>
<IV_DATA CI_END="0.9574537772326197" CI_START="-14.957453777232619" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1632" SE="4.06" STUDY_ID="STD-Bronski-1995-Salb-MDI" TOTAL_1="0" TOTAL_2="22" WEIGHT="1.5467311846265148"/>
<IV_DATA CI_END="11.173049815532027" CI_START="-5.173049815532027" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1631" SE="4.17" STUDY_ID="STD-Bronski-1995-Salb-Pwd" TOTAL_1="0" TOTAL_2="22" WEIGHT="1.5223346923884336"/>
<IV_DATA CI_END="2.1238415319762396" CI_START="-15.12384153197624" EFFECT_SIZE="-6.5" ESTIMABLE="YES" ESTIMATE="-6.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 14:33:54 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1587" SE="4.4" STUDY_ID="STD-Bronski-1999-Salm-Disk" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.4717901155311863"/>
<IV_DATA CI_END="1.8514483749136286" CI_START="-14.65144837491363" EFFECT_SIZE="-6.4" ESTIMABLE="YES" ESTIMATE="-6.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 14:35:04 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1588" SE="4.21" STUDY_ID="STD-Bronski-1999-Salm-Diskhal" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.5134956500868246"/>
<IV_DATA CI_END="-9.73621249121368" CI_START="-32.863787508786324" EFFECT_SIZE="-21.3" ESTIMABLE="YES" ESTIMATE="-21.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1585" SE="5.9" STUDY_ID="STD-Bronski-2002-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.1678592808789892"/>
<IV_DATA CI_END="-12.136212491213678" CI_START="-35.26378750878632" EFFECT_SIZE="-23.7" ESTIMABLE="YES" ESTIMATE="-23.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1619" SE="5.9" STUDY_ID="STD-Bronski-2002-Form-24" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.1678592808789892"/>
<IV_DATA CI_END="-16.93621249121368" CI_START="-40.06378750878632" EFFECT_SIZE="-28.5" ESTIMABLE="YES" ESTIMATE="-28.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1622" SE="5.9" STUDY_ID="STD-Bronski-2002-Salb" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.1678592808789892"/>
<IV_DATA CI_END="-0.3181962842567039" CI_START="-21.681803715743296" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1621" SE="5.45" STUDY_ID="STD-Carlsen-1995-Salm-25" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.253426547955323"/>
<IV_DATA CI_END="-2.023783318691123" CI_START="-21.976216681308877" EFFECT_SIZE="-12.0" ESTIMABLE="YES" ESTIMATE="-12.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:41 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1624" SE="5.09" STUDY_ID="STD-Carlsen-1995-Salm-50" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.3255801248015306"/>
<IV_DATA CI_END="-6.93117888263863" CI_START="-48.168821117361375" EFFECT_SIZE="-27.55" ESTIMABLE="YES" ESTIMATE="-27.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1623" SE="10.52" STUDY_ID="STD-Cavagni-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.5798856247114839"/>
<IV_DATA CI_END="6.991632642308552" CI_START="-32.99163264230855" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1626" SE="10.2" STUDY_ID="STD-Cavagni-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.6065774461666485"/>
<IV_DATA CI_END="-23.369316329935625" CI_START="-36.03068367006438" EFFECT_SIZE="-29.7" ESTIMABLE="YES" ESTIMATE="-29.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1625" SE="3.23" STUDY_ID="STD-Clarke-1990-Fen" TOTAL_1="0" TOTAL_2="20" WEIGHT="1.7322753339722037"/>
<IV_DATA CI_END="-16.924530015810404" CI_START="-31.075469984189596" EFFECT_SIZE="-24.0" ESTIMABLE="YES" ESTIMATE="-24.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1628" SE="3.61" STUDY_ID="STD-Daugbjerg-1996-Form-12" TOTAL_1="0" TOTAL_2="16" WEIGHT="1.647384374374745"/>
<IV_DATA CI_END="-18.824530015810403" CI_START="-32.975469984189594" EFFECT_SIZE="-25.9" ESTIMABLE="YES" ESTIMATE="-25.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1599" SE="3.61" STUDY_ID="STD-Debelic-1988-Reproterol" TOTAL_1="0" TOTAL_2="16" WEIGHT="1.647384374374745"/>
<IV_DATA CI_END="-3.0446380621902414" CI_START="-28.95536193780976" EFFECT_SIZE="-16.0" ESTIMABLE="YES" ESTIMATE="-16.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1594" SE="6.61" STUDY_ID="STD-DeBenedictis-1996-Salm-25" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.0439265553593355"/>
<IV_DATA CI_END="-6.731043824663834" CI_START="-33.268956175336164" EFFECT_SIZE="-20.0" ESTIMABLE="YES" ESTIMATE="-20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1597" SE="6.77" STUDY_ID="STD-DeBenedictis-1996-Salm-50" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.0178915640436381"/>
<IV_DATA CI_END="-11.925785119464122" CI_START="-32.07421488053588" EFFECT_SIZE="-22.0" ESTIMABLE="YES" ESTIMATE="-22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1600" SE="5.14" STUDY_ID="STD-DeBenedictis-1998-Salb" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.3153728367286472"/>
<IV_DATA CI_END="2.3410029954340956" CI_START="-19.101002995434097" EFFECT_SIZE="-8.38" ESTIMABLE="YES" ESTIMATE="-8.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1604" SE="5.47" STUDY_ID="STD-Del-Col-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.2495118183353202"/>
<IV_DATA CI_END="-3.8029916022469106" CI_START="-24.65700839775309" EFFECT_SIZE="-14.23" ESTIMABLE="YES" ESTIMATE="-14.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1598" SE="5.32" STUDY_ID="STD-Del-Col-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.2791173833365053"/>
<IV_DATA CI_END="-23.308659671466206" CI_START="-51.57134032853379" EFFECT_SIZE="-37.44" ESTIMABLE="YES" ESTIMATE="-37.44" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1602" SE="7.21" STUDY_ID="STD-Dinh-Xuan-1989-Terb" TOTAL_1="0" TOTAL_2="10" WEIGHT="0.9498277769564212"/>
<IV_DATA CI_END="-14.610935778283995" CI_START="-29.389064221716005" EFFECT_SIZE="-22.0" ESTIMABLE="YES" ESTIMATE="-22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1603" SE="3.77" STUDY_ID="STD-Egglestone-1981-Terb-250" TOTAL_1="0" TOTAL_2="17" WEIGHT="1.6115075889989412"/>
<IV_DATA CI_END="-16.324530015810403" CI_START="-30.475469984189594" EFFECT_SIZE="-23.4" ESTIMABLE="YES" ESTIMATE="-23.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1591" SE="3.61" STUDY_ID="STD-Ferrari-2000-Form-12" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.647384374374745"/>
<IV_DATA CI_END="-18.166896161278054" CI_START="-28.633103838721944" EFFECT_SIZE="-23.4" ESTIMABLE="YES" ESTIMATE="-23.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1586" SE="2.67" STUDY_ID="STD-Green-1992-Salm-50" TOTAL_1="0" TOTAL_2="13" WEIGHT="1.8536998124362116"/>
<IV_DATA CI_END="-2.2813271345736084" CI_START="-16.11867286542639" EFFECT_SIZE="-9.2" ESTIMABLE="YES" ESTIMATE="-9.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1589" SE="3.53" STUDY_ID="STD-Gronnerod-2000-Form-4.5" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.6653189224938003"/>
<IV_DATA CI_END="-6.081327134573609" CI_START="-19.91867286542639" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1592" SE="3.53" STUDY_ID="STD-Gronnerod-2000-Form-9" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.6653189224938003"/>
<IV_DATA CI_END="-7.593337939211592" CI_START="-22.60666206078841" EFFECT_SIZE="-15.1" ESTIMABLE="YES" ESTIMATE="-15.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1595" SE="3.83" STUDY_ID="STD-Gronnerod-2000-Terb-500" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.5980674983692016"/>
<IV_DATA CI_END="-12.753301923751646" CI_START="-23.846698076248355" EFFECT_SIZE="-18.3" ESTIMABLE="YES" ESTIMATE="-18.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1590" SE="2.83" STUDY_ID="STD-Hawksworth-2002-Salb-HFA" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.8197264857715212"/>
<IV_DATA CI_END="-13.253301923751646" CI_START="-24.346698076248355" EFFECT_SIZE="-18.8" ESTIMABLE="YES" ESTIMATE="-18.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1593" SE="2.83" STUDY_ID="STD-Hawksworth-2002-Salb-MDI" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.8197264857715212"/>
<IV_DATA CI_END="0.524588229095519" CI_START="-22.52458822909552" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1596" SE="5.88" STUDY_ID="STD-Henricksen-1983-Terb" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.1715485128216434"/>
<IV_DATA CI_END="-11.731462192548404" CI_START="-40.268537807451594" EFFECT_SIZE="-26.0" ESTIMABLE="YES" ESTIMATE="-26.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1567" SE="7.28" STUDY_ID="STD-Henricksen-1992-Salb" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.939469114554574"/>
<IV_DATA CI_END="-24.82820528812169" CI_START="-47.171794711878306" EFFECT_SIZE="-36.0" ESTIMABLE="YES" ESTIMATE="-36.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1568" SE="5.7" STUDY_ID="STD-Henriksen-1992-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.2052323853504767"/>
<IV_DATA CI_END="-31.142964590651953" CI_START="-49.057035409348046" EFFECT_SIZE="-40.1" ESTIMABLE="YES" ESTIMATE="-40.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1613" SE="4.57" STUDY_ID="STD-Hills-1976-Salb" TOTAL_1="0" TOTAL_2="10" WEIGHT="1.4349323871731088"/>
<IV_DATA CI_END="-28.65297359451694" CI_START="-47.54702640548307" EFFECT_SIZE="-38.1" ESTIMABLE="YES" ESTIMATE="-38.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1566" SE="4.82" STUDY_ID="STD-Hills-1976-Salmefamol" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.3816663839678918"/>
<IV_DATA CI_END="-14.453301923751646" CI_START="-25.546698076248354" EFFECT_SIZE="-20.0" ESTIMABLE="YES" ESTIMATE="-20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1615" SE="2.83" STUDY_ID="STD-Kemp-1994-Salb" TOTAL_1="0" TOTAL_2="26" WEIGHT="1.8197264857715212"/>
<IV_DATA CI_END="-8.453301923751646" CI_START="-19.546698076248354" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1614" SE="2.83" STUDY_ID="STD-Kemp-1994-Salm-42" TOTAL_1="0" TOTAL_2="26" WEIGHT="1.8197264857715212"/>
<IV_DATA CI_END="-10.806513808853428" CI_START="-23.193486191146572" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1609" SE="3.16" STUDY_ID="STD-Konig-1981-Metaprot" TOTAL_1="0" TOTAL_2="24" WEIGHT="1.7477745996890293"/>
<IV_DATA CI_END="-11.740216092759674" CI_START="-35.259783907240326" EFFECT_SIZE="-23.5" ESTIMABLE="YES" ESTIMATE="-23.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1616" SE="6.0" STUDY_ID="STD-Konig-1984-Fen-0.4" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.1495747188217549"/>
<IV_DATA CI_END="-12.61903302002585" CI_START="-37.980966979974156" EFFECT_SIZE="-25.3" ESTIMABLE="YES" ESTIMATE="-25.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1611" SE="6.47" STUDY_ID="STD-Konig-1984-Fen-0.8" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.0672768681407867"/>
<IV_DATA CI_END="-3.684584039000322" CI_START="-23.715415960999678" EFFECT_SIZE="-13.7" ESTIMABLE="YES" ESTIMATE="-13.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1610" SE="5.11" STUDY_ID="STD-Larsson-1982-Fen" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.3214902501736292"/>
<IV_DATA CI_END="-15.768569632816344" CI_START="-34.231430367183656" EFFECT_SIZE="-25.0" ESTIMABLE="YES" ESTIMATE="-25.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1605" SE="4.71" STUDY_ID="STD-McAlpine-1990-Form-12" TOTAL_1="0" TOTAL_2="11" WEIGHT="1.4049559483382001"/>
<IV_DATA CI_END="-2.3893343376655967" CI_START="-17.010665662334404" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1612" SE="3.73" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_" TOTAL_1="0" TOTAL_2="15" WEIGHT="1.6204737283625497"/>
<IV_DATA CI_END="-8.869316329935625" CI_START="-21.530683670064374" EFFECT_SIZE="-15.2" ESTIMABLE="YES" ESTIMATE="-15.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1607" SE="3.23" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_" TOTAL_1="0" TOTAL_2="20" WEIGHT="1.7322753339722037"/>
<IV_DATA CI_END="-16.604093640195856" CI_START="-26.795906359804142" EFFECT_SIZE="-21.7" ESTIMABLE="YES" ESTIMATE="-21.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1606" SE="2.6" STUDY_ID="STD-Morton-1989-Rimet" TOTAL_1="0" TOTAL_2="10" WEIGHT="1.8683219090295589"/>
<IV_DATA CI_END="-7.7966848822881705" CI_START="-38.80331511771183" EFFECT_SIZE="-23.3" ESTIMABLE="YES" ESTIMATE="-23.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1601" SE="7.91" STUDY_ID="STD-Newnham-1993-Salb-200" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.851821644955032"/>
<IV_DATA CI_END="1.2032250790619656" CI_START="-39.603225079061964" EFFECT_SIZE="-19.2" ESTIMABLE="YES" ESTIMATE="-19.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1608" SE="10.41" STUDY_ID="STD-Newnham-1993-Salm-50" TOTAL_1="0" TOTAL_2="5" WEIGHT="0.5888835747631455"/>
<IV_DATA CI_END="-12.452973594516937" CI_START="-31.34702640548306" EFFECT_SIZE="-21.9" ESTIMABLE="YES" ESTIMATE="-21.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1584" SE="4.82" STUDY_ID="STD-Patel-1986-Salb-200" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.3816663839678918"/>
<IV_DATA CI_END="-5.538632659871249" CI_START="-30.86136734012875" EFFECT_SIZE="-18.2" ESTIMABLE="YES" ESTIMATE="-18.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1581" SE="6.46" STUDY_ID="STD-Patel-1986-Tulob-200" TOTAL_1="0" TOTAL_2="5" WEIGHT="1.0689651659445931"/>
<IV_DATA CI_END="-6.029460391775405" CI_START="-34.37053960822459" EFFECT_SIZE="-20.2" ESTIMABLE="YES" ESTIMATE="-20.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1582" SE="7.23" STUDY_ID="STD-Patel-1986-Tulob-400" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.9468551836419372"/>
<IV_DATA CI_END="-12.326950184467973" CI_START="-28.673049815532025" EFFECT_SIZE="-20.5" ESTIMABLE="YES" ESTIMATE="-20.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1573" SE="4.17" STUDY_ID="STD-Patessio-1991-Form-24" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.5223346923884336"/>
<IV_DATA CI_END="5.101403355588696" CI_START="-16.301403355588697" EFFECT_SIZE="-5.6" ESTIMABLE="YES" ESTIMATE="-5.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1572" SE="5.46" STUDY_ID="STD-Pearlman-2006-Form-12" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.251467914178755"/>
<IV_DATA CI_END="3.4014033555886956" CI_START="-18.001403355588696" EFFECT_SIZE="-7.3" ESTIMABLE="YES" ESTIMATE="-7.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1571" SE="5.46" STUDY_ID="STD-Pearlman-2006-Form-24" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.251467914178755"/>
<IV_DATA CI_END="3.1014033555886957" CI_START="-18.301403355588697" EFFECT_SIZE="-7.6" ESTIMABLE="YES" ESTIMATE="-7.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1570" SE="5.46" STUDY_ID="STD-Pearlman-2006-Salb-180" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.251467914178755"/>
<IV_DATA CI_END="-11.52611344869883" CI_START="-23.87388655130117" EFFECT_SIZE="-17.7" ESTIMABLE="YES" ESTIMATE="-17.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1577" SE="3.15" STUDY_ID="STD-Pearlman-2007-Salb-90" TOTAL_1="0" TOTAL_2="15" WEIGHT="1.7499834108860268"/>
<IV_DATA CI_END="-8.454048620870926" CI_START="-13.745951379129073" EFFECT_SIZE="-11.1" ESTIMABLE="YES" ESTIMATE="-11.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1576" SE="1.35" STUDY_ID="STD-Philip-2007-Salm-50" TOTAL_1="0" TOTAL_2="46" WEIGHT="2.0888568311985725"/>
<IV_DATA CI_END="-11.481745502458178" CI_START="-27.31825449754182" EFFECT_SIZE="-19.4" ESTIMABLE="YES" ESTIMATE="-19.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1575" SE="4.04" STUDY_ID="STD-Richter-2002-Form-12" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.551179563929211"/>
<IV_DATA CI_END="-9.326950184467973" CI_START="-25.673049815532025" EFFECT_SIZE="-17.5" ESTIMABLE="YES" ESTIMATE="-17.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1574" SE="4.17" STUDY_ID="STD-Richter-2002-Salm-50" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.5223346923884336"/>
<IV_DATA CI_END="-8.27015306570477" CI_START="-24.929846934295234" EFFECT_SIZE="-16.6" ESTIMABLE="YES" ESTIMATE="-16.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1565" SE="4.25" STUDY_ID="STD-Richter-2002-Terb-500" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.5046757365030115"/>
<IV_DATA CI_END="-6.211862552703005" CI_START="-34.788137447297" EFFECT_SIZE="-20.5" ESTIMABLE="YES" ESTIMATE="-20.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1564" SE="7.29" STUDY_ID="STD-Shapiro-2002-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.9379996651985838"/>
<IV_DATA CI_END="0.12291475755722914" CI_START="-30.92291475755723" EFFECT_SIZE="-15.4" ESTIMABLE="YES" ESTIMATE="-15.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1563" SE="7.92" STUDY_ID="STD-Shapiro-2002-Form-24" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.8505090871915207"/>
<IV_DATA CI_END="-2.5979399859418884" CI_START="-39.60206001405811" EFFECT_SIZE="-21.1" ESTIMABLE="YES" ESTIMATE="-21.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1562" SE="9.44" STUDY_ID="STD-Shapiro-2002-Salb-180" TOTAL_1="0" TOTAL_2="5" WEIGHT="0.6766981386934573"/>
<IV_DATA CI_END="-13.477323533027612" CI_START="-26.922676466972387" EFFECT_SIZE="-20.2" ESTIMABLE="YES" ESTIMATE="-20.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1569" SE="3.43" STUDY_ID="STD-Sturani-1983-Fen-400" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.6877068321463071"/>
<IV_DATA CI_END="-5.685330736119604" CI_START="-19.9146692638804" EFFECT_SIZE="-12.8" ESTIMABLE="YES" ESTIMATE="-12.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1583" SE="3.63" STUDY_ID="STD-Sturani-1983-Salb-200" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.6428991488036473"/>
<IV_DATA CI_END="-0.2845840390003236" CI_START="-20.31541596099968" EFFECT_SIZE="-10.3" ESTIMABLE="YES" ESTIMATE="-10.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 18:13:27 +0000" MODIFIED_BY="Christopher J Cates" ORDER="457" SE="5.11" STUDY_ID="STD-VanHaitsma-2010-Salb" TOTAL_1="0" TOTAL_2="10" WEIGHT="1.3214902501736292"/>
<IV_DATA CI_END="-9.366896161278055" CI_START="-19.833103838721946" EFFECT_SIZE="-14.6" ESTIMABLE="YES" ESTIMATE="-14.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1579" SE="2.67" STUDY_ID="STD-Vasquez-1984-Salb-400" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.8536998124362116"/>
<IV_DATA CI_END="-9.086167471888746" CI_START="-27.313832528111252" EFFECT_SIZE="-18.2" ESTIMABLE="YES" ESTIMATE="-18.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1578" SE="4.65" STUDY_ID="STD-Walker-1986-Bitolterol" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.4177586609324933"/>
<IV_DATA CI_END="-9.630535418129396" CI_START="-24.369464581870602" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 15:24:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1580" SE="3.76" STUDY_ID="STD-Wolley-1990-Terb-500" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.6137487503834644"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="19.90266301499526" CI_END="0.1278456996014682" CI_START="0.0554217517620925" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="OR" EFFECT_SIZE="0.08417501189286294" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="321" I2="9.559841381837876" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.8933138759345818" LOG_CI_START="-1.2563197512245388" LOG_EFFECT_SIZE="-1.0748168135795604" METHOD="MH" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3383263582482595" P_Q="1.0" P_Z="3.8221651827383173E-31" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08034226641616547" TOTALS="YES" TOTAL_1="392" TOTAL_2="381" WEIGHT="100.0" Z="11.606436082674175">
<NAME>Number of participants with an FEV<SUB>1</SUB> fall &gt; 10%</NAME>
<GROUP_LABEL_1>Beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2606558500454099" CI_START="0.003632166943367051" EFFECT_SIZE="0.03076923076923077" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" LOG_CI_END="-0.5839325235129849" LOG_CI_START="-2.439834198444764" LOG_EFFECT_SIZE="-1.5118833609788744" MODIFIED="2011-02-16 11:14:02 +0000" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.0901658307163817" STUDY_ID="STD-Anderson-2001-Salb-Disk" TOTAL_1="27" TOTAL_2="27" VAR="1.1884615384615385" WEIGHT="3.583505208933805"/>
<DICH_DATA CI_END="0.165360397502743" CI_START="0.0022364634506939086" EFFECT_SIZE="0.019230769230769232" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="26" LOG_CI_END="-0.7815684923976989" LOG_CI_START="-2.650438194871899" LOG_EFFECT_SIZE="-1.7160033436347992" MODIFIED="2011-02-16 11:13:16 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="1.0977833142875715" STUDY_ID="STD-Anderson-2001-Salb-MDI" TOTAL_1="27" TOTAL_2="27" VAR="1.205128205128205" WEIGHT="3.537043552958301"/>
<DICH_DATA CI_END="0.8440513582968059" CI_START="0.02417881692233437" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="-0.07363112689768593" LOG_CI_START="-1.6165649531308277" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2010-12-21 12:45:29 +0000" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.9063269671749657" STUDY_ID="STD-Debelic-1988-Reproterol" TOTAL_1="16" TOTAL_2="16" VAR="0.8214285714285714" WEIGHT="5.042040453161257"/>
<DICH_DATA CI_END="0.48771634752596793" CI_START="0.004236306026976741" EFFECT_SIZE="0.045454545454545456" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.31183268725991076" LOG_CI_START="-2.3730126743845013" LOG_EFFECT_SIZE="-1.3424226808222062" MODIFIED="2011-02-16 11:14:53 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="1.210747327442473" STUDY_ID="STD-DeBenedictis-1996-Salm-25" TOTAL_1="12" TOTAL_2="12" VAR="1.4659090909090908" WEIGHT="2.9405083606583795"/>
<DICH_DATA CI_END="0.1413553969907157" CI_START="1.9257256958128173E-4" EFFECT_SIZE="0.0052173913043478265" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.8496876053666013" LOG_CI_START="-3.715405574573335" LOG_EFFECT_SIZE="-2.282546589969968" MODIFIED="2011-02-16 11:15:57 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="1.6833369206447641" STUDY_ID="STD-DeBenedictis-1996-Salm-50" TOTAL_1="12" TOTAL_2="12" VAR="2.833623188405797" WEIGHT="1.5603359457712178"/>
<DICH_DATA CI_END="0.23253958849025635" CI_START="0.0014216010036955302" EFFECT_SIZE="0.01818181818181818" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.6335031004115607" LOG_CI_START="-2.8472222785769272" LOG_EFFECT_SIZE="-1.7403626894942439" MODIFIED="2010-12-21 12:45:00 +0000" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="1.300349603340998" STUDY_ID="STD-DeBenedictis-1998-Salb" TOTAL_1="12" TOTAL_2="12" VAR="1.690909090909091" WEIGHT="2.566979003341623"/>
<DICH_DATA CI_END="0.22930383768124588" CI_START="6.646892255145985E-4" EFFECT_SIZE="0.012345679012345678" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.639588676757888" LOG_CI_START="-3.1773813609994117" LOG_EFFECT_SIZE="-1.9084850188786497" MODIFIED="2010-12-21 12:44:40 +0000" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="1.4907119849998598" STUDY_ID="STD-Dinh-Xuan-1989-Terb" TOTAL_1="10" TOTAL_2="10" VAR="2.2222222222222223" WEIGHT="1.9746526389725547"/>
<DICH_DATA CI_END="0.32508507209502685" CI_START="0.006355615436796755" EFFECT_SIZE="0.045454545454545456" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="-0.48800297284655575" LOG_CI_START="-2.1968423887978568" LOG_EFFECT_SIZE="-1.3424226808222062" MODIFIED="2010-12-21 12:45:22 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.0037807318213263" STUDY_ID="STD-Ferrari-2000-Form-12" TOTAL_1="14" TOTAL_2="14" VAR="1.0075757575757576" WEIGHT="4.179326882746857"/>
<DICH_DATA CI_END="0.27677278928392934" CI_START="0.046555580060885685" EFFECT_SIZE="0.11351351351351352" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="37" LOG_CI_END="-0.5578766094635883" LOG_CI_START="-1.3320282578746008" LOG_EFFECT_SIZE="-0.9449524336690945" MODIFIED="2011-02-16 11:16:47 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.45474051038909186" STUDY_ID="STD-Kemp-1994-Salb" TOTAL_1="54" TOTAL_2="49" VAR="0.20678893178893176" WEIGHT="15.835148086717272"/>
<DICH_DATA CI_END="0.28426164136053705" CI_START="0.04768344691271435" EFFECT_SIZE="0.11642411642411643" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="37" LOG_CI_END="-0.5462817406239846" LOG_CI_START="-1.321632358111278" LOG_EFFECT_SIZE="-0.9339570493676314" MODIFIED="2011-02-16 11:17:30 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.45544479075949196" STUDY_ID="STD-Kemp-1994-Salm-42" TOTAL_1="53" TOTAL_2="49" VAR="0.2074299574299574" WEIGHT="15.799874578324566"/>
<DICH_DATA CI_END="1.830496416032352" CI_START="0.004721952908554314" EFFECT_SIZE="0.09297052154195011" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.26256888290403085" LOG_CI_START="-2.325878348400237" LOG_EFFECT_SIZE="-1.0316547327481032" MODIFIED="2011-02-16 11:31:47 +0000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="1.5204667166885675" STUDY_ID="STD-Konig-1981-Metaprot" TOTAL_1="24" TOTAL_2="24" VAR="2.3118190365577123" WEIGHT="1.9006933346183026"/>
<DICH_DATA CI_END="0.32094996481293436" CI_START="6.766615954048702E-4" EFFECT_SIZE="0.014736842105263158" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.49356266759319223" LOG_CI_START="-3.169628471628027" LOG_EFFECT_SIZE="-1.8315955696106097" MODIFIED="2011-02-16 11:25:43 +0000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="1.5719343000294326" STUDY_ID="STD-Konig-1984-Fen-0.4" TOTAL_1="12" TOTAL_2="12" VAR="2.4709774436090224" WEIGHT="1.7821228072781972"/>
<DICH_DATA CI_END="0.22119764397154612" CI_START="4.100538605079927E-4" EFFECT_SIZE="0.009523809523809525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.65521950311601" LOG_CI_START="-3.387159095023866" LOG_EFFECT_SIZE="-2.021189299069938" MODIFIED="2011-02-16 11:31:10 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="1.6047548396057558" STUDY_ID="STD-Konig-1984-Fen-0.8" TOTAL_1="12" TOTAL_2="12" VAR="2.5752380952380953" WEIGHT="1.7121549434346368"/>
<DICH_DATA CI_END="1.1003836057986924" CI_START="0.08874745996339892" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.04154411137576909" LOG_CI_START="-1.0518440680155812" LOG_EFFECT_SIZE="-0.5051499783199059" MODIFIED="2011-02-16 11:33:55 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.6422616289332564" STUDY_ID="STD-Pearlman-2006-Form-12" TOTAL_1="22" TOTAL_2="22" VAR="0.4125" WEIGHT="9.225598845158519"/>
<DICH_DATA CI_END="0.5971836836977361" CI_START="0.045072403417963716" EFFECT_SIZE="0.1640625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.22389206661486322" LOG_CI_START="-1.346089283213035" LOG_EFFECT_SIZE="-0.7849906749139491" MODIFIED="2011-02-16 11:34:08 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.6591841999955775" STUDY_ID="STD-Pearlman-2006-Form-24" TOTAL_1="23" TOTAL_2="22" VAR="0.43452380952380953" WEIGHT="8.830966451991221"/>
<DICH_DATA CI_END="0.4077108461259746" CI_START="0.026613700733121512" EFFECT_SIZE="0.10416666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.3896477350771396" LOG_CI_START="-1.5748947310019974" LOG_EFFECT_SIZE="-0.9822712330395684" MODIFIED="2011-02-16 11:33:32 +0000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.6962199524735141" STUDY_ID="STD-Pearlman-2006-Salb-180" TOTAL_1="23" TOTAL_2="22" VAR="0.48472222222222217" WEIGHT="8.046453343494356"/>
<DICH_DATA CI_END="0.2713286156248856" CI_START="0.005452023323900101" EFFECT_SIZE="0.038461538461538464" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.5665044010315361" LOG_CI_START="-2.2634422949101003" LOG_EFFECT_SIZE="-1.414973347970818" MODIFIED="2010-12-21 12:45:14 +0000" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.9967897188423162" STUDY_ID="STD-Pearlman-2007-Salb-90" TOTAL_1="15" TOTAL_2="15" VAR="0.9935897435897436" WEIGHT="4.233755025021804"/>
<DICH_DATA CI_END="0.692618646497044" CI_START="0.014437959547545455" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.15950582066734778" LOG_CI_START="-1.840494179332652" LOG_EFFECT_SIZE="-1.0" MODIFIED="2012-05-31 12:14:33 +0100" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="0.9874208829065749" STUDY_ID="STD-Walker-1986-Bitolterol" TOTAL_1="12" TOTAL_2="12" VAR="0.975" WEIGHT="4.308332176758762"/>
<DICH_DATA CI_END="1.9508653901038713" CI_START="0.016945224107906953" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.29022730406805153" LOG_CI_START="-1.7709526830565392" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2012-05-31 11:33:46 +0100" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="1.210747327442473" STUDY_ID="STD-Wolley-1990-Terb-500" TOTAL_1="12" TOTAL_2="12" VAR="1.4659090909090908" WEIGHT="2.9405083606583795"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.600856417088835" CI_END="0.1510923077167028" CI_START="0.02563028830877817" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="0.06222973090105501" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="173" I2="63.191151034578965" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.8207576455301184" LOG_CI_START="-1.5912465085169964" LOG_EFFECT_SIZE="-1.2060020770235573" METHOD="MH" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0011169476149537338" P_Q="1.0" P_Z="8.48177355804779E-10" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.4787092723447897" TOTALS="YES" TOTAL_1="229" TOTAL_2="228" WEIGHT="100.0" Z="6.13563868290963">
<NAME>Number of participants with an FEV<SUB>1</SUB> fall &gt; 15%</NAME>
<GROUP_LABEL_1>Beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20778276871081838" CI_START="0.007700349792849279" EFFECT_SIZE="0.04" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.6823904710430283" LOG_CI_START="-2.113489546301047" LOG_EFFECT_SIZE="-1.3979400086720375" MODIFIED="2012-08-02 23:12:07 +0100" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.8406346808612327" STUDY_ID="STD-Anderson-2001-Salb-Disk" TOTAL_1="27" TOTAL_2="27" VAR="0.7066666666666667" WEIGHT="9.373068221803445"/>
<DICH_DATA CI_END="0.08327734129601684" CI_START="0.0023244351442477658" EFFECT_SIZE="0.01391304347826087" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="25" LOG_CI_END="-1.0794731485179392" LOG_CI_START="-2.6336825668774346" LOG_EFFECT_SIZE="-1.8565778576976868" MODIFIED="2012-08-02 23:12:11 +0100" MODIFIED_BY="[Empty name]" ORDER="574" O_E="0.0" SE="0.912950305805067" STUDY_ID="STD-Anderson-2001-Salb-MDI" TOTAL_1="27" TOTAL_2="27" VAR="0.8334782608695652" WEIGHT="8.859003637203319"/>
<DICH_DATA CI_END="1.6018597947570306" CI_START="0.14783425275415465" EFFECT_SIZE="0.48663101604278075" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.20462450111898092" LOG_CI_START="-0.8302249295497917" LOG_EFFECT_SIZE="-0.3128002142154054" MODIFIED="2011-02-16 11:42:42 +0000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.6078756781621348" STUDY_ID="STD-Bronski-1999-Salm-Disk" TOTAL_1="24" TOTAL_2="24" VAR="0.3695128401010754" WEIGHT="11.082909152912817"/>
<DICH_DATA CI_END="1.1084425401592903" CI_START="0.08726115481416695" EFFECT_SIZE="0.31100478468899523" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.04471318492137752" LOG_CI_START="-1.0591790438577742" LOG_EFFECT_SIZE="-0.5072329294681984" MODIFIED="2011-02-16 11:43:04 +0000" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.6484317595395342" STUDY_ID="STD-Bronski-1999-Salm-Diskhal" TOTAL_1="24" TOTAL_2="24" VAR="0.4204637467795363" WEIGHT="10.78557749103175"/>
<DICH_DATA CI_END="0.6675324774934459" CI_START="0.05307985325988125" EFFECT_SIZE="0.18823529411764706" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="-0.17552759969662562" LOG_CI_START="-1.2750702864201102" LOG_EFFECT_SIZE="-0.725298943058368" MODIFIED="2011-02-16 11:43:51 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.645876817005455" STUDY_ID="STD-Carlsen-1995-Salm-25" TOTAL_1="23" TOTAL_2="23" VAR="0.417156862745098" WEIGHT="10.804390345666976"/>
<DICH_DATA CI_END="1.117071403104776" CI_START="0.0937015127107313" EFFECT_SIZE="0.3235294117647059" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.04808093406753065" LOG_CI_START="-1.0282533978355908" LOG_EFFECT_SIZE="-0.49008623188403005" MODIFIED="2011-02-16 11:44:17 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.6322441145007643" STUDY_ID="STD-Carlsen-1995-Salm-50" TOTAL_1="23" TOTAL_2="23" VAR="0.39973262032085566" WEIGHT="10.904610808894555"/>
<DICH_DATA CI_END="0.22930383768124588" CI_START="6.646892255145985E-4" EFFECT_SIZE="0.012345679012345678" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.639588676757888" LOG_CI_START="-3.1773813609994117" LOG_EFFECT_SIZE="-1.9084850188786497" MODIFIED="2012-08-03 07:52:31 +0100" MODIFIED_BY="[Empty name]" ORDER="582" O_E="0.0" SE="1.4907119849998598" STUDY_ID="STD-Dinh-Xuan-1989-Terb" TOTAL_1="10" TOTAL_2="10" VAR="2.2222222222222223" WEIGHT="5.534735727130399"/>
<DICH_DATA CI_END="0.2662086512996983" CI_START="5.725425884235537E-4" EFFECT_SIZE="0.012345679012345678" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.5747778348468121" LOG_CI_START="-3.2421922029104877" LOG_EFFECT_SIZE="-1.9084850188786497" MODIFIED="2010-12-21 14:29:40 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="1.566852403714675" STUDY_ID="STD-Green-1992-Salm-50" TOTAL_1="13" TOTAL_2="13" VAR="2.455026455026455" WEIGHT="5.207181973134365"/>
<DICH_DATA CI_END="0.5569822890196373" CI_START="9.18996961877304E-4" EFFECT_SIZE="0.02262443438914027" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.2541586143475123" LOG_CI_START="-3.0366859243506714" LOG_EFFECT_SIZE="-1.6454222693490919" MODIFIED="2010-12-21 14:36:13 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="1.6344703156281801" STUDY_ID="STD-Larsson-1982-Fen" TOTAL_1="8" TOTAL_2="8" VAR="2.671493212669683" WEIGHT="4.935585152918318"/>
<DICH_DATA CI_END="0.12532177036961198" CI_START="4.102950710227177E-5" EFFECT_SIZE="0.0022675736961451248" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.9019734786457212" LOG_CI_START="-4.386903700289955" LOG_EFFECT_SIZE="-2.6444385894678386" MODIFIED="2010-12-21 14:37:01 +0000" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="2.047065262876636" STUDY_ID="STD-Morton-1989-Rimet" TOTAL_1="10" TOTAL_2="10" VAR="4.190476190476191" WEIGHT="3.613160638503699"/>
<DICH_DATA CI_END="0.48771634752596793" CI_START="0.004236306026976741" EFFECT_SIZE="0.045454545454545456" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.31183268725991076" LOG_CI_START="-2.3730126743845013" LOG_EFFECT_SIZE="-1.3424226808222062" MODIFIED="2011-02-16 11:45:55 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="1.210747327442473" STUDY_ID="STD-Patessio-1991-Form-24" TOTAL_1="12" TOTAL_2="12" VAR="1.4659090909090908" WEIGHT="6.956309864211788"/>
<DICH_DATA CI_END="0.35454155601149473" CI_START="0.0035976324423878775" EFFECT_SIZE="0.03571428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.4503328536014808" LOG_CI_START="-2.443983209082958" LOG_EFFECT_SIZE="-1.4471580313422192" MODIFIED="2012-08-02 23:37:34 +0100" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="1.1710800875382399" STUDY_ID="STD-Pearlman-2007-Salb-90" TOTAL_1="15" TOTAL_2="15" VAR="1.3714285714285714" WEIGHT="7.1869077530381285"/>
<DICH_DATA CI_END="0.13043363380904116" CI_START="1.7892446010763836E-4" EFFECT_SIZE="0.004830917874396135" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.8846104063477974" LOG_CI_START="-3.7473302845660377" LOG_EFFECT_SIZE="-2.315970345456918" MODIFIED="2010-12-21 14:37:50 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="1.6815758271573336" STUDY_ID="STD-Vasquez-1984-Salb-400" TOTAL_1="13" TOTAL_2="12" VAR="2.827697262479871" WEIGHT="4.756559233550428"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="32.95610041805796" CI_END="0.14137951617346553" CI_START="0.06343783103253994" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="OR" EFFECT_SIZE="0.09470380065485522" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="344" I2="27.175850007880648" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.8496135089072397" LOG_CI_START="-1.1976516741567569" LOG_EFFECT_SIZE="-1.0236325915319984" METHOD="MH" MODIFIED="2013-09-13 10:51:51 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.10500317991401287" P_Q="1.0" P_Z="9.412496860402385E-31" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.27038918427170533" TOTALS="YES" TOTAL_1="513" TOTAL_2="508" WEIGHT="100.00000000000001" Z="11.529097743437209">
<NAME>Number of participants with an FEV<SUB>1</SUB> fall &gt; 20%</NAME>
<GROUP_LABEL_1>Beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.29117514787816445" CI_START="0.021730835838677298" EFFECT_SIZE="0.07954545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="22" LOG_CI_END="-0.5358456952929526" LOG_CI_START="-1.6629235689788708" LOG_EFFECT_SIZE="-1.0993846321359118" MODIFIED="2012-08-02 23:11:43 +0100" MODIFIED_BY="[Empty name]" ORDER="575" O_E="0.0" SE="0.6620511221285621" STUDY_ID="STD-Anderson-2001-Salb-Disk" TOTAL_1="27" TOTAL_2="27" VAR="0.4383116883116883" WEIGHT="5.897473221757913"/>
<DICH_DATA CI_END="0.16663411607651218" CI_START="0.009375512896859986" EFFECT_SIZE="0.039525691699604744" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" LOG_CI_END="-0.7782360779175929" LOG_CI_START="-2.0280049644340425" LOG_EFFECT_SIZE="-1.403120521175818" MODIFIED="2012-08-02 23:11:46 +0100" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="0.7341204303955249" STUDY_ID="STD-Anderson-2001-Salb-MDI" TOTAL_1="27" TOTAL_2="27" VAR="0.5389328063241107" WEIGHT="5.164254112532004"/>
<DICH_DATA CI_END="0.4318095944602874" CI_START="0.04009410539434864" EFFECT_SIZE="0.13157894736842105" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="-0.3647077122221039" LOG_CI_START="-1.396919472339479" LOG_EFFECT_SIZE="-0.8808135922807914" MODIFIED="2011-02-16 11:55:34 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.6063262974235641" STUDY_ID="STD-Bronski-1995-Salb-MDI" TOTAL_1="44" TOTAL_2="44" VAR="0.3676315789473684" WEIGHT="6.550796869383267"/>
<DICH_DATA CI_END="0.2919291601333548" CI_START="0.013447970512092757" EFFECT_SIZE="0.06265664160401002" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="19" LOG_CI_END="-0.5347225221668561" LOG_CI_START="-1.8713432518625652" LOG_EFFECT_SIZE="-1.2030328870147107" MODIFIED="2011-02-16 11:56:02 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.785137633002579" STUDY_ID="STD-Bronski-1995-Salb-Pwd" TOTAL_1="44" TOTAL_2="44" VAR="0.6164411027568923" WEIGHT="4.7129022084946595"/>
<DICH_DATA CI_END="2.3375397266095974" CI_START="0.19013342934242802" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.36875900046465115" LOG_CI_START="-0.7209415185760136" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2012-08-03 07:46:07 +0100" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="0.6400954789890507" STUDY_ID="STD-Bronski-1999-Salm-Disk" TOTAL_1="24" TOTAL_2="24" VAR="0.4097222222222222" WEIGHT="6.145382033574742"/>
<DICH_DATA CI_END="1.9317638917109976" CI_START="0.14339656696034228" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.28595404402913455" LOG_CI_START="-0.8434612459347925" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2012-08-03 07:46:16 +0100" MODIFIED_BY="[Empty name]" ORDER="580" O_E="0.0" SE="0.6634241320206617" STUDY_ID="STD-Bronski-1999-Salm-Diskhal" TOTAL_1="24" TOTAL_2="24" VAR="0.44013157894736843" WEIGHT="5.882367743007614"/>
<DICH_DATA CI_END="0.1971902129886261" CI_START="0.004139792326606649" EFFECT_SIZE="0.02857142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.7051146439105886" LOG_CI_START="-2.3830214447899625" LOG_EFFECT_SIZE="-1.5440680443502757" MODIFIED="2012-08-02 23:25:25 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.9856107606091623" STUDY_ID="STD-Bronski-2002-Form-12" TOTAL_1="17" TOTAL_2="17" VAR="0.9714285714285714" WEIGHT="3.3656664990589804"/>
<DICH_DATA CI_END="0.33845157689209393" CI_START="0.00911923584882702" EFFECT_SIZE="0.05555555555555555" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.4705034581247384" LOG_CI_START="-2.040041552081874" LOG_EFFECT_SIZE="-1.255272505103306" MODIFIED="2012-08-02 23:25:07 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.9219544457292888" STUDY_ID="STD-Bronski-2002-Form-24" TOTAL_1="17" TOTAL_2="17" VAR="0.85" WEIGHT="3.7304398123174405"/>
<DICH_DATA CI_END="0.1971902129886261" CI_START="0.004139792326606649" EFFECT_SIZE="0.02857142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.7051146439105886" LOG_CI_START="-2.3830214447899625" LOG_EFFECT_SIZE="-1.5440680443502757" MODIFIED="2011-02-16 11:56:23 +0000" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.9856107606091623" STUDY_ID="STD-Bronski-2002-Salb" TOTAL_1="17" TOTAL_2="17" VAR="0.9714285714285714" WEIGHT="3.3656664990589804"/>
<DICH_DATA CI_END="0.36749717876556653" CI_START="0.0020996213926415663" EFFECT_SIZE="0.027777777777777776" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.4347459905967921" LOG_CI_START="-2.677859010937782" LOG_EFFECT_SIZE="-1.5563025007672873" MODIFIED="2012-08-03 07:53:35 +0100" MODIFIED_BY="[Empty name]" ORDER="581" O_E="0.0" SE="1.3176156917368247" STUDY_ID="STD-Dinh-Xuan-1989-Terb" TOTAL_1="10" TOTAL_2="10" VAR="1.7361111111111112" WEIGHT="2.0830021445372493"/>
<DICH_DATA CI_END="0.3999266148829973" CI_START="0.02108883361438975" EFFECT_SIZE="0.09183673469387756" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" LOG_CI_END="-0.3980196928602232" LOG_CI_START="-1.6759474396461165" LOG_EFFECT_SIZE="-1.03698356625317" MODIFIED="2011-02-16 12:01:23 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.7506610843064022" STUDY_ID="STD-Hawksworth-2002-Salb-HFA" TOTAL_1="23" TOTAL_2="24" VAR="0.5634920634920635" WEIGHT="5.012157821638722"/>
<DICH_DATA CI_END="0.3130704061524898" CI_START="0.01629678409731719" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" LOG_CI_END="-0.5043579833320125" LOG_CI_START="-1.7878980880244635" LOG_EFFECT_SIZE="-1.146128035678238" MODIFIED="2011-02-16 12:01:57 +0000" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.753957811122334" STUDY_ID="STD-Hawksworth-2002-Salb-MDI" TOTAL_1="24" TOTAL_2="24" VAR="0.5684523809523809" WEIGHT="4.982519454887189"/>
<DICH_DATA CI_END="1.0157534923320288" CI_START="0.010356248060372083" EFFECT_SIZE="0.10256410256410256" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.006788324178780757" LOG_CI_START="-1.9847975555758548" LOG_EFFECT_SIZE="-0.9890046156985368" MODIFIED="2010-12-21 14:57:15 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="1.1698674042769734" STUDY_ID="STD-Henricksen-1983-Terb" TOTAL_1="14" TOTAL_2="14" VAR="1.3685897435897436" WEIGHT="2.5500903930171512"/>
<DICH_DATA CI_END="0.22119764397154612" CI_START="4.100538605079927E-4" EFFECT_SIZE="0.009523809523809525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.65521950311601" LOG_CI_START="-3.387159095023866" LOG_EFFECT_SIZE="-2.021189299069938" MODIFIED="2011-02-16 12:02:24 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.6047548396057558" STUDY_ID="STD-Henricksen-1992-Salb" TOTAL_1="12" TOTAL_2="12" VAR="2.5752380952380953" WEIGHT="1.4687603146034698"/>
<DICH_DATA CI_END="0.22119764397154612" CI_START="4.100538605079927E-4" EFFECT_SIZE="0.009523809523809525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.65521950311601" LOG_CI_START="-3.387159095023866" LOG_EFFECT_SIZE="-2.021189299069938" MODIFIED="2011-02-16 12:06:35 +0000" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="1.6047548396057558" STUDY_ID="STD-Henriksen-1992-Form-12" TOTAL_1="12" TOTAL_2="12" VAR="2.5752380952380953" WEIGHT="1.4687603146034698"/>
<DICH_DATA CI_END="0.721520303484277" CI_START="0.0018524367164178697" EFFECT_SIZE="0.03655913978494624" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="-0.14175144341023832" LOG_CI_START="-2.7322566196131217" LOG_EFFECT_SIZE="-1.4370040315116799" MODIFIED="2010-12-21 14:57:47 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="1.5216755637090058" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_" TOTAL_1="15" TOTAL_2="15" VAR="2.3154965211891207" WEIGHT="1.6162912419024342"/>
<DICH_DATA CI_END="0.44665958631808816" CI_START="0.0010039925713248576" EFFECT_SIZE="0.021176470588235293" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.35002334063998" LOG_CI_START="-2.9982695005819933" LOG_EFFECT_SIZE="-1.6741464206109866" MODIFIED="2011-02-16 12:11:00 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="1.5555929033798501" STUDY_ID="STD-Newnham-1993-Salb-200" TOTAL_1="12" TOTAL_2="12" VAR="2.419869281045752" WEIGHT="1.5535847102348341"/>
<DICH_DATA CI_END="0.22119764397154612" CI_START="4.100538605079927E-4" EFFECT_SIZE="0.009523809523809525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.65521950311601" LOG_CI_START="-3.387159095023866" LOG_EFFECT_SIZE="-2.021189299069938" MODIFIED="2011-02-16 12:10:59 +0000" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="1.6047548396057558" STUDY_ID="STD-Newnham-1993-Salm-50" TOTAL_1="12" TOTAL_2="12" VAR="2.5752380952380953" WEIGHT="1.4687603146034698"/>
<DICH_DATA CI_END="0.4336808169172993" CI_START="0.028050104853641747" EFFECT_SIZE="0.11029411764705882" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.36282978765344187" LOG_CI_START="-1.5520655109756305" LOG_EFFECT_SIZE="-0.9574476493145363" MODIFIED="2012-08-03 08:12:18 +0100" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="0.6985629506912254" STUDY_ID="STD-Pearlman-2006-Form-12" TOTAL_1="22" TOTAL_2="22" VAR="0.4879901960784314" WEIGHT="5.511152500437675"/>
<DICH_DATA CI_END="0.4962309916153012" CI_START="0.035300699339718834" EFFECT_SIZE="0.1323529411764706" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="16" LOG_CI_END="-0.30431611578488516" LOG_CI_START="-1.4522166907489378" LOG_EFFECT_SIZE="-0.8782664032669114" MODIFIED="2012-08-03 08:12:41 +0100" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.6742824799333719" STUDY_ID="STD-Pearlman-2006-Form-24" TOTAL_1="23" TOTAL_2="22" VAR="0.454656862745098" WEIGHT="5.764522729961409"/>
<DICH_DATA CI_END="1.4537374468766502" CI_START="0.0710694539461627" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.16248597758982242" LOG_CI_START="-1.148317021395611" LOG_EFFECT_SIZE="-0.49291552190289434" MODIFIED="2012-08-03 08:13:19 +0100" MODIFIED_BY="[Empty name]" ORDER="586" O_E="0.0" SE="0.7699721701835351" STUDY_ID="STD-Pearlman-2006-Salb-180" TOTAL_1="23" TOTAL_2="22" VAR="0.5928571428571427" WEIGHT="4.841659080320874"/>
<DICH_DATA CI_END="0.7887480224349355" CI_START="0.008448693190053548" EFFECT_SIZE="0.08163265306122448" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.10306171661839157" LOG_CI_START="-2.073210460782711" LOG_EFFECT_SIZE="-1.0881360887005513" MODIFIED="2012-08-02 23:39:46 +0100" MODIFIED_BY="[Empty name]" ORDER="578" O_E="0.0" SE="1.1572751247156894" STUDY_ID="STD-Pearlman-2007-Salb-90" TOTAL_1="15" TOTAL_2="15" VAR="1.3392857142857142" WEIGHT="2.5965146266756793"/>
<DICH_DATA CI_END="0.39532445644585423" CI_START="0.017030094588092216" EFFECT_SIZE="0.08205128205128205" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.4030463175291888" LOG_CI_START="-1.7687829398839978" LOG_EFFECT_SIZE="-1.0859146287065933" MODIFIED="2011-02-16 12:21:05 +0000" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.8022404524765274" STUDY_ID="STD-Shapiro-2002-Form-12" TOTAL_1="19" TOTAL_2="17" VAR="0.6435897435897435" WEIGHT="4.572911137105135"/>
<DICH_DATA CI_END="0.5927270739579067" CI_START="0.0277303933298323" EFFECT_SIZE="0.1282051282051282" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.22714523506571996" LOG_CI_START="-1.557043970315241" LOG_EFFECT_SIZE="-0.8920946026904805" MODIFIED="2011-02-16 12:21:28 +0000" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.781189100190479" STUDY_ID="STD-Shapiro-2002-Form-24" TOTAL_1="17" TOTAL_2="17" VAR="0.6102564102564103" WEIGHT="4.7460004844929635"/>
<DICH_DATA CI_END="0.6423289319775063" CI_START="0.0329379913314092" EFFECT_SIZE="0.14545454545454545" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.1922425159195766" LOG_CI_START="-1.4823028890850238" LOG_EFFECT_SIZE="-0.8372727025023002" MODIFIED="2011-02-16 12:12:13 +0000" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.7577878490992214" STUDY_ID="STD-Shapiro-2002-Salb-180" TOTAL_1="19" TOTAL_2="17" VAR="0.5742424242424242" WEIGHT="4.9483637317926785"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="1.4224665720689724" CI_END="-11.651938346626439" CI_START="-37.57131870139642" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="-24.61162852401143" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-01-25 11:38:46 +0000" MODIFIED_BY="Christopher J Cates" NO="5" P_CHI2="0.9218400044629" P_Q="1.0" P_Z="1.975339315454622E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="92" WEIGHT="100.0" Z="3.722149592134351">
<NAME>Maximal percentage fall in PEF</NAME>
<GROUP_LABEL_1>Beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-20.0" ESTIMABLE="NO" ESTIMATE="-20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="668" SE="0.0" STUDY_ID="STD-Bronski-2002-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-22.0" ESTIMABLE="NO" ESTIMATE="-22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="674" SE="0.0" STUDY_ID="STD-Bronski-2002-Form-24" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-19.0" ESTIMABLE="NO" ESTIMATE="-19.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="673" SE="0.0" STUDY_ID="STD-Bronski-2002-Salb" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-28.22" ESTIMABLE="NO" ESTIMATE="-28.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="676" SE="0.0" STUDY_ID="STD-Cavagni-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-22.3" ESTIMABLE="NO" ESTIMATE="-22.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="675" SE="0.0" STUDY_ID="STD-Cavagni-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-12.4" ESTIMABLE="NO" ESTIMATE="-12.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="670" SE="0.0" STUDY_ID="STD-Del-Col-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="7" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-9.8" ESTIMABLE="NO" ESTIMATE="-9.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="669" SE="0.0" STUDY_ID="STD-Del-Col-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="8" WEIGHT="0.0"/>
<IV_DATA CI_END="6.623887015115457" CI_START="-66.62388701511546" EFFECT_SIZE="-30.0" ESTIMABLE="YES" ESTIMATE="-30.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="672" SE="18.686" STUDY_ID="STD-Henricksen-1992-Salb" TOTAL_1="0" TOTAL_2="6" WEIGHT="12.521615597910689"/>
<IV_DATA CI_END="-6.072605059727088" CI_START="-71.9273949402729" EFFECT_SIZE="-39.0" ESTIMABLE="YES" ESTIMATE="-39.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="671" SE="16.8" STUDY_ID="STD-Henriksen-1992-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="15.490823039763956"/>
<IV_DATA CI_END="15.66225592411006" CI_START="-52.262255924110065" EFFECT_SIZE="-18.3" ESTIMABLE="YES" ESTIMATE="-18.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="679" SE="17.328" STUDY_ID="STD-Shapiro-2002-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="14.56116682937581"/>
<IV_DATA CI_END="22.195987314658865" CI_START="-53.195987314658865" EFFECT_SIZE="-15.5" ESTIMABLE="YES" ESTIMATE="-15.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="678" SE="19.233" STUDY_ID="STD-Shapiro-2002-Form-24" TOTAL_1="0" TOTAL_2="6" WEIGHT="11.819496953048759"/>
<IV_DATA CI_END="24.89915418043571" CI_START="-54.09915418043571" EFFECT_SIZE="-14.6" ESTIMABLE="YES" ESTIMATE="-14.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:59 +0000" MODIFIED_BY="Christopher J Cates" ORDER="681" SE="20.153" STUDY_ID="STD-Shapiro-2002-Salb-180" TOTAL_1="0" TOTAL_2="5" WEIGHT="10.764990389744279"/>
<IV_DATA CI_END="-3.1444834451823134" CI_START="-47.055516554817686" EFFECT_SIZE="-25.1" ESTIMABLE="YES" ESTIMATE="-25.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:47 +0000" MODIFIED_BY="Christopher J Cates" ORDER="680" SE="11.202" STUDY_ID="STD-VanHaitsma-2010-Salb" TOTAL_1="0" TOTAL_2="10" WEIGHT="34.841907190156505"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-15.8" ESTIMABLE="NO" ESTIMATE="-15.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 10:49:26 +0000" MODIFIED_BY="Christopher J Cates" ORDER="677" SE="0.0" STUDY_ID="STD-Walker-1986-Bitolterol" TOTAL_1="0" TOTAL_2="12" WEIGHT="0.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.777456786990289" CI_END="-14.320643697757301" CI_START="-27.173044831219467" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="-20.746844264488384" ESTIMABLE="YES" I2="58.136722336321455" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-01-25 11:33:14 +0000" MODIFIED_BY="Christopher J Cates" NO="6" P_CHI2="0.0917465208833319" P_Q="1.0" P_Z="2.4884277904990026E-10" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="106" WEIGHT="99.99999999999997" Z="6.32769972381104">
<NAME>Maximal percentage fall in FEF 25-75</NAME>
<GROUP_LABEL_1>Beta2-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta2-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-35.6" ESTIMABLE="NO" ESTIMATE="-35.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 11:01:52 +0000" MODIFIED_BY="Christopher J Cates" ORDER="689" SE="0.0" STUDY_ID="STD-Cavagni-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-18.3" ESTIMABLE="NO" ESTIMATE="-18.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 11:01:52 +0000" MODIFIED_BY="Christopher J Cates" ORDER="685" SE="0.0" STUDY_ID="STD-Cavagni-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.0"/>
<IV_DATA CI_END="-17.886585839773318" CI_START="-38.11341416022668" EFFECT_SIZE="-28.0" ESTIMABLE="YES" ESTIMATE="-28.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 11:01:52 +0000" MODIFIED_BY="Christopher J Cates" ORDER="686" SE="5.16" STUDY_ID="STD-Egglestone-1981-Terb-250" TOTAL_1="0" TOTAL_2="17" WEIGHT="40.375040120722204"/>
<IV_DATA CI_END="-1.8101890811647152" CI_START="-22.389810918835284" EFFECT_SIZE="-12.1" ESTIMABLE="YES" ESTIMATE="-12.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 11:01:52 +0000" MODIFIED_BY="Christopher J Cates" ORDER="687" SE="5.25" STUDY_ID="STD-Konig-1981-Metaprot" TOTAL_1="0" TOTAL_2="24" WEIGHT="39.0026183487819"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-18.0" ESTIMABLE="NO" ESTIMATE="-18.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 11:01:52 +0000" MODIFIED_BY="Christopher J Cates" ORDER="688" SE="0.0" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_" TOTAL_1="0" TOTAL_2="15" WEIGHT="0.0"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-15.5" ESTIMABLE="NO" ESTIMATE="-15.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 11:01:52 +0000" MODIFIED_BY="Christopher J Cates" ORDER="682" SE="0.0" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_" TOTAL_1="0" TOTAL_2="20" WEIGHT="0.0"/>
<IV_DATA CI_END="-8.749060031620807" CI_START="-37.05093996837919" EFFECT_SIZE="-22.9" ESTIMABLE="YES" ESTIMATE="-22.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 11:33:14 +0000" MODIFIED_BY="Christopher J Cates" ORDER="683" SE="7.22" STUDY_ID="STD-VanHaitsma-2010-Salb" TOTAL_1="0" TOTAL_2="10" WEIGHT="20.622341530495873"/>
<IV_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="-27.8" ESTIMABLE="NO" ESTIMATE="-27.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-25 11:01:52 +0000" MODIFIED_BY="Christopher J Cates" ORDER="684" SE="0.0" STUDY_ID="STD-Walker-1986-Bitolterol" TOTAL_1="0" TOTAL_2="12" WEIGHT="0.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="17.83115037293934" CI_END="1.5867782634514822" CI_START="0.4293062868889527" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8253568224704126" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="54" I2="32.702042498552025" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.2005162426417057" LOG_CI_START="-0.3672327515364282" LOG_EFFECT_SIZE="-0.08335825444736124" METHOD="MH" MODIFIED="2013-01-24 16:02:15 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.12091446452935461" P_Q="1.0" P_Z="0.5649307970805552" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="55" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.44552943289544095" TOTALS="YES" TOTAL_1="1084" TOTAL_2="1081" WEIGHT="99.99999999999999" Z="0.5755331253997533">
<NAME>Side effects</NAME>
<GROUP_LABEL_1>Beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:36:15 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Blake-1999-Salb-180" TOTAL_1="24" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:36:20 +0000" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.0" STUDY_ID="STD-Blake-1999-Salm-25" TOTAL_1="25" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:38:09 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.0" STUDY_ID="STD-Blake-1999-Salm-50" TOTAL_1="24" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:39:09 +0000" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.0" STUDY_ID="STD-Boner-1994-Form-12" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:38:31 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Boner-1994-Salb-200" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:39:24 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Bronski-1995-Salb-MDI" TOTAL_1="46" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:39:41 +0000" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.0" STUDY_ID="STD-Bronski-1995-Salb-Pwd" TOTAL_1="46" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:39:56 +0000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-Bronski-1999-Salm-Disk" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:40:12 +0000" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.0" STUDY_ID="STD-Bronski-1999-Salm-Diskhal" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.407796925395194" CI_START="0.26999488968548585" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.6442215776286928" LOG_CI_START="-0.5686444558498933" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2011-02-16 10:41:56 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.712443511849015" STUDY_ID="STD-Bronski-2002-Form-12" TOTAL_1="17" TOTAL_2="18" VAR="0.5075757575757576" WEIGHT="11.669362104614741"/>
<DICH_DATA CI_END="2.7269716237008073" CI_START="0.13887134782067698" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.43568061878714703" LOG_CI_START="-0.8573873494169333" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2011-02-16 10:47:17 +0000" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.75955452531275" STUDY_ID="STD-Bronski-2002-Form-24" TOTAL_1="17" TOTAL_2="18" VAR="0.576923076923077" WEIGHT="10.877893579008731"/>
<DICH_DATA CI_END="1.1805486498940925" CI_START="0.013235371537972393" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07208388886938188" LOG_CI_START="-1.8782638628532689" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2011-02-16 10:41:41 +0000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="1.14564392373896" STUDY_ID="STD-Bronski-2002-Salb" TOTAL_1="17" TOTAL_2="18" VAR="1.3125" WEIGHT="6.326475190508207"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:48:27 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Cavagni-1993-Salb-Jet" TOTAL_1="8" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:47:38 +0000" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.0" STUDY_ID="STD-Cavagni-1993-Salb-MDI" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 15:18:37 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Debelic-1988-Reproterol" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:48:38 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.0" STUDY_ID="STD-DeBenedictis-1996-Salm-25" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:48:51 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-DeBenedictis-1996-Salm-50" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 15:18:40 +0000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-DeBenedictis-1998-Salb" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:49:11 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-Del-Col-1993-Salb-Jet" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:49:43 +0000" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.0" STUDY_ID="STD-Del-Col-1993-Salb-MDI" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:10:22 +0000" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.0" STUDY_ID="STD-Egglestone-1981-Terb-250" TOTAL_1="17" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 15:18:31 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.0" STUDY_ID="STD-Ferrari-2000-Form-12" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:10:41 +0000" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.0" STUDY_ID="STD-Green-1992-Salm-50" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:50:05 +0000" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.0" STUDY_ID="STD-Gronnerod-2000-Form-4.5" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:50:15 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.0" STUDY_ID="STD-Gronnerod-2000-Form-9" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:50:03 +0000" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.0" STUDY_ID="STD-Gronnerod-2000-Terb-500" TOTAL_1="27" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:50:41 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.0" STUDY_ID="STD-Hawksworth-2002-Salb-HFA" TOTAL_1="23" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:51:06 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.0" STUDY_ID="STD-Hawksworth-2002-Salb-MDI" TOTAL_1="24" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:11:44 +0000" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.0" STUDY_ID="STD-Henricksen-1983-Terb" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 15:18:32 +0000" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.0" STUDY_ID="STD-Henricksen-1992-Salb" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:54:49 +0000" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.0" STUDY_ID="STD-Henriksen-1992-Form-12" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.908679956389632" CI_START="0.01254512355454697" EFFECT_SIZE="0.3149847094801223" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8981040011339438" LOG_CI_START="-1.9015250570441715" LOG_EFFECT_SIZE="-0.501710527955114" MODIFIED="2011-02-16 10:55:14 +0000" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="1.6445159671611682" STUDY_ID="STD-Kemp-1994-Salb" TOTAL_1="54" TOTAL_2="52" VAR="2.7044327662480327" WEIGHT="3.530877162405475"/>
<DICH_DATA CI_END="53.772800694457416" CI_START="0.7252504987086561" EFFECT_SIZE="6.244897959183674" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.7305626567946257" LOG_CI_START="-0.1395119638884931" LOG_EFFECT_SIZE="0.7955253464530664" MODIFIED="2011-02-16 10:55:32 +0000" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="1.0984910892079316" STUDY_ID="STD-Kemp-1994-Salm-42" TOTAL_1="55" TOTAL_2="52" VAR="1.2066826730692277" WEIGHT="6.731659664787649"/>
<DICH_DATA CI_END="16.969595377382827" CI_START="0.05892892421776925" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.229671487134124" LOG_CI_START="-1.2296714871341243" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:12:06 +0000" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="1.4446302370292305" STUDY_ID="STD-Konig-1981-Metaprot" TOTAL_1="24" TOTAL_2="24" VAR="2.086956521739131" WEIGHT="4.391783326988323"/>
<DICH_DATA CI_END="88.34712311919732" CI_START="0.12035785598830115" EFFECT_SIZE="3.260869565217391" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.946192411977474" LOG_CI_START="-0.9195255572292595" LOG_EFFECT_SIZE="0.5133334273741071" MODIFIED="2011-02-16 10:56:07 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.6833369206447641" STUDY_ID="STD-Konig-1984-Fen-0.4" TOTAL_1="12" TOTAL_2="12" VAR="2.833623188405797" WEIGHT="3.3917694221206207"/>
<DICH_DATA CI_END="138.24852748221622" CI_START="0.25628366281749543" EFFECT_SIZE="5.9523809523809526" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.140660514228065" LOG_CI_START="-0.5912790776797909" LOG_EFFECT_SIZE="0.7746907182741372" MODIFIED="2011-02-16 10:56:26 +0000" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="1.6047548396057558" STUDY_ID="STD-Konig-1984-Fen-0.8" TOTAL_1="12" TOTAL_2="12" VAR="2.5752380952380953" WEIGHT="3.681888621951763"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:56:40 +0000" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.0" STUDY_ID="STD-McAlpine-1990-Form-12" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:56:55 +0000" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.0" STUDY_ID="STD-McAlpine-1990-Salb" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:12:42 +0000" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.0" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:12:50 +0000" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.0" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:12:58 +0000" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.0" STUDY_ID="STD-Morton-1989-Rimet" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:57:21 +0000" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.0" STUDY_ID="STD-Newnham-1993-Salb-200" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:57:31 +0000" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.0" STUDY_ID="STD-Newnham-1993-Salm-50" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:57:44 +0000" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.0" STUDY_ID="STD-Patessio-1991-Form-24" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 10:57:58 +0000" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.0" STUDY_ID="STD-Patessio-1991-Salb-200" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 11:06:38 +0000" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.0" STUDY_ID="STD-Pearlman-2006-Form-12" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 11:06:39 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.0" STUDY_ID="STD-Pearlman-2006-Form-24" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 11:06:36 +0000" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.0" STUDY_ID="STD-Pearlman-2006-Salb-180" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:14:12 +0000" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.0" STUDY_ID="STD-Pearlman-2007-Salb-90" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2919109630996666" CI_START="0.049642676517076836" EFFECT_SIZE="0.2532467532467532" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.11123258365368344" LOG_CI_START="-1.3041448112736111" LOG_EFFECT_SIZE="-0.5964561138099639" MODIFIED="2010-12-21 11:14:26 +0000" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.8313996880113927" STUDY_ID="STD-Philip-2007-Salm-50" TOTAL_1="46" TOTAL_2="46" VAR="0.6912254412254412" WEIGHT="9.784105478322756"/>
<DICH_DATA CI_END="3.7369040936092808" CI_START="0.26760119471895577" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.5725119519703892" LOG_CI_START="-0.5725119519703891" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 11:08:04 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.6725927091345493" STUDY_ID="STD-Shapiro-2002-Form-12" TOTAL_1="19" TOTAL_2="19" VAR="0.45238095238095233" WEIGHT="12.386681091757975"/>
<DICH_DATA CI_END="0.9914059083803276" CI_START="0.011579103714934535" EFFECT_SIZE="0.10714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="-0.0037484972027791662" LOG_CI_START="-1.9363250560423342" LOG_EFFECT_SIZE="-0.9700367766225568" MODIFIED="2011-02-16 11:09:02 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.135205037070606" STUDY_ID="STD-Shapiro-2002-Form-24" TOTAL_1="17" TOTAL_2="19" VAR="1.288690476190476" WEIGHT="6.413332895744771"/>
<DICH_DATA CI_END="2.43994915070024" CI_START="0.15362771595853747" EFFECT_SIZE="0.6122448979591837" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3873807756008577" LOG_CI_START="-0.8135304262185602" LOG_EFFECT_SIZE="-0.21307482530885122" MODIFIED="2011-02-16 11:07:40 +0000" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.7054211845550484" STUDY_ID="STD-Shapiro-2002-Salb-180" TOTAL_1="19" TOTAL_2="19" VAR="0.4976190476190476" WEIGHT="11.792554217262891"/>
<DICH_DATA CI_END="23.906751226101267" CI_START="0.7378668825875739" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="1.3785205622955898" LOG_CI_START="-0.13202198149978886" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2010-12-21 11:15:26 +0000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.8873001675315897" STUDY_ID="STD-Walker-1986-Bitolterol" TOTAL_1="12" TOTAL_2="12" VAR="0.7873015873015872" WEIGHT="9.021617244526105"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-21 11:20:19 +0000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.0" STUDY_ID="STD-Wolley-1990-Terb-500" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="245.0955107629717" CI_END="-15.842249550064459" CI_START="-19.50639872482668" CI_STUDY="95" CI_TOTAL="95" DF="71" EFFECT_SIZE="-17.67432413744557" ESTIMABLE="YES" I2="71.03170116050674" I2_Q="70.6166681809697" ID="CMP-001.08" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-09-10 03:34:54 +0100" MODIFIED_BY="Christopher J Cates" NO="8" P_CHI2="0.0" P_Q="0.06506661349670395" P_Z="0.0" Q="3.4032900222443243" RANDOM="YES" SCALE="57.94" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="72" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="40.00688164670221" TOTALS="YES" TOTAL_1="0" TOTAL_2="799" WEIGHT="99.99999999999997" Z="18.908094134965584">
<NAME>Subgroup analysis: maximal percentage fall in FEV<SUB>1</SUB> SABA vs LABA</NAME>
<GROUP_LABEL_1>beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="146.27511839361742" CI_END="-16.596284855158313" CI_START="-21.38319614858911" DF="43" EFFECT_SIZE="-18.98974050187371" ESTIMABLE="YES" I2="70.6033394659168" ID="CMP-001.08.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-03-17 15:27:43 +0000" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="3.523847880160247E-13" P_Z="1.5809997179986578E-54" STUDIES="44" TAU2="42.35653565213279" TOTAL_1="0" TOTAL_2="487" WEIGHT="60.899669609100734" Z="15.550406171307555">
<NAME>SABA</NAME>
<IV_DATA CI_END="-16.65057143358934" CI_START="-35.30942856641066" EFFECT_SIZE="-25.98" ESTIMABLE="YES" ESTIMATE="-25.98" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1620" SE="4.76" STUDY_ID="STD-Anderson-2001-Salb-Disk" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.3943399402893544"/>
<IV_DATA CI_END="-21.10977971714513" CI_START="-40.67022028285487" EFFECT_SIZE="-30.89" ESTIMABLE="YES" ESTIMATE="-30.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1617" SE="4.99" STUDY_ID="STD-Anderson-2001-Salb-MDI" TOTAL_1="0" TOTAL_2="13" WEIGHT="1.346166273346736"/>
<IV_DATA CI_END="-1.2329555867869644" CI_START="-18.167044413213034" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1618" SE="4.32" STUDY_ID="STD-Blake-1999-Salb-180" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.4892902579528595"/>
<IV_DATA CI_END="0.9574537772326197" CI_START="-14.957453777232619" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1632" SE="4.06" STUDY_ID="STD-Bronski-1995-Salb-MDI" TOTAL_1="0" TOTAL_2="22" WEIGHT="1.546731184626515"/>
<IV_DATA CI_END="11.173049815532027" CI_START="-5.173049815532027" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1631" SE="4.17" STUDY_ID="STD-Bronski-1995-Salb-Pwd" TOTAL_1="0" TOTAL_2="22" WEIGHT="1.5223346923884338"/>
<IV_DATA CI_END="-16.93621249121368" CI_START="-40.06378750878632" EFFECT_SIZE="-28.5" ESTIMABLE="YES" ESTIMATE="-28.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1622" SE="5.9" STUDY_ID="STD-Bronski-2002-Salb" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.1678592808789896"/>
<IV_DATA CI_END="-6.93117888263863" CI_START="-48.168821117361375" EFFECT_SIZE="-27.55" ESTIMABLE="YES" ESTIMATE="-27.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1623" SE="10.52" STUDY_ID="STD-Cavagni-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.5798856247114839"/>
<IV_DATA CI_END="6.991632642308552" CI_START="-32.99163264230855" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1626" SE="10.2" STUDY_ID="STD-Cavagni-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.6065774461666487"/>
<IV_DATA CI_END="-23.369316329935625" CI_START="-36.03068367006438" EFFECT_SIZE="-29.7" ESTIMABLE="YES" ESTIMATE="-29.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1625" SE="3.23" STUDY_ID="STD-Clarke-1990-Fen" TOTAL_1="0" TOTAL_2="20" WEIGHT="1.732275333972204"/>
<IV_DATA CI_END="-18.824530015810403" CI_START="-32.975469984189594" EFFECT_SIZE="-25.9" ESTIMABLE="YES" ESTIMATE="-25.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1599" SE="3.61" STUDY_ID="STD-Debelic-1988-Reproterol" TOTAL_1="0" TOTAL_2="16" WEIGHT="1.6473843743747452"/>
<IV_DATA CI_END="-11.925785119464122" CI_START="-32.07421488053588" EFFECT_SIZE="-22.0" ESTIMABLE="YES" ESTIMATE="-22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1600" SE="5.14" STUDY_ID="STD-DeBenedictis-1998-Salb" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.3153728367286475"/>
<IV_DATA CI_END="2.3410029954340956" CI_START="-19.101002995434097" EFFECT_SIZE="-8.38" ESTIMABLE="YES" ESTIMATE="-8.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1604" SE="5.47" STUDY_ID="STD-Del-Col-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.2495118183353202"/>
<IV_DATA CI_END="-3.8029916022469106" CI_START="-24.65700839775309" EFFECT_SIZE="-14.23" ESTIMABLE="YES" ESTIMATE="-14.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1598" SE="5.32" STUDY_ID="STD-Del-Col-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.2791173833365055"/>
<IV_DATA CI_END="-23.308659671466206" CI_START="-51.57134032853379" EFFECT_SIZE="-37.44" ESTIMABLE="YES" ESTIMATE="-37.44" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1602" SE="7.21" STUDY_ID="STD-Dinh-Xuan-1989-Terb" TOTAL_1="0" TOTAL_2="10" WEIGHT="0.9498277769564214"/>
<IV_DATA CI_END="-14.610935778283995" CI_START="-29.389064221716005" EFFECT_SIZE="-22.0" ESTIMABLE="YES" ESTIMATE="-22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1603" SE="3.77" STUDY_ID="STD-Egglestone-1981-Terb-250" TOTAL_1="0" TOTAL_2="17" WEIGHT="1.611507588998941"/>
<IV_DATA CI_END="-7.593337939211592" CI_START="-22.60666206078841" EFFECT_SIZE="-15.1" ESTIMABLE="YES" ESTIMATE="-15.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1595" SE="3.83" STUDY_ID="STD-Gronnerod-2000-Terb-500" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.5980674983692018"/>
<IV_DATA CI_END="-12.753301923751646" CI_START="-23.846698076248355" EFFECT_SIZE="-18.3" ESTIMABLE="YES" ESTIMATE="-18.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1590" SE="2.83" STUDY_ID="STD-Hawksworth-2002-Salb-HFA" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.8197264857715212"/>
<IV_DATA CI_END="-13.253301923751646" CI_START="-24.346698076248355" EFFECT_SIZE="-18.8" ESTIMABLE="YES" ESTIMATE="-18.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1593" SE="2.83" STUDY_ID="STD-Hawksworth-2002-Salb-MDI" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.8197264857715212"/>
<IV_DATA CI_END="0.524588229095519" CI_START="-22.52458822909552" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1596" SE="5.88" STUDY_ID="STD-Henricksen-1983-Terb" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.1715485128216436"/>
<IV_DATA CI_END="-11.731462192548404" CI_START="-40.268537807451594" EFFECT_SIZE="-26.0" ESTIMABLE="YES" ESTIMATE="-26.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1567" SE="7.28" STUDY_ID="STD-Henricksen-1992-Salb" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.9394691145545742"/>
<IV_DATA CI_END="-31.142964590651953" CI_START="-49.057035409348046" EFFECT_SIZE="-40.1" ESTIMABLE="YES" ESTIMATE="-40.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1613" SE="4.57" STUDY_ID="STD-Hills-1976-Salb" TOTAL_1="0" TOTAL_2="10" WEIGHT="1.434932387173109"/>
<IV_DATA CI_END="-28.65297359451694" CI_START="-47.54702640548307" EFFECT_SIZE="-38.1" ESTIMABLE="YES" ESTIMATE="-38.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1566" SE="4.82" STUDY_ID="STD-Hills-1976-Salmefamol" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.381666383967892"/>
<IV_DATA CI_END="-14.453301923751646" CI_START="-25.546698076248354" EFFECT_SIZE="-20.0" ESTIMABLE="YES" ESTIMATE="-20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1615" SE="2.83" STUDY_ID="STD-Kemp-1994-Salb" TOTAL_1="0" TOTAL_2="26" WEIGHT="1.8197264857715212"/>
<IV_DATA CI_END="-10.806513808853428" CI_START="-23.193486191146572" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1609" SE="3.16" STUDY_ID="STD-Konig-1981-Metaprot" TOTAL_1="0" TOTAL_2="24" WEIGHT="1.7477745996890293"/>
<IV_DATA CI_END="-11.740216092759674" CI_START="-35.259783907240326" EFFECT_SIZE="-23.5" ESTIMABLE="YES" ESTIMATE="-23.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1616" SE="6.0" STUDY_ID="STD-Konig-1984-Fen-0.4" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.149574718821755"/>
<IV_DATA CI_END="-12.61903302002585" CI_START="-37.980966979974156" EFFECT_SIZE="-25.3" ESTIMABLE="YES" ESTIMATE="-25.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1611" SE="6.47" STUDY_ID="STD-Konig-1984-Fen-0.8" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.0672768681407867"/>
<IV_DATA CI_END="-3.684584039000322" CI_START="-23.715415960999678" EFFECT_SIZE="-13.7" ESTIMABLE="YES" ESTIMATE="-13.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1610" SE="5.11" STUDY_ID="STD-Larsson-1982-Fen" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.3214902501736294"/>
<IV_DATA CI_END="-2.3893343376655967" CI_START="-17.010665662334404" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1612" SE="3.73" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_" TOTAL_1="0" TOTAL_2="15" WEIGHT="1.6204737283625499"/>
<IV_DATA CI_END="-8.869316329935625" CI_START="-21.530683670064374" EFFECT_SIZE="-15.2" ESTIMABLE="YES" ESTIMATE="-15.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1607" SE="3.23" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_" TOTAL_1="0" TOTAL_2="20" WEIGHT="1.732275333972204"/>
<IV_DATA CI_END="-16.604093640195856" CI_START="-26.795906359804142" EFFECT_SIZE="-21.7" ESTIMABLE="YES" ESTIMATE="-21.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1606" SE="2.6" STUDY_ID="STD-Morton-1989-Rimet" TOTAL_1="0" TOTAL_2="10" WEIGHT="1.8683219090295589"/>
<IV_DATA CI_END="-7.7966848822881705" CI_START="-38.80331511771183" EFFECT_SIZE="-23.3" ESTIMABLE="YES" ESTIMATE="-23.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1601" SE="7.91" STUDY_ID="STD-Newnham-1993-Salb-200" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.8518216449550322"/>
<IV_DATA CI_END="-12.452973594516937" CI_START="-31.34702640548306" EFFECT_SIZE="-21.9" ESTIMABLE="YES" ESTIMATE="-21.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1584" SE="4.82" STUDY_ID="STD-Patel-1986-Salb-200" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.381666383967892"/>
<IV_DATA CI_END="-5.538632659871249" CI_START="-30.86136734012875" EFFECT_SIZE="-18.2" ESTIMABLE="YES" ESTIMATE="-18.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1581" SE="6.46" STUDY_ID="STD-Patel-1986-Tulob-200" TOTAL_1="0" TOTAL_2="5" WEIGHT="1.0689651659445933"/>
<IV_DATA CI_END="-6.029460391775405" CI_START="-34.37053960822459" EFFECT_SIZE="-20.2" ESTIMABLE="YES" ESTIMATE="-20.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1582" SE="7.23" STUDY_ID="STD-Patel-1986-Tulob-400" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.9468551836419374"/>
<IV_DATA CI_END="3.1014033555886957" CI_START="-18.301403355588697" EFFECT_SIZE="-7.6" ESTIMABLE="YES" ESTIMATE="-7.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1570" SE="5.46" STUDY_ID="STD-Pearlman-2006-Salb-180" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.2514679141787552"/>
<IV_DATA CI_END="-11.52611344869883" CI_START="-23.87388655130117" EFFECT_SIZE="-17.7" ESTIMABLE="YES" ESTIMATE="-17.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1577" SE="3.15" STUDY_ID="STD-Pearlman-2007-Salb-90" TOTAL_1="0" TOTAL_2="15" WEIGHT="1.7499834108860268"/>
<IV_DATA CI_END="-8.27015306570477" CI_START="-24.929846934295234" EFFECT_SIZE="-16.6" ESTIMABLE="YES" ESTIMATE="-16.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1565" SE="4.25" STUDY_ID="STD-Richter-2002-Terb-500" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.5046757365030117"/>
<IV_DATA CI_END="-2.5979399859418884" CI_START="-39.60206001405811" EFFECT_SIZE="-21.1" ESTIMABLE="YES" ESTIMATE="-21.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1562" SE="9.44" STUDY_ID="STD-Shapiro-2002-Salb-180" TOTAL_1="0" TOTAL_2="5" WEIGHT="0.6766981386934573"/>
<IV_DATA CI_END="-13.477323533027612" CI_START="-26.922676466972387" EFFECT_SIZE="-20.2" ESTIMABLE="YES" ESTIMATE="-20.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1569" SE="3.43" STUDY_ID="STD-Sturani-1983-Fen-400" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.6877068321463073"/>
<IV_DATA CI_END="-5.685330736119604" CI_START="-19.9146692638804" EFFECT_SIZE="-12.8" ESTIMABLE="YES" ESTIMATE="-12.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1583" SE="3.63" STUDY_ID="STD-Sturani-1983-Salb-200" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.6428991488036475"/>
<IV_DATA CI_END="-0.2845840390003236" CI_START="-20.31541596099968" EFFECT_SIZE="-10.3" ESTIMABLE="YES" ESTIMATE="-10.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 18:14:05 +0000" MODIFIED_BY="Christopher J Cates" ORDER="457" SE="5.11" STUDY_ID="STD-VanHaitsma-2010-Salb" TOTAL_1="0" TOTAL_2="10" WEIGHT="1.3214902501736294"/>
<IV_DATA CI_END="-9.366896161278055" CI_START="-19.833103838721946" EFFECT_SIZE="-14.6" ESTIMABLE="YES" ESTIMATE="-14.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1579" SE="2.67" STUDY_ID="STD-Vasquez-1984-Salb-400" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.8536998124362116"/>
<IV_DATA CI_END="-9.086167471888746" CI_START="-27.313832528111252" EFFECT_SIZE="-18.2" ESTIMABLE="YES" ESTIMATE="-18.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1578" SE="4.65" STUDY_ID="STD-Walker-1986-Bitolterol" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.4177586609324935"/>
<IV_DATA CI_END="-9.630535418129396" CI_START="-24.369464581870602" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:35 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1580" SE="3.76" STUDY_ID="STD-Wolley-1990-Terb-500" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.6137487503834644"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="81.0129714907078" CI_END="-12.916527697928462" CI_START="-18.28962526293316" DF="27" EFFECT_SIZE="-15.603076480430811" ESTIMABLE="YES" I2="66.67200387397602" ID="CMP-001.08.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-07-03 12:42:07 +0100" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="2.6495981286789316E-7" P_Z="5.071613628973184E-30" STUDIES="28" TAU2="30.630823864871218" TOTAL_1="0" TOTAL_2="312" WEIGHT="39.100330390899245" Z="11.383179843540269">
<NAME>LABA</NAME>
<IV_DATA CI_END="2.5354429725946375" CI_START="-14.555442972594637" EFFECT_SIZE="-6.01" ESTIMABLE="YES" ESTIMATE="-6.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:08 +0000" MODIFIED_BY="[Empty name]" ORDER="1627" SE="4.36" STUDY_ID="STD-Blake-1999-Salm-25" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.4805286109835145"/>
<IV_DATA CI_END="1.9050426124400364" CI_START="-15.225042612440037" EFFECT_SIZE="-6.66" ESTIMABLE="YES" ESTIMATE="-6.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:08 +0000" MODIFIED_BY="[Empty name]" ORDER="1630" SE="4.37" STUDY_ID="STD-Blake-1999-Salm-50" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.4783417771779985"/>
<IV_DATA CI_END="-5.7341206517908185" CI_START="-18.865879348209184" EFFECT_SIZE="-12.3" ESTIMABLE="YES" ESTIMATE="-12.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:08 +0000" MODIFIED_BY="[Empty name]" ORDER="1629" SE="3.35" STUDY_ID="STD-Boner-1994-Form-12" TOTAL_1="0" TOTAL_2="15" WEIGHT="1.7055757221530068"/>
<IV_DATA CI_END="2.1238415319762396" CI_START="-15.12384153197624" EFFECT_SIZE="-6.5" ESTIMABLE="YES" ESTIMATE="-6.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:27 +0000" MODIFIED_BY="[Empty name]" ORDER="1587" SE="4.4" STUDY_ID="STD-Bronski-1999-Salm-Disk" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.4717901155311865"/>
<IV_DATA CI_END="1.8514483749136286" CI_START="-14.65144837491363" EFFECT_SIZE="-6.4" ESTIMABLE="YES" ESTIMATE="-6.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:27 +0000" MODIFIED_BY="[Empty name]" ORDER="1588" SE="4.21" STUDY_ID="STD-Bronski-1999-Salm-Diskhal" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.5134956500868249"/>
<IV_DATA CI_END="-9.73621249121368" CI_START="-32.863787508786324" EFFECT_SIZE="-21.3" ESTIMABLE="YES" ESTIMATE="-21.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:27 +0000" MODIFIED_BY="[Empty name]" ORDER="1585" SE="5.9" STUDY_ID="STD-Bronski-2002-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.1678592808789896"/>
<IV_DATA CI_END="-12.136212491213678" CI_START="-35.26378750878632" EFFECT_SIZE="-23.7" ESTIMABLE="YES" ESTIMATE="-23.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:27 +0000" MODIFIED_BY="[Empty name]" ORDER="1619" SE="5.9" STUDY_ID="STD-Bronski-2002-Form-24" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.1678592808789896"/>
<IV_DATA CI_END="-0.3181962842567039" CI_START="-21.681803715743296" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:43 +0000" MODIFIED_BY="[Empty name]" ORDER="1621" SE="5.45" STUDY_ID="STD-Carlsen-1995-Salm-25" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.2534265479553233"/>
<IV_DATA CI_END="-2.023783318691123" CI_START="-21.976216681308877" EFFECT_SIZE="-12.0" ESTIMABLE="YES" ESTIMATE="-12.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:27:43 +0000" MODIFIED_BY="[Empty name]" ORDER="1624" SE="5.09" STUDY_ID="STD-Carlsen-1995-Salm-50" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.3255801248015304"/>
<IV_DATA CI_END="-16.924530015810404" CI_START="-31.075469984189596" EFFECT_SIZE="-24.0" ESTIMABLE="YES" ESTIMATE="-24.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:25:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1628" SE="3.61" STUDY_ID="STD-Daugbjerg-1996-Form-12" TOTAL_1="0" TOTAL_2="16" WEIGHT="1.6473843743747452"/>
<IV_DATA CI_END="-3.0446380621902414" CI_START="-28.95536193780976" EFFECT_SIZE="-16.0" ESTIMABLE="YES" ESTIMATE="-16.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:25:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1594" SE="6.61" STUDY_ID="STD-DeBenedictis-1996-Salm-25" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.043926555359336"/>
<IV_DATA CI_END="-6.731043824663834" CI_START="-33.268956175336164" EFFECT_SIZE="-20.0" ESTIMABLE="YES" ESTIMATE="-20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:25:26 +0000" MODIFIED_BY="[Empty name]" ORDER="1597" SE="6.77" STUDY_ID="STD-DeBenedictis-1996-Salm-50" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.0178915640436383"/>
<IV_DATA CI_END="-16.324530015810403" CI_START="-30.475469984189594" EFFECT_SIZE="-23.4" ESTIMABLE="YES" ESTIMATE="-23.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:25:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1591" SE="3.61" STUDY_ID="STD-Ferrari-2000-Form-12" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.6473843743747452"/>
<IV_DATA CI_END="-18.166896161278054" CI_START="-28.633103838721944" EFFECT_SIZE="-23.4" ESTIMABLE="YES" ESTIMATE="-23.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:25:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1586" SE="2.67" STUDY_ID="STD-Green-1992-Salm-50" TOTAL_1="0" TOTAL_2="13" WEIGHT="1.8536998124362116"/>
<IV_DATA CI_END="-2.2813271345736084" CI_START="-16.11867286542639" EFFECT_SIZE="-9.2" ESTIMABLE="YES" ESTIMATE="-9.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:25:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1589" SE="3.53" STUDY_ID="STD-Gronnerod-2000-Form-4.5" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.6653189224938005"/>
<IV_DATA CI_END="-6.081327134573609" CI_START="-19.91867286542639" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:25:07 +0000" MODIFIED_BY="[Empty name]" ORDER="1592" SE="3.53" STUDY_ID="STD-Gronnerod-2000-Form-9" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.6653189224938005"/>
<IV_DATA CI_END="-24.82820528812169" CI_START="-47.171794711878306" EFFECT_SIZE="-36.0" ESTIMABLE="YES" ESTIMATE="-36.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:55 +0000" MODIFIED_BY="[Empty name]" ORDER="1568" SE="5.7" STUDY_ID="STD-Henriksen-1992-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.205232385350477"/>
<IV_DATA CI_END="-8.453301923751646" CI_START="-19.546698076248354" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:42 +0000" MODIFIED_BY="[Empty name]" ORDER="1614" SE="2.83" STUDY_ID="STD-Kemp-1994-Salm-42" TOTAL_1="0" TOTAL_2="26" WEIGHT="1.8197264857715212"/>
<IV_DATA CI_END="-15.768569632816344" CI_START="-34.231430367183656" EFFECT_SIZE="-25.0" ESTIMABLE="YES" ESTIMATE="-25.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1605" SE="4.71" STUDY_ID="STD-McAlpine-1990-Form-12" TOTAL_1="0" TOTAL_2="11" WEIGHT="1.4049559483382004"/>
<IV_DATA CI_END="1.2032250790619656" CI_START="-39.603225079061964" EFFECT_SIZE="-19.2" ESTIMABLE="YES" ESTIMATE="-19.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:30 +0000" MODIFIED_BY="[Empty name]" ORDER="1608" SE="10.41" STUDY_ID="STD-Newnham-1993-Salm-50" TOTAL_1="0" TOTAL_2="5" WEIGHT="0.5888835747631456"/>
<IV_DATA CI_END="-12.326950184467973" CI_START="-28.673049815532025" EFFECT_SIZE="-20.5" ESTIMABLE="YES" ESTIMATE="-20.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1573" SE="4.17" STUDY_ID="STD-Patessio-1991-Form-24" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.5223346923884338"/>
<IV_DATA CI_END="5.101403355588696" CI_START="-16.301403355588697" EFFECT_SIZE="-5.6" ESTIMABLE="YES" ESTIMATE="-5.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1572" SE="5.46" STUDY_ID="STD-Pearlman-2006-Form-12" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.2514679141787552"/>
<IV_DATA CI_END="3.4014033555886956" CI_START="-18.001403355588696" EFFECT_SIZE="-7.3" ESTIMABLE="YES" ESTIMATE="-7.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1571" SE="5.46" STUDY_ID="STD-Pearlman-2006-Form-24" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.2514679141787552"/>
<IV_DATA CI_END="-8.454048620870926" CI_START="-13.745951379129073" EFFECT_SIZE="-11.1" ESTIMABLE="YES" ESTIMATE="-11.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1576" SE="1.35" STUDY_ID="STD-Philip-2007-Salm-50" TOTAL_1="0" TOTAL_2="46" WEIGHT="2.088856831198573"/>
<IV_DATA CI_END="-11.481745502458178" CI_START="-27.31825449754182" EFFECT_SIZE="-19.4" ESTIMABLE="YES" ESTIMATE="-19.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1575" SE="4.04" STUDY_ID="STD-Richter-2002-Form-12" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.5511795639292112"/>
<IV_DATA CI_END="-9.326950184467973" CI_START="-25.673049815532025" EFFECT_SIZE="-17.5" ESTIMABLE="YES" ESTIMATE="-17.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:24:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1574" SE="4.17" STUDY_ID="STD-Richter-2002-Salm-50" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.5223346923884338"/>
<IV_DATA CI_END="-6.211862552703005" CI_START="-34.788137447297" EFFECT_SIZE="-20.5" ESTIMABLE="YES" ESTIMATE="-20.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:23:58 +0000" MODIFIED_BY="[Empty name]" ORDER="1564" SE="7.29" STUDY_ID="STD-Shapiro-2002-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.9379996651985841"/>
<IV_DATA CI_END="0.12291475755722914" CI_START="-30.92291475755723" EFFECT_SIZE="-15.4" ESTIMABLE="YES" ESTIMATE="-15.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:23:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1563" SE="7.92" STUDY_ID="STD-Shapiro-2002-Form-24" TOTAL_1="0" TOTAL_2="6" WEIGHT="0.8505090871915209"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="81.01297149070778" CI_END="-12.916527697928467" CI_START="-18.289625262933164" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_SIZE="-15.603076480430815" ESTIMABLE="YES" I2="66.67200387397602" I2_Q="77.21161901310947" ID="CMP-001.09" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-09-10 03:35:12 +0100" MODIFIED_BY="Christopher J Cates" NO="9" P_CHI2="2.6495981308993777E-7" P_Q="0.03618850965751286" P_Z="5.071613628972821E-30" Q="4.388201165213404" RANDOM="YES" SCALE="57.94" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="30.630823864871203" TOTALS="YES" TOTAL_1="0" TOTAL_2="312" WEIGHT="100.0" Z="11.383179843540274">
<NAME>Subgroup analysis: maximal percentage fall in FEV<SUB>1</SUB>: salmeterol versus formoterol</NAME>
<GROUP_LABEL_1>beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="29.403990685966704" CI_END="-9.365711233939635" CI_START="-16.09806099114636" DF="12" EFFECT_SIZE="-12.731886112542998" ESTIMABLE="YES" I2="59.18921302839652" ID="CMP-001.09.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-03-17 15:37:52 +0000" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.003430380156527857" P_Z="1.2331243746735726E-13" STUDIES="13" TAU2="18.967429802705215" TOTAL_1="0" TOTAL_2="174" WEIGHT="47.52165375466782" Z="7.4131734493258">
<NAME>Salmeterol</NAME>
<IV_DATA CI_END="2.5354429725946375" CI_START="-14.555442972594637" EFFECT_SIZE="-6.01" ESTIMABLE="YES" ESTIMATE="-6.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1627" SE="4.36" STUDY_ID="STD-Blake-1999-Salm-25" TOTAL_1="0" TOTAL_2="8" WEIGHT="3.7849295359118926"/>
<IV_DATA CI_END="1.9050426124400364" CI_START="-15.225042612440037" EFFECT_SIZE="-6.66" ESTIMABLE="YES" ESTIMATE="-6.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1630" SE="4.37" STUDY_ID="STD-Blake-1999-Salm-50" TOTAL_1="0" TOTAL_2="8" WEIGHT="3.7782848652371803"/>
<IV_DATA CI_END="2.1238415319762396" CI_START="-15.12384153197624" EFFECT_SIZE="-6.5" ESTIMABLE="YES" ESTIMATE="-6.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1587" SE="4.4" STUDY_ID="STD-Bronski-1999-Salm-Disk" TOTAL_1="0" TOTAL_2="12" WEIGHT="3.7583998809302424"/>
<IV_DATA CI_END="1.8514483749136286" CI_START="-14.65144837491363" EFFECT_SIZE="-6.4" ESTIMABLE="YES" ESTIMATE="-6.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1588" SE="4.21" STUDY_ID="STD-Bronski-1999-Salm-Diskhal" TOTAL_1="0" TOTAL_2="12" WEIGHT="3.8855506625630603"/>
<IV_DATA CI_END="-0.3181962842567039" CI_START="-21.681803715743296" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1621" SE="5.45" STUDY_ID="STD-Carlsen-1995-Salm-25" TOTAL_1="0" TOTAL_2="12" WEIGHT="3.1141249052040387"/>
<IV_DATA CI_END="-2.023783318691123" CI_START="-21.976216681308877" EFFECT_SIZE="-12.0" ESTIMABLE="YES" ESTIMATE="-12.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1624" SE="5.09" STUDY_ID="STD-Carlsen-1995-Salm-50" TOTAL_1="0" TOTAL_2="12" WEIGHT="3.3231178384361466"/>
<IV_DATA CI_END="-3.0446380621902414" CI_START="-28.95536193780976" EFFECT_SIZE="-16.0" ESTIMABLE="YES" ESTIMATE="-16.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1594" SE="6.61" STUDY_ID="STD-DeBenedictis-1996-Salm-25" TOTAL_1="0" TOTAL_2="6" WEIGHT="2.5279617201677516"/>
<IV_DATA CI_END="-6.731043824663834" CI_START="-33.268956175336164" EFFECT_SIZE="-20.0" ESTIMABLE="YES" ESTIMATE="-20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1597" SE="6.77" STUDY_ID="STD-DeBenedictis-1996-Salm-50" TOTAL_1="0" TOTAL_2="6" WEIGHT="2.457184884081412"/>
<IV_DATA CI_END="-18.166896161278054" CI_START="-28.633103838721944" EFFECT_SIZE="-23.4" ESTIMABLE="YES" ESTIMATE="-23.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1586" SE="2.67" STUDY_ID="STD-Green-1992-Salm-50" TOTAL_1="0" TOTAL_2="13" WEIGHT="4.975817808777228"/>
<IV_DATA CI_END="-8.453301923751646" CI_START="-19.546698076248354" EFFECT_SIZE="-14.0" ESTIMABLE="YES" ESTIMATE="-14.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1614" SE="2.83" STUDY_ID="STD-Kemp-1994-Salm-42" TOTAL_1="0" TOTAL_2="26" WEIGHT="4.862496096462798"/>
<IV_DATA CI_END="1.2032250790619656" CI_START="-39.603225079061964" EFFECT_SIZE="-19.2" ESTIMABLE="YES" ESTIMATE="-19.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1608" SE="10.41" STUDY_ID="STD-Newnham-1993-Salm-50" TOTAL_1="0" TOTAL_2="5" WEIGHT="1.3517047559590527"/>
<IV_DATA CI_END="-8.454048620870926" CI_START="-13.745951379129073" EFFECT_SIZE="-11.1" ESTIMABLE="YES" ESTIMATE="-11.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1576" SE="1.35" STUDY_ID="STD-Philip-2007-Salm-50" TOTAL_1="0" TOTAL_2="46" WEIGHT="5.789407188109677"/>
<IV_DATA CI_END="-9.326950184467973" CI_START="-25.673049815532025" EFFECT_SIZE="-17.5" ESTIMABLE="YES" ESTIMATE="-17.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="1574" SE="4.17" STUDY_ID="STD-Richter-2002-Salm-50" TOTAL_1="0" TOTAL_2="8" WEIGHT="3.9126736128273354"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="39.21568221883809" CI_END="-14.3366172067397" CI_START="-22.152423322828742" DF="14" EFFECT_SIZE="-18.24452026478422" ESTIMABLE="YES" I2="64.29999630791887" ID="CMP-001.09.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-03-17 15:37:52 +0000" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="3.3776753239522783E-4" P_Z="5.675988658567342E-20" STUDIES="15" TAU2="36.29560541686654" TOTAL_1="0" TOTAL_2="138" WEIGHT="52.47834624533219" Z="9.150330011533478">
<NAME>Formoterol</NAME>
<IV_DATA CI_END="-5.7341206517908185" CI_START="-18.865879348209184" EFFECT_SIZE="-12.3" ESTIMABLE="YES" ESTIMATE="-12.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:12 +0000" MODIFIED_BY="[Empty name]" ORDER="1629" SE="3.35" STUDY_ID="STD-Boner-1994-Form-12" TOTAL_1="0" TOTAL_2="15" WEIGHT="4.489141819845635"/>
<IV_DATA CI_END="-9.73621249121368" CI_START="-32.863787508786324" EFFECT_SIZE="-21.3" ESTIMABLE="YES" ESTIMATE="-21.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1585" SE="5.9" STUDY_ID="STD-Bronski-2002-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="2.871074894309117"/>
<IV_DATA CI_END="-12.136212491213678" CI_START="-35.26378750878632" EFFECT_SIZE="-23.7" ESTIMABLE="YES" ESTIMATE="-23.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:19 +0000" MODIFIED_BY="[Empty name]" ORDER="1619" SE="5.9" STUDY_ID="STD-Bronski-2002-Form-24" TOTAL_1="0" TOTAL_2="6" WEIGHT="2.871074894309117"/>
<IV_DATA CI_END="-16.924530015810404" CI_START="-31.075469984189596" EFFECT_SIZE="-24.0" ESTIMABLE="YES" ESTIMATE="-24.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1628" SE="3.61" STUDY_ID="STD-Daugbjerg-1996-Form-12" TOTAL_1="0" TOTAL_2="16" WEIGHT="4.303090352877147"/>
<IV_DATA CI_END="-16.324530015810403" CI_START="-30.475469984189594" EFFECT_SIZE="-23.4" ESTIMABLE="YES" ESTIMATE="-23.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:27 +0000" MODIFIED_BY="[Empty name]" ORDER="1591" SE="3.61" STUDY_ID="STD-Ferrari-2000-Form-12" TOTAL_1="0" TOTAL_2="14" WEIGHT="4.303090352877147"/>
<IV_DATA CI_END="-2.2813271345736084" CI_START="-16.11867286542639" EFFECT_SIZE="-9.2" ESTIMABLE="YES" ESTIMATE="-9.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1589" SE="3.53" STUDY_ID="STD-Gronnerod-2000-Form-4.5" TOTAL_1="0" TOTAL_2="9" WEIGHT="4.360129732811705"/>
<IV_DATA CI_END="-6.081327134573609" CI_START="-19.91867286542639" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1592" SE="3.53" STUDY_ID="STD-Gronnerod-2000-Form-9" TOTAL_1="0" TOTAL_2="9" WEIGHT="4.360129732811705"/>
<IV_DATA CI_END="-24.82820528812169" CI_START="-47.171794711878306" EFFECT_SIZE="-36.0" ESTIMABLE="YES" ESTIMATE="-36.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1568" SE="5.7" STUDY_ID="STD-Henriksen-1992-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="2.9766009845429324"/>
<IV_DATA CI_END="-15.768569632816344" CI_START="-34.231430367183656" EFFECT_SIZE="-25.0" ESTIMABLE="YES" ESTIMATE="-25.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1605" SE="4.71" STUDY_ID="STD-McAlpine-1990-Form-12" TOTAL_1="0" TOTAL_2="11" WEIGHT="3.5574321179000115"/>
<IV_DATA CI_END="-12.326950184467973" CI_START="-28.673049815532025" EFFECT_SIZE="-20.5" ESTIMABLE="YES" ESTIMATE="-20.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:44 +0000" MODIFIED_BY="[Empty name]" ORDER="1573" SE="4.17" STUDY_ID="STD-Patessio-1991-Form-24" TOTAL_1="0" TOTAL_2="12" WEIGHT="3.9126736128273354"/>
<IV_DATA CI_END="5.101403355588696" CI_START="-16.301403355588697" EFFECT_SIZE="-5.6" ESTIMABLE="YES" ESTIMATE="-5.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:44 +0000" MODIFIED_BY="[Empty name]" ORDER="1572" SE="5.46" STUDY_ID="STD-Pearlman-2006-Form-12" TOTAL_1="0" TOTAL_2="7" WEIGHT="3.108503836334973"/>
<IV_DATA CI_END="3.4014033555886956" CI_START="-18.001403355588696" EFFECT_SIZE="-7.3" ESTIMABLE="YES" ESTIMATE="-7.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:44 +0000" MODIFIED_BY="[Empty name]" ORDER="1571" SE="5.46" STUDY_ID="STD-Pearlman-2006-Form-24" TOTAL_1="0" TOTAL_2="7" WEIGHT="3.108503836334973"/>
<IV_DATA CI_END="-11.481745502458178" CI_START="-27.31825449754182" EFFECT_SIZE="-19.4" ESTIMABLE="YES" ESTIMATE="-19.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:48 +0000" MODIFIED_BY="[Empty name]" ORDER="1575" SE="4.04" STUDY_ID="STD-Richter-2002-Form-12" TOTAL_1="0" TOTAL_2="8" WEIGHT="4.001614634466369"/>
<IV_DATA CI_END="-6.211862552703005" CI_START="-34.788137447297" EFFECT_SIZE="-20.5" ESTIMABLE="YES" ESTIMATE="-20.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:52 +0000" MODIFIED_BY="[Empty name]" ORDER="1564" SE="7.29" STUDY_ID="STD-Shapiro-2002-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="2.242741596093786"/>
<IV_DATA CI_END="0.12291475755722914" CI_START="-30.92291475755723" EFFECT_SIZE="-15.4" ESTIMABLE="YES" ESTIMATE="-15.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:37:52 +0000" MODIFIED_BY="[Empty name]" ORDER="1563" SE="7.92" STUDY_ID="STD-Shapiro-2002-Form-24" TOTAL_1="0" TOTAL_2="6" WEIGHT="2.012543846990237"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="181.48244876315903" CI_END="-14.388586700603954" CI_START="-19.117435715716184" CI_STUDY="95" CI_TOTAL="95" DF="50" EFFECT_SIZE="-16.753011208160068" ESTIMABLE="YES" I2="72.44912643577355" I2_Q="63.450179521669305" ID="CMP-001.10" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Christopher J Cates" NO="10" P_CHI2="-2.220446049250313E-16" P_Q="0.09811066618591768" P_Z="7.571067878228118E-44" Q="2.735991550472513" RANDOM="YES" SCALE="57.94" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="51" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="49.962580296020846" TOTALS="YES" TOTAL_1="0" TOTAL_2="524" WEIGHT="100.0" Z="13.887226467013905">
<NAME>Subgroup analysis: maximal percentage fall in FEV<SUB>1</SUB>: adults versus children</NAME>
<GROUP_LABEL_1>beta<SUB>2</SUB>-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours beta<SUB>2</SUB>-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="20.329135157408473" CI_END="-16.759841348583283" CI_START="-20.7783470606628" DF="18" EFFECT_SIZE="-18.76909420462304" ESTIMABLE="YES" I2="11.457128595850152" ID="CMP-001.10.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-03-17 15:50:41 +0000" MODIFIED_BY="Christopher J Cates" NO="1" P_CHI2="0.31459774276861796" P_Z="7.057178142186216E-75" STUDIES="19" TAU2="2.249925088039867" TOTAL_1="0" TOTAL_2="202" WEIGHT="38.262078233622354" Z="18.30867058514843">
<NAME>Adults</NAME>
<IV_DATA CI_END="-16.65057143358934" CI_START="-35.30942856641066" EFFECT_SIZE="-25.98" ESTIMABLE="YES" ESTIMATE="-25.98" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1620" SE="4.76" STUDY_ID="STD-Anderson-2001-Salb-Disk" TOTAL_1="0" TOTAL_2="14" WEIGHT="2.003998534407663"/>
<IV_DATA CI_END="-21.10977971714513" CI_START="-40.67022028285487" EFFECT_SIZE="-30.89" ESTIMABLE="YES" ESTIMATE="-30.89" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1617" SE="4.99" STUDY_ID="STD-Anderson-2001-Salb-MDI" TOTAL_1="0" TOTAL_2="13" WEIGHT="1.9439690685157236"/>
<IV_DATA CI_END="-14.610935778283995" CI_START="-29.389064221716005" EFFECT_SIZE="-22.0" ESTIMABLE="YES" ESTIMATE="-22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1603" SE="3.77" STUDY_ID="STD-Egglestone-1981-Terb-250" TOTAL_1="0" TOTAL_2="17" WEIGHT="2.2676999721756594"/>
<IV_DATA CI_END="-12.753301923751646" CI_START="-23.846698076248355" EFFECT_SIZE="-18.3" ESTIMABLE="YES" ESTIMATE="-18.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1590" SE="2.83" STUDY_ID="STD-Hawksworth-2002-Salb-HFA" TOTAL_1="0" TOTAL_2="12" WEIGHT="2.510385005497872"/>
<IV_DATA CI_END="-13.253301923751646" CI_START="-24.346698076248355" EFFECT_SIZE="-18.8" ESTIMABLE="YES" ESTIMATE="-18.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1593" SE="2.83" STUDY_ID="STD-Hawksworth-2002-Salb-MDI" TOTAL_1="0" TOTAL_2="12" WEIGHT="2.510385005497872"/>
<IV_DATA CI_END="-3.684584039000322" CI_START="-23.715415960999678" EFFECT_SIZE="-13.7" ESTIMABLE="YES" ESTIMATE="-13.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1610" SE="5.11" STUDY_ID="STD-Larsson-1982-Fen" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.9129983105464088"/>
<IV_DATA CI_END="-15.768569632816344" CI_START="-34.231430367183656" EFFECT_SIZE="-25.0" ESTIMABLE="YES" ESTIMATE="-25.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1605" SE="4.71" STUDY_ID="STD-McAlpine-1990-Form-12" TOTAL_1="0" TOTAL_2="11" WEIGHT="2.0171508139324965"/>
<IV_DATA CI_END="-2.3893343376655967" CI_START="-17.010665662334404" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1612" SE="3.73" STUDY_ID="STD-McFadden-1986-Salb-_x0028_I_x0029_" TOTAL_1="0" TOTAL_2="15" WEIGHT="2.278350537752621"/>
<IV_DATA CI_END="-8.869316329935625" CI_START="-21.530683670064374" EFFECT_SIZE="-15.2" ESTIMABLE="YES" ESTIMATE="-15.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1607" SE="3.23" STUDY_ID="STD-McFadden-1986-Salb-_x0028_II_x0029_" TOTAL_1="0" TOTAL_2="20" WEIGHT="2.4096295644698156"/>
<IV_DATA CI_END="-7.7966848822881705" CI_START="-38.80331511771183" EFFECT_SIZE="-23.3" ESTIMABLE="YES" ESTIMATE="-23.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1601" SE="7.91" STUDY_ID="STD-Newnham-1993-Salb-200" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.2932538441855674"/>
<IV_DATA CI_END="1.2032250790619656" CI_START="-39.603225079061964" EFFECT_SIZE="-19.2" ESTIMABLE="YES" ESTIMATE="-19.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1608" SE="10.41" STUDY_ID="STD-Newnham-1993-Salm-50" TOTAL_1="0" TOTAL_2="5" WEIGHT="0.9191568848788906"/>
<IV_DATA CI_END="-12.452973594516937" CI_START="-31.34702640548306" EFFECT_SIZE="-21.9" ESTIMABLE="YES" ESTIMATE="-21.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1584" SE="4.82" STUDY_ID="STD-Patel-1986-Salb-200" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.9882611388524092"/>
<IV_DATA CI_END="-5.538632659871249" CI_START="-30.86136734012875" EFFECT_SIZE="-18.2" ESTIMABLE="YES" ESTIMATE="-18.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1581" SE="6.46" STUDY_ID="STD-Patel-1986-Tulob-200" TOTAL_1="0" TOTAL_2="5" WEIGHT="1.5871316414173942"/>
<IV_DATA CI_END="-6.029460391775405" CI_START="-34.37053960822459" EFFECT_SIZE="-20.2" ESTIMABLE="YES" ESTIMATE="-20.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1582" SE="7.23" STUDY_ID="STD-Patel-1986-Tulob-400" TOTAL_1="0" TOTAL_2="4" WEIGHT="1.423485608521275"/>
<IV_DATA CI_END="-11.52611344869883" CI_START="-23.87388655130117" EFFECT_SIZE="-17.7" ESTIMABLE="YES" ESTIMATE="-17.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1577" SE="3.15" STUDY_ID="STD-Pearlman-2007-Salb-90" TOTAL_1="0" TOTAL_2="15" WEIGHT="2.430166815545141"/>
<IV_DATA CI_END="-11.481745502458178" CI_START="-27.31825449754182" EFFECT_SIZE="-19.4" ESTIMABLE="YES" ESTIMATE="-19.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1575" SE="4.04" STUDY_ID="STD-Richter-2002-Form-12" TOTAL_1="0" TOTAL_2="8" WEIGHT="2.1955575860139662"/>
<IV_DATA CI_END="-9.326950184467973" CI_START="-25.673049815532025" EFFECT_SIZE="-17.5" ESTIMABLE="YES" ESTIMATE="-17.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1574" SE="4.17" STUDY_ID="STD-Richter-2002-Salm-50" TOTAL_1="0" TOTAL_2="8" WEIGHT="2.160765201329125"/>
<IV_DATA CI_END="-8.27015306570477" CI_START="-24.929846934295234" EFFECT_SIZE="-16.6" ESTIMABLE="YES" ESTIMATE="-16.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1565" SE="4.25" STUDY_ID="STD-Richter-2002-Terb-500" TOTAL_1="0" TOTAL_2="8" WEIGHT="2.1393688070392316"/>
<IV_DATA CI_END="-9.630535418129396" CI_START="-24.369464581870602" EFFECT_SIZE="-17.0" ESTIMABLE="YES" ESTIMATE="-17.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-24 16:02:42 +0000" MODIFIED_BY="Christopher J Cates" ORDER="1580" SE="3.76" STUDY_ID="STD-Wolley-1990-Terb-500" TOTAL_1="0" TOTAL_2="12" WEIGHT="2.2703638930432177"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="151.79761607848494" CI_END="-11.754816416465145" CI_START="-18.879862240801316" DF="31" EFFECT_SIZE="-15.31733932863323" ESTIMABLE="YES" I2="79.57807190860503" ID="CMP-001.10.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2013-03-17 15:55:18 +0000" MODIFIED_BY="Christopher J Cates" NO="2" P_CHI2="-8.881784197001252E-16" P_Z="3.5459492297907074E-17" STUDIES="32" TAU2="79.33588333736138" TOTAL_1="0" TOTAL_2="322" WEIGHT="61.73792176637764" Z="8.427014832819582">
<NAME>Children</NAME>
<IV_DATA CI_END="-1.2329555867869644" CI_START="-18.167044413213034" EFFECT_SIZE="-9.7" ESTIMABLE="YES" ESTIMATE="-9.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1618" SE="4.32" STUDY_ID="STD-Blake-1999-Salb-180" TOTAL_1="0" TOTAL_2="8" WEIGHT="2.1206670552601166"/>
<IV_DATA CI_END="2.5354429725946375" CI_START="-14.555442972594637" EFFECT_SIZE="-6.01" ESTIMABLE="YES" ESTIMATE="-6.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1627" SE="4.36" STUDY_ID="STD-Blake-1999-Salm-25" TOTAL_1="0" TOTAL_2="8" WEIGHT="2.109991800419307"/>
<IV_DATA CI_END="1.9050426124400364" CI_START="-15.225042612440037" EFFECT_SIZE="-6.66" ESTIMABLE="YES" ESTIMATE="-6.66" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1630" SE="4.37" STUDY_ID="STD-Blake-1999-Salm-50" TOTAL_1="0" TOTAL_2="8" WEIGHT="2.1073245013984185"/>
<IV_DATA CI_END="-5.7341206517908185" CI_START="-18.865879348209184" EFFECT_SIZE="-12.3" ESTIMABLE="YES" ESTIMATE="-12.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1629" SE="3.35" STUDY_ID="STD-Boner-1994-Form-12" TOTAL_1="0" TOTAL_2="15" WEIGHT="2.3785330374259654"/>
<IV_DATA CI_END="0.9574537772326197" CI_START="-14.957453777232619" EFFECT_SIZE="-7.0" ESTIMABLE="YES" ESTIMATE="-7.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1632" SE="4.06" STUDY_ID="STD-Bronski-1995-Salb-MDI" TOTAL_1="0" TOTAL_2="22" WEIGHT="2.1902046774291586"/>
<IV_DATA CI_END="11.173049815532027" CI_START="-5.173049815532027" EFFECT_SIZE="3.0" ESTIMABLE="YES" ESTIMATE="3.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1631" SE="4.17" STUDY_ID="STD-Bronski-1995-Salb-Pwd" TOTAL_1="0" TOTAL_2="22" WEIGHT="2.160765201329125"/>
<IV_DATA CI_END="2.1238415319762396" CI_START="-15.12384153197624" EFFECT_SIZE="-6.5" ESTIMABLE="YES" ESTIMATE="-6.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1587" SE="4.4" STUDY_ID="STD-Bronski-1999-Salm-Disk" TOTAL_1="0" TOTAL_2="12" WEIGHT="2.099326572383798"/>
<IV_DATA CI_END="1.8514483749136286" CI_START="-14.65144837491363" EFFECT_SIZE="-6.4" ESTIMABLE="YES" ESTIMATE="-6.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1588" SE="4.21" STUDY_ID="STD-Bronski-1999-Salm-Diskhal" TOTAL_1="0" TOTAL_2="12" WEIGHT="2.1500645953558677"/>
<IV_DATA CI_END="-0.3181962842567039" CI_START="-21.681803715743296" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1621" SE="5.45" STUDY_ID="STD-Carlsen-1995-Salm-25" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.8267820021128518"/>
<IV_DATA CI_END="-2.023783318691123" CI_START="-21.976216681308877" EFFECT_SIZE="-12.0" ESTIMABLE="YES" ESTIMATE="-12.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1624" SE="5.09" STUDY_ID="STD-Carlsen-1995-Salm-50" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.9181419530421508"/>
<IV_DATA CI_END="-6.93117888263863" CI_START="-48.168821117361375" EFFECT_SIZE="-27.55" ESTIMABLE="YES" ESTIMATE="-27.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1623" SE="10.52" STUDY_ID="STD-Cavagni-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.9059829096954825"/>
<IV_DATA CI_END="6.991632642308552" CI_START="-32.99163264230855" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1626" SE="10.2" STUDY_ID="STD-Cavagni-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="4" WEIGHT="0.9449889385094046"/>
<IV_DATA CI_END="-16.924530015810404" CI_START="-31.075469984189596" EFFECT_SIZE="-24.0" ESTIMABLE="YES" ESTIMATE="-24.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1628" SE="3.61" STUDY_ID="STD-Daugbjerg-1996-Form-12" TOTAL_1="0" TOTAL_2="16" WEIGHT="2.31020673805751"/>
<IV_DATA CI_END="-3.0446380621902414" CI_START="-28.95536193780976" EFFECT_SIZE="-16.0" ESTIMABLE="YES" ESTIMATE="-16.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1594" SE="6.61" STUDY_ID="STD-DeBenedictis-1996-Salm-25" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.553907764370739"/>
<IV_DATA CI_END="-6.731043824663834" CI_START="-33.268956175336164" EFFECT_SIZE="-20.0" ESTIMABLE="YES" ESTIMATE="-20.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1597" SE="6.77" STUDY_ID="STD-DeBenedictis-1996-Salm-50" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.5191816402186893"/>
<IV_DATA CI_END="-11.925785119464122" CI_START="-32.07421488053588" EFFECT_SIZE="-22.0" ESTIMABLE="YES" ESTIMATE="-22.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1600" SE="5.14" STUDY_ID="STD-DeBenedictis-1998-Salb" TOTAL_1="0" TOTAL_2="12" WEIGHT="1.9052969464558156"/>
<IV_DATA CI_END="2.3410029954340956" CI_START="-19.101002995434097" EFFECT_SIZE="-8.38" ESTIMABLE="YES" ESTIMATE="-8.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1604" SE="5.47" STUDY_ID="STD-Del-Col-1993-Salb-Jet" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.8217876129377306"/>
<IV_DATA CI_END="-3.8029916022469106" CI_START="-24.65700839775309" EFFECT_SIZE="-14.23" ESTIMABLE="YES" ESTIMATE="-14.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1598" SE="5.32" STUDY_ID="STD-Del-Col-1993-Salb-MDI" TOTAL_1="0" TOTAL_2="8" WEIGHT="1.8594617200592987"/>
<IV_DATA CI_END="-23.308659671466206" CI_START="-51.57134032853379" EFFECT_SIZE="-37.44" ESTIMABLE="YES" ESTIMATE="-37.44" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:21 +0000" MODIFIED_BY="[Empty name]" ORDER="1602" SE="7.21" STUDY_ID="STD-Dinh-Xuan-1989-Terb" TOTAL_1="0" TOTAL_2="10" WEIGHT="1.4275181345686876"/>
<IV_DATA CI_END="-18.166896161278054" CI_START="-28.633103838721944" EFFECT_SIZE="-23.4" ESTIMABLE="YES" ESTIMATE="-23.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1586" SE="2.67" STUDY_ID="STD-Green-1992-Salm-50" TOTAL_1="0" TOTAL_2="13" WEIGHT="2.5490797248042143"/>
<IV_DATA CI_END="-2.2813271345736084" CI_START="-16.11867286542639" EFFECT_SIZE="-9.2" ESTIMABLE="YES" ESTIMATE="-9.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1589" SE="3.53" STUDY_ID="STD-Gronnerod-2000-Form-4.5" TOTAL_1="0" TOTAL_2="9" WEIGHT="2.331346060673308"/>
<IV_DATA CI_END="-6.081327134573609" CI_START="-19.91867286542639" EFFECT_SIZE="-13.0" ESTIMABLE="YES" ESTIMATE="-13.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1592" SE="3.53" STUDY_ID="STD-Gronnerod-2000-Form-9" TOTAL_1="0" TOTAL_2="9" WEIGHT="2.331346060673308"/>
<IV_DATA CI_END="-7.593337939211592" CI_START="-22.60666206078841" EFFECT_SIZE="-15.1" ESTIMABLE="YES" ESTIMATE="-15.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:48:57 +0000" MODIFIED_BY="[Empty name]" ORDER="1595" SE="3.83" STUDY_ID="STD-Gronnerod-2000-Terb-500" TOTAL_1="0" TOTAL_2="9" WEIGHT="2.251700474986737"/>
<IV_DATA CI_END="0.524588229095519" CI_START="-22.52458822909552" EFFECT_SIZE="-11.0" ESTIMABLE="YES" ESTIMATE="-11.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:49:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1596" SE="5.88" STUDY_ID="STD-Henricksen-1983-Terb" TOTAL_1="0" TOTAL_2="14" WEIGHT="1.7215038243860268"/>
<IV_DATA CI_END="-11.731462192548404" CI_START="-40.268537807451594" EFFECT_SIZE="-26.0" ESTIMABLE="YES" ESTIMATE="-26.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:49:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1567" SE="7.28" STUDY_ID="STD-Henricksen-1992-Salb" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.4134552183092453"/>
<IV_DATA CI_END="-24.82820528812169" CI_START="-47.171794711878306" EFFECT_SIZE="-36.0" ESTIMABLE="YES" ESTIMATE="-36.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:49:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1568" SE="5.7" STUDY_ID="STD-Henriksen-1992-Form-12" TOTAL_1="0" TOTAL_2="6" WEIGHT="1.7650234153881217"/>
<IV_DATA CI_END="-31.142964590651953" CI_START="-49.057035409348046" EFFECT_SIZE="-40.1" ESTIMABLE="YES" ESTIMATE="-40.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:49:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1613" SE="4.57" STUDY_ID="STD-Hills-1976-Salb" TOTAL_1="0" TOTAL_2="10" WEIGHT="2.054141294419751"/>
<IV_DATA CI_END="-28.65297359451694" CI_START="-47.54702640548307" EFFECT_SIZE="-38.1" ESTIMABLE="YES" ESTIMATE="-38.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:49:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1566" SE="4.82" STUDY_ID="STD-Hills-1976-Salmefamol" TOTAL_1="0" TOTAL_2="9" WEIGHT="1.9882611388524092"/>
<IV_DATA CI_END="5.101403355588696" CI_START="-16.301403355588697" EFFECT_SIZE="-5.6" ESTIMABLE="YES" ESTIMATE="-5.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:50:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1572" SE="5.46" STUDY_ID="STD-Pearlman-2006-Form-12" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.8242836760167271"/>
<IV_DATA CI_END="3.4014033555886956" CI_START="-18.001403355588696" EFFECT_SIZE="-7.3" ESTIMABLE="YES" ESTIMATE="-7.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:50:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1571" SE="5.46" STUDY_ID="STD-Pearlman-2006-Form-24" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.8242836760167271"/>
<IV_DATA CI_END="3.1014033555886957" CI_START="-18.301403355588697" EFFECT_SIZE="-7.6" ESTIMABLE="YES" ESTIMATE="-7.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:50:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1570" SE="5.46" STUDY_ID="STD-Pearlman-2006-Salb-180" TOTAL_1="0" TOTAL_2="7" WEIGHT="1.8242836760167271"/>
<IV_DATA CI_END="-9.366896161278055" CI_START="-19.833103838721946" EFFECT_SIZE="-14.6" ESTIMABLE="YES" ESTIMATE="-14.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-17 15:50:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1579" SE="2.67" STUDY_ID="STD-Vasquez-1984-Salb-400" TOTAL_1="0" TOTAL_2="12" WEIGHT="2.5490797248042143"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-09-13 10:49:45 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-08-21 13:28:15 +0100" MODIFIED_BY="Emma J Welsh" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAICCAYAAADlDEskAAA0D0lEQVR42u2dD4QVXR/HH5IkSSSP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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-03-17 18:02:23 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYUAAAtLCAIAAAAS01iVAACAAElEQVR42uydwU4suZauQ0JCDHLA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-09-11 11:08:03 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Beta<SUB>2</SUB>-agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV<SUB>1</SUB>.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-09-11 11:08:03 +0100" MODIFIED_BY="Christopher J Cates" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 beta<SUB>2</SUB>-agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3wAAATwCAMAAACYH7I9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.07" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Beta<SUB>2</SUB>-agonists versus placebo (single administration), outcome: 1.1 Side effects.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxYAAAPwCAMAAACbfRgKAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.08" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Beta<SUB>2</SUB>-agonists versus placebo (single administration), outcome: 1.8 Subgroup analysis: maximal percentage fall in FEV<SUB>1</SUB> SABA versus LABA.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAusAAAWACAMAAADXs/gYAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.09" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Beta<SUB>2</SUB>-agonists versus placebo (single administration), outcome: 1.9 Subgroup analysis: maximal percentage fall in FEV<SUB>1</SUB>: salmeterol versus formoterol.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAusAAALACAMAAAAdTMz6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2013-09-13 10:49:45 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.10" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Beta<SUB>2</SUB>-agonists versus placebo (single administration), outcome: 1.10 Subgroup analysis: maximal percentage fall in FEV<SUB>1</SUB>: adults versus children.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAusAAAQwCAMAAABrDuDZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-11-07 09:39:06 +0000" MODIFIED_BY="[Empty name]">Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches: core databases</HEADING>
<TABLE COLS="2" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P>
<B>Database</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Frequency of search</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL (<I>The Cochrane Library</I>)</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE (Ovid)</P>
</TD>
<TD VALIGN="TOP">
<P>Weekly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE (Ovid)</P>
</TD>
<TD VALIGN="TOP">
<P>Weekly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>PsycINFO (Ovid)</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CINAHL (EBSCO)</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>AMED (EBSCO)</P>
</TD>
<TD VALIGN="TOP">
<P>Monthly</P>
</TD>
</TR>
</TABLE>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Handsearches: core respiratory conference abstracts</HEADING>
<TABLE COLS="2" ROWS="9">
<TR>
<TD VALIGN="TOP">
<P>
<B>Conference</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Years searched</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>American Academy of Allergy, Asthma &amp; Immunology (AAAAI)</P>
</TD>
<TD VALIGN="TOP">
<P>2001 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>American Thoracic Society (ATS)</P>
</TD>
<TD VALIGN="TOP">
<P>2001 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Asia Pacific Society of Respirology (APSR)</P>
</TD>
<TD VALIGN="TOP">
<P>2004 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>British Thoracic Society Winter Meeting (BTS)</P>
</TD>
<TD VALIGN="TOP">
<P>2000 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Chest Meeting</P>
</TD>
<TD VALIGN="TOP">
<P>2003 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>European Respiratory Society (ERS)</P>
</TD>
<TD VALIGN="TOP">
<P>1992, 1994, 2000 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>International Primary Care Respiratory Group Congress (IPCRG)</P>
</TD>
<TD VALIGN="TOP">
<P>2002 onwards</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Thoracic Society of Australia and New Zealand (TSANZ)</P>
</TD>
<TD VALIGN="TOP">
<P>1999 onwards</P>
</TD>
</TR>
</TABLE>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE search strategy used to identify trials for the CAGR</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Asthma search</HEADING>
<P>1. exp Asthma/</P>
<P>2. asthma$.mp.</P>
<P>3. (antiasthma$ or anti-asthma$).mp.</P>
<P>4. Respiratory Sounds/</P>
<P>5. wheez$.mp.</P>
<P>6. Bronchial Spasm/</P>
<P>7. bronchospas$.mp.</P>
<P>8. (bronch$ adj3 spasm$).mp.</P>
<P>9. bronchoconstrict$.mp.</P>
<P>10. exp Bronchoconstriction/</P>
<P>11. (bronch$ adj3 constrict$).mp.</P>
<P>12. Bronchial Hyperreactivity/</P>
<P>13. Respiratory Hypersensitivity/</P>
<P>14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.</P>
<P>15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.</P>
<P>16. or/1-15</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Filter to identify RCTs</HEADING>
<P>1. exp "clinical trial [publication type]"/</P>
<P>2. (randomised or randomised).ab,ti.</P>
<P>3. placebo.ab,ti.</P>
<P>4. dt.fs.</P>
<P>5. randomly.ab,ti.</P>
<P>6. trial.ab,ti.</P>
<P>7. groups.ab,ti.</P>
<P>8. or/1-7</P>
<P>9. Animals/</P>
<P>10. Humans/</P>
<P>11. 9 not (9 and 10)</P>
<P>12. 8 not 11</P>
<P>The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-11-07 09:56:07 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-11-07 09:51:03 +0000" MODIFIED_BY="[Empty name]">Cochrane Airways Group Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-07 09:56:07 +0000" MODIFIED_BY="[Empty name]">
<P>(physical* OR exercis* OR exert* or train* or bronchoconstrict* or bronchospasm* or EIB or EIA OR athlet*)</P>
<P>AND</P>
<P>(bronchodilat* or ((beta* or B2) and (agonist* or adrenergic*)) or salmeterol or formoterol or salbutamol or albuterol or terbutaline or clenbuterol)</P>
<P>
<I>[Limited to records coded as 'asthma']</I>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Christopher J Cates" NO="3">
<TITLE MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Christopher J Cates">Raw data for the maximal percent fall in FEV<SUB>1</SUB> calculations</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-13 10:49:43 +0100" MODIFIED_BY="Christopher J Cates">
<TABLE COLS="8" ROWS="74">
<TR>
<TH ROWSPAN="2">
<P>Study ID</P>
</TH>
<TH COLSPAN="3">
<P>Beta-agonist arm</P>
</TH>
<TH COLSPAN="3">
<P>Placebo arm</P>
</TH>
<TH>
<P>Correlation</P>
</TH>
</TR>
<TR>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Anderson-2001-Salb-Disk" TYPE="STUDY">Anderson 2001 Salb Disk</LINK>
</P>
</TD>
<TD>
<P>13.42</P>
</TD>
<TD>
<P>13.23</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>39.4</P>
</TD>
<TD>
<P>17.58</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>0.46</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Anderson-2001-Salb-MDI" TYPE="STUDY">Anderson 2001 Salb MDI</LINK>
</P>
</TD>
<TD>
<P>8.51</P>
</TD>
<TD>
<P>13.75</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>39.4</P>
</TD>
<TD>
<P>17.58</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>0.46</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blake-1999-Salb-180" TYPE="STUDY">Blake 1999 Salb 180</LINK>
</P>
</TD>
<TD>
<P>3.8</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>13.5</P>
</TD>
<TD>
<P>12.7</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blake-1999-Salm-25" TYPE="STUDY">Blake 1999 Salm 25</LINK>
</P>
</TD>
<TD>
<P>7.99</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>14.0</P>
</TD>
<TD>
<P>11.5</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Blake-1999-Salm-50" TYPE="STUDY">Blake 1999 Salm 50</LINK>
</P>
</TD>
<TD>
<P>7.34</P>
</TD>
<TD>
<P>10.3</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>14.0</P>
</TD>
<TD>
<P>11.5</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Boner-1994-Form-12" TYPE="STUDY">Boner 1994 Form 12</LINK>
</P>
</TD>
<TD>
<P>2.2</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>14.5</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bronski-1995-Salb-MDI" TYPE="STUDY">Bronski 1995 Salb MDI</LINK>
</P>
</TD>
<TD>
<P>16.0</P>
</TD>
<TD>
<P>11.0</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>23.0</P>
</TD>
<TD>
<P>20.0</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bronski-1995-Salb-Pwd" TYPE="STUDY">Bronski 1995 Salb Pwd</LINK>
</P>
</TD>
<TD>
<P>26.0</P>
</TD>
<TD>
<P>13.0</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>23.0</P>
</TD>
<TD>
<P>20.0</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bronski-1999-Salm-Disk" TYPE="STUDY">Bronski 1999 Salm Disk</LINK>
</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>12.1</P>
</TD>
<TD>
<P>15.6</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bronski-1999-Salm-Diskhal" TYPE="STUDY">Bronski 1999 Salm Diskhal</LINK>
</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>6.36</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>12.1</P>
</TD>
<TD>
<P>15.6</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bronski-2002-Form-12" TYPE="STUDY">Bronski 2002 Form 12</LINK>
</P>
</TD>
<TD>
<P>17.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>38.3</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bronski-2002-Form-24" TYPE="STUDY">Bronski 2002 Form 24</LINK>
</P>
</TD>
<TD>
<P>14.6</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>38.3</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bronski-2002-Salb" TYPE="STUDY">Bronski 2002 Salb</LINK>
</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>37.1</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carlsen-1995-Salm-25" TYPE="STUDY">Carlsen 1995 Salm 25</LINK>
</P>
</TD>
<TD>
<P>19.0</P>
</TD>
<TD>
<P>16.7</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>30.0</P>
</TD>
<TD>
<P>16.7</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Carlsen-1995-Salm-50" TYPE="STUDY">Carlsen 1995 Salm 50</LINK>
</P>
</TD>
<TD>
<P>18.0</P>
</TD>
<TD>
<P>14.3</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>30.0</P>
</TD>
<TD>
<P>16.7</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cavagni-1993-Salb-Jet" TYPE="STUDY">Cavagni 1993 Salb Jet</LINK>
</P>
</TD>
<TD>
<P>7.15</P>
</TD>
<TD>
<P>4.9</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>34.7</P>
</TD>
<TD>
<P>22.3</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cavagni-1993-Salb-MDI" TYPE="STUDY">Cavagni 1993 Salb MDI</LINK>
</P>
</TD>
<TD>
<P>15.9</P>
</TD>
<TD>
<P>9.3</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>28.9</P>
</TD>
<TD>
<P>21.8</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Clarke-1990-Fen" TYPE="STUDY">Clarke 1990 Fen</LINK>
</P>
</TD>
<TD>
<P>-19.9</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>9.8</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Daugbjerg-1996-Form-12" TYPE="STUDY">Daugbjerg 1996 Form 12</LINK>
</P>
</TD>
<TD>
<P>11.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>35.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Debelic-1988-Reproterol" TYPE="STUDY">Debelic 1988 Reproterol</LINK>
</P>
</TD>
<TD>
<P>12.6</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>38.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-DeBenedictis-1996-Salm-25" TYPE="STUDY">DeBenedictis 1996 Salm 25</LINK>
</P>
</TD>
<TD>
<P>19.0</P>
</TD>
<TD>
<P>12.0</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>35.0</P>
</TD>
<TD>
<P>16.0</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0.28</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-DeBenedictis-1996-Salm-50" TYPE="STUDY">DeBenedictis 1996 Salm 50</LINK>
</P>
</TD>
<TD>
<P>15.0</P>
</TD>
<TD>
<P>13.0</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>35.0</P>
</TD>
<TD>
<P>16.0</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0.33</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-DeBenedictis-1998-Salb" TYPE="STUDY">DeBenedictis 1998 Salb</LINK>
</P>
</TD>
<TD>
<P>3.7</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>25.7</P>
</TD>
<TD>
<P>18.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Del-Col-1993-Salb-Jet" TYPE="STUDY">Del Col 1993 Salb Jet</LINK>
</P>
</TD>
<TD>
<P>20.76</P>
</TD>
<TD>
<P>2.1</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>29.14</P>
</TD>
<TD>
<P>15.1</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Del-Col-1993-Salb-MDI" TYPE="STUDY">Del Col 1993 Salb MDI</LINK>
</P>
</TD>
<TD>
<P>12.37</P>
</TD>
<TD>
<P>5.1</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>26.6</P>
</TD>
<TD>
<P>16.1</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dinh-Xuan-1989-Terb" TYPE="STUDY">Dinh Xuan 1989 Terb</LINK>
</P>
</TD>
<TD>
<P>-2.24</P>
</TD>
<TD>
<P>17.7</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>35.2</P>
</TD>
<TD>
<P>22.1</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Egglestone-1981-Terb-250" TYPE="STUDY">Egglestone 1981 Terb 250</LINK>
</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>8.24</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>32.0</P>
</TD>
<TD>
<P>16.49</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ferrari-2000-Form-12" TYPE="STUDY">Ferrari 2000 Form 12</LINK>
</P>
</TD>
<TD>
<P>5.9</P>
</TD>
<TD>
<P>7.2</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>29.3</P>
</TD>
<TD>
<P>14.3</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Green-1992-Salm-50" TYPE="STUDY">Green 1992 Salm 50</LINK>
</P>
</TD>
<TD>
<P>3.2</P>
</TD>
<TD>
<P>4.8</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>26.6</P>
</TD>
<TD>
<P>10.27</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>0.30</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gronnerod-2000-Form-4.5" TYPE="STUDY">Gronnerod 2000 Form 4.5</LINK>
</P>
</TD>
<TD>
<P>9.2</P>
</TD>
<TD>
<P>8.5</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>18.4</P>
</TD>
<TD>
<P>10.1</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gronnerod-2000-Form-9" TYPE="STUDY">Gronnerod 2000 Form 9</LINK>
</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>8.5</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>18.4</P>
</TD>
<TD>
<P>10.1</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gronnerod-2000-Terb-500" TYPE="STUDY">Gronnerod 2000 Terb 500</LINK>
</P>
</TD>
<TD>
<P>3.3</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P>18.4</P>
</TD>
<TD>
<P>10.1</P>
</TD>
<TD>
<P>27</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hawksworth-2002-Salb-HFA" TYPE="STUDY">Hawksworth 2002 Salb HFA</LINK>
</P>
</TD>
<TD>
<P>15.4</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>33.7</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hawksworth-2002-Salb-MDI" TYPE="STUDY">Hawksworth 2002 Salb MDI</LINK>
</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>33.7</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Henricksen-1983-Terb" TYPE="STUDY">Henricksen 1983 Terb</LINK>
</P>
</TD>
<TD>
<P>26.0</P>
</TD>
<TD>
<P>22.4</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>37.0</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Henricksen-1992-Salb" TYPE="STUDY">Henricksen 1992 Salb</LINK>
</P>
</TD>
<TD>
<P>18.0</P>
</TD>
<TD>
<P>17.3</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>44.0</P>
</TD>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Henriksen-1992-Form-12" TYPE="STUDY">Henriksen 1992 Form 12</LINK>
</P>
</TD>
<TD>
<P>8.0</P>
</TD>
<TD>
<P>10.4</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>44.0</P>
</TD>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hills-1976-Salb" TYPE="STUDY">Hills 1976 Salb</LINK>
</P>
</TD>
<TD>
<P>-4.6</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hills-1976-Salmefamol" TYPE="STUDY">Hills 1976 Salmefamol</LINK>
</P>
</TD>
<TD>
<P>-2.6</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>35.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kemp-1994-Salb" TYPE="STUDY">Kemp 1994 Salb</LINK>
</P>
</TD>
<TD>
<P>7.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>27.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kemp-1994-Salm-42" TYPE="STUDY">Kemp 1994 Salm 42</LINK>
</P>
</TD>
<TD>
<P>13.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>27.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Konig-1981-Metaprot" TYPE="STUDY">Konig 1981 Metaprot</LINK>
</P>
</TD>
<TD>
<P>19.0</P>
</TD>
<TD>
<P>12.0</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>36.0</P>
</TD>
<TD>
<P>15.0</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Konig-1984-Fen-0.4" TYPE="STUDY">Konig 1984 Fen 0.4</LINK>
</P>
</TD>
<TD>
<P>4.3</P>
</TD>
<TD>
<P>10.1</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>27.8</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Konig-1984-Fen-0.8" TYPE="STUDY">Konig 1984 Fen 0.8</LINK>
</P>
</TD>
<TD>
<P>2.5</P>
</TD>
<TD>
<P>13.0</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>27.8</P>
</TD>
<TD>
<P>14.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Larsson-1982-Fen" TYPE="STUDY">Larsson 1982 Fen</LINK>
</P>
</TD>
<TD>
<P>-2.7</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>11.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-McAlpine-1990-Form-12" TYPE="STUDY">McAlpine 1990 Form 12</LINK>
</P>
</TD>
<TD>
<P>7.7</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>32.7</P>
</TD>
<TD>
<P>16.5</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-McFadden-1986-Salb-_x0028_I_x0029_" TYPE="STUDY">McFadden 1986 Salb (I)</LINK>
</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-McFadden-1986-Salb-_x0028_II_x0029_" TYPE="STUDY">McFadden 1986 Salb (II)</LINK>
</P>
</TD>
<TD>
<P>-1.1</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>14.1</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morton-1989-Rimet" TYPE="STUDY">Morton 1989 Rimet</LINK>
</P>
</TD>
<TD>
<P>2.8</P>
</TD>
<TD>
<P>5.5</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>24.5</P>
</TD>
<TD>
<P>8.4</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Newnham-1993-Salb-200" TYPE="STUDY">Newnham 1993 Salb 200</LINK>
</P>
</TD>
<TD>
<P>3.8</P>
</TD>
<TD>
<P>18.2</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P>27.1</P>
</TD>
<TD>
<P>15.9</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Newnham-1993-Salm-50" TYPE="STUDY">Newnham 1993 Salm 50</LINK>
</P>
</TD>
<TD>
<P>12.8</P>
</TD>
<TD>
<P>16.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>32.0</P>
</TD>
<TD>
<P>23.2</P>
</TD>
<TD>
<P>11</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Patel-1986-Salb-200" TYPE="STUDY">Patel 1986 Salb 200</LINK>
</P>
</TD>
<TD>
<P>6.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>27.9</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Patel-1986-Tulob-200" TYPE="STUDY">Patel 1986 Tulob 200</LINK>
</P>
</TD>
<TD>
<P>9.7</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>27.9</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Patel-1986-Tulob-400" TYPE="STUDY">Patel 1986 Tulob 400</LINK>
</P>
</TD>
<TD>
<P>7.7</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>27.9</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Patessio-1991-Form-24" TYPE="STUDY">Patessio 1991 Form 24</LINK>
</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>30.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pearlman-2006-Form-12" TYPE="STUDY">Pearlman 2006 Form 12</LINK>
</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>13.2</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pearlman-2006-Form-24" TYPE="STUDY">Pearlman 2006 Form 24</LINK>
</P>
</TD>
<TD>
<P>5.9</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>23</P>
</TD>
<TD>
<P>13.2</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pearlman-2006-Salb-180" TYPE="STUDY">Pearlman 2006 Salb 180</LINK>
</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P>0.0</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pearlman-2007-Salb-90" TYPE="STUDY">Pearlman 2007 Salb 90</LINK>
</P>
</TD>
<TD>
<P>4.8</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>22.5</P>
</TD>
<TD>
<P>10.8</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>0.39</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Philip-2007-Salm-50" TYPE="STUDY">Philip 2007 Salm 50</LINK>
</P>
</TD>
<TD>
<P>10.7</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P>21.8</P>
</TD>
<TD>
<P>8.1</P>
</TD>
<TD>
<P>46</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Richter-2002-Form-12" TYPE="STUDY">Richter 2002 Form 12</LINK>
</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>5.3</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>25.1</P>
</TD>
<TD>
<P>12.2</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Richter-2002-Salm-50" TYPE="STUDY">Richter 2002 Salm 50</LINK>
</P>
</TD>
<TD>
<P>7.6</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>25.1</P>
</TD>
<TD>
<P>12.2</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Richter-2002-Terb-500" TYPE="STUDY">Richter 2002 Terb 500</LINK>
</P>
</TD>
<TD>
<P>8.5</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>25.1</P>
</TD>
<TD>
<P>12.2</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shapiro-2002-Form-12" TYPE="STUDY">Shapiro 2002 Form 12</LINK>
</P>
</TD>
<TD>
<P>12.4</P>
</TD>
<TD>
<P>14.6</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>32.9</P>
</TD>
<TD>
<P>16.8</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shapiro-2002-Form-24" TYPE="STUDY">Shapiro 2002 Form 24</LINK>
</P>
</TD>
<TD>
<P>17.5</P>
</TD>
<TD>
<P>17.5</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>32.9</P>
</TD>
<TD>
<P>16.8</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shapiro-2002-Salb-180" TYPE="STUDY">Shapiro 2002 Salb 180</LINK>
</P>
</TD>
<TD>
<P>10.0</P>
</TD>
<TD>
<P>18.6</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>31.1</P>
</TD>
<TD>
<P>18.7</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sturani-1983-Fen-400" TYPE="STUDY">Sturani 1983 Fen 400</LINK>
</P>
</TD>
<TD>
<P>15.8</P>
</TD>
<TD>
<P>7.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>36.0</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sturani-1983-Salb-200" TYPE="STUDY">Sturani 1983 Salb 200</LINK>
</P>
</TD>
<TD>
<P>23.2</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>36.0</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-VanHaitsma-2010-Salb" TYPE="STUDY">VanHaitsma 2010 Salb</LINK>
</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>16.4</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>14.3</P>
</TD>
<TD>
<P>11.1</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vasquez-1984-Salb-400" TYPE="STUDY">Vasquez 1984 Salb 400</LINK>
</P>
</TD>
<TD>
<P>-0.3</P>
</TD>
<TD>
<P>4.9</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P>14.3</P>
</TD>
<TD>
<P>9.8</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Walker-1986-Bitolterol" TYPE="STUDY">Walker 1986 Bitolterol</LINK>
</P>
</TD>
<TD>
<P>5.0</P>
</TD>
<TD>
<P>11.4</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>23.2</P>
</TD>
<TD>
<P>16.2</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wolley-1990-Terb-500" TYPE="STUDY">Wolley 1990 Terb 500</LINK>
</P>
</TD>
<TD>
<P>17.0</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>34.0</P>
</TD>
<TD>
<P>13.8</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>


<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;53 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;212 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2402 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2400 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;2190 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;158 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;1 article awaiting classification&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_E6274AB982E26AA2013849DFB68C9785_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="E6274AB982E26AA2013849DFB68C9785"><ADDRESS><ORGANISATION>Institute of Translational Pharmacology (IFT), CNR</ORGANISATION><CITY>Rome</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></ALIAS></EXTENSION><EXTENSION ID="AFF_E6274AB982E26AA2013849DFB68C9785_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="E6274AB982E26AA2013849DFB68C9785"><ADDRESS><DEPARTMENT>Section of Allergy and Clinical Immunology</DEPARTMENT><ORGANISATION>National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital</ORGANISATION><CITY>London</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>